(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/026338 A1

(51) International Patent Classification:
C07D 405/14 (2006.01) *A61P 3/00* (2006.01)
C07D 401/14 (2006.01) *A61P 3/10* (2006.01)
C07D 403/12 (2006.01) *A61K 31/4184* (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:
PCT/US2023/071000

(22) International Filing Date:
26 July 2023 (26.07.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/392,857 27 July 2022 (27.07.2022) US

(71) Applicant: **CARMOT THERAPEUTICS, INC.** [US/US]; 740 Heinz Avenue, Berkeley, California 94710 (US).

(72) Inventors: **DU, Xiaohui**; 740 Heinz Avenue, Berkeley, California 94710 (US). **FUCINI, Ray**; 740 Heinz Avenue, Berkeley, California 94710 (US). **GARAI, Sumanta**; 740 Heinz Avenue, Berkeley, California 94710 (US). **ZHOU, Xiang**; 740 Heinz Avenue, Berkeley, California 94710 (US). **YEH, Chien-Hung**; 740 Heinz Avenue, Berkeley, California 94710 (US). **VACCA, Joseph**; 740 Heinz Avenue, Berkeley, California 94710 (US). **LLOYD, David**; 740 Heinz Avenue, Berkeley, California 94710 (US). **HANSEN, Stig**; 740 Heinz Avenue, Berkeley, California 94710 (US).

(74) Agent: **BERVEN, Heidi**; Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, Michigan 49002-0402 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2024/026338 A1

(54) Title: *N*-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE

(57) Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE

FIELD

[0001] Provided herein are GLP-1 receptor modulator compounds; pharmaceutical compositions comprising the compounds; methods of producing the compounds; and methods of using the compounds, and compositions for therapy. The compounds, and compositions are useful, for instance, in methods of treatment, and prevention of metabolic diseases or conditions, methods of detection of metabolic diseases or conditions, and methods of diagnosis of metabolic diseases or conditions.

BACKGROUND

[0002] Diabetes is a serious chronic disease that occurs when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin it produces. Complications of diabetes include, damage to the heart, blood vessels, eyes, kidneys, and nerves. Diabetes can increase risk of heart disease, and stroke. The results include serious effects on quality of life, health, and mortality. *WHO Global Report on Diabetes*, 2016, World Health Organization. As of 2017, approximately 462 million individuals worldwide, about 6.28% of the population was affected by type 2 diabetes, and this prevalence was increasing measurably. Khan *et al.*, 2020, *J. Epidemiol. Glob. Health* 10(1):107-111. The global economic burden of diabetes in 2015 was estimated to be $1.3T, and estimated to increase to $2.1T by 2030. Bommer *et al.*, 2018, *Diabetes Care* 41(5):963-970. Approximately 90-95% of all diabetes cases are type 2 diabetes. Tripathi & Srivastava, 2016, *Med. Sci. Monit.* 12(7):RA130-147.

[0003] The glucagon-like peptide-1 receptor (GLP-1 receptor, or GLP1R) has emerged as a potential target for treating type 2 diabetes. Its ligand, glucagon-like peptide-1 (GLP-1) enhances glucose-induced insulin secretion, and increases insulin synthesis among many other effects. Doyle and Egan, 2007, *Pharmacol. Ther.* 113(3):546-593. GLP-1 is known to delay gastric emptying, suppress food intake, increase satiety, and reduce weight in humans. Shah and Vella, 2014 *Rev Endocr Metab Disord.* 15(3): 181–187. Activating the GLP-1 receptor has been shown to have beneficial effects on insulin secretion and the maintenance of beta cell glucose sensing, transcription, synthesis, proliferation, and survival. Doyle and Egan, 2007, *supra*. While the GLP-1 receptor is a promising therapeutic target, only a handful of GLP-1 receptor drugs have been approved to date, and most, or all of these are peptide, or polypeptide drugs.

[0004] There is a need for additional therapies for treating metabolic diseases, and conditions, like type 2 diabetes. Small molecules targeting GLP-1 receptor should provide safe, stable, and easy to administer therapeutics for metabolic diseases, and conditions such as type 2 diabetes.

SUMMARY

[0005] Provided herein are GLP-1 receptor modulator compounds of Formulas (**LVII**)-(**LXIV**), and sub-formulas thereof, compositions comprising the compounds, methods of producing the compounds, and methods of using the compounds, and compositions in treatment, and diagnosis. The compounds of Formula (**LVII**)-(**LXIV**), and embodiments thereof, are useful for modulating the activity of GLP-1 receptor. In certain embodiments, the compounds can be used to agonize the activity of GLP-1 receptor. In certain embodiments, the compounds can be used for treating diseases, or conditions modulated by GLP-1 receptor.

[0006] In one aspect, provided are compounds of Formula (**LVII**), (**LVIII**), (**LIX**), (**LX**), (**LXI**), or (**LXII**), and compounds **552**, **553**, **561**, **562**, **572**, **573**, **576**, **578**, **581**, **640**, and **641**; or a pharmaceutically acceptable salt, or stereoisomer thereof:



(LVII);



(LVIII);



(LIX);



(LX);



(LXI)

; or



(LXII)

.

[0007] In certain embodiments, when the compound is according to Formula (**LVII**):

$\mathbf{B^4}$ is -CH-, -C($\mathbf{R^2}$)-, or -N-;

$\mathbf{D^1}$ is -CH-or -N-;

$\mathbf{D^2}$ is -CH-, -N-, -C(CH_3)-;

$\mathbf{D^4}$ is -CH- or -N-;

W is N, C$\mathbf{R^{14}}$, or C; when **W** is C$\mathbf{R^{14}}$, the adjacent dashed line indicates a single bond; when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=;

$\mathbf{L^1}$ is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -$NHCH_2$-, -CH_2NH-, -N(Me)CH_2-, and -SO_2NH-;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and  ;

$\mathbf{L^3}$ is -CH_2-, -C(O)-, or -$CH(CH_3)$-;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^3}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

$\mathbf{R^4}$ is selected from the group consisting of alkyl, substituted alkyl, unsubstituted arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl;

$\mathbf{R^5}$ is selected from the group consisting of H, -COOH, -CH_2COOH, -$(CH_2)_2$COOH, -$COCF_3$, -C(OH)CF_3, -CONHCN, -CONHOH, CONHOMe, -

$CONHSO_2N(Me)_2$, $-PO_3H_2$, -PO(Me)(OH), $-SO_3H$, $-SO_2NH_2$, $-SO_2NHMe$, $-B(OH)_2$,






tetrazolyl, ,
and ;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

$\mathbf{R^{14}}$ is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0008] In certain embodiments, when the compound is according to Formula (**LVIII**), $\mathbf{R^3}$ is independently selected from the group consisting of $-CH_2CH_3$, $-CH_2F$, $-CH_2CN$, and $-CF_3$; and all the other variables are as in Formula (**LVII**); wherein when $\mathbf{B^4}$ is -C- and $\mathbf{R^3}$ is $-CH_2F$, then the compound is not ; wherein when **B4** is -N- and $\mathbf{R^3}$ is $-CH_2F$, then the compound is not .

[0009] In certain embodiments, when the compound is according to Formula (**LIX**), the variables are as in Formula (**LVII**).

[0010] In certain embodiments, when the compound is according to Formula (**LX**), $\mathbf{R^4}$ is selected from the group consisting of: (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-

dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, , , , , , , , , , , , and , wherein $\mathbf{R^7}$ is $-CH_2F$ or $-CHF_2$; and all the other variables are as in Formula (**LVII**).

[0011] In certain embodiments, the compound is according to Formula (**LXI**), and all the other variables are as in Formula (**LVII**).

[0012] In certain embodiments, when the compound is according to Formula (**LXII**), either (a), (b), (c), (d), or (e):

(a) wherein when $\mathbf{D^1}$ is -N- and $\mathbf{D^2}$ and $\mathbf{D^4}$ are -CH-, then the compound is not one of the following compounds.

Compound No.	Structure
486	
512	 , and

Compound No.	Structure
513	

and all the other variables are as in Formula (**LVII**);

or

(b) wherein $\mathbf{D^1}$ and $\mathbf{D^4}$ are -CH- and $\mathbf{D^2}$ is -N- and all the other variables are as in Formula (**I**);

or

(c) wherein $\mathbf{D^1}$ is -CH-, $\mathbf{D^4}$ is -CH- or -N-, and $\mathbf{D^2}$ is $-C(CH_3)$; and all the other variables are as in Formula (**LVII**);

or

(d) wherein $\mathbf{D^1}$, $\mathbf{D^2}$, and $\mathbf{D^4}$ are -CH- or -N-, wherein zero or one of $\mathbf{D^1}$, $\mathbf{D^2}$, and $\mathbf{D^4}$ is -N-and $\mathbf{R^5}$ is selected from group consisting of: -H, $-CH_2OH$, $-CH_2COOH$, $-(CH_2)_2COOH$, , , and , and $\mathbf{R^{13}}$ is $-CH_3$ or -cyclopropyl; and all the other variables are as in Formula (**LVII**);

or

(e) $\mathbf{D^1}$, $\mathbf{D^2}$, and $\mathbf{D^4}$ are -CH- or -N-, wherein zero or one of $\mathbf{D^1}$, $\mathbf{D^2}$, and $\mathbf{D^4}$ is -N and $\mathbf{L^3}$ is $-CH(CH_3)-$; and all the other variables are as in Formula (**LVII**).

[0013] In certain embodiments, provided are compounds **552**, **553**, **558**, **561**, **562**, **572**, **573**, **576**, **578**, **581**, **590**, and **591**:

Compound No.	Structure
552	

Compound No.	Structure
553	
558	
561	
562	
572	

Compound No.	Structure
573	
576	
578	
581	

Compound No.	Structure
640	 , and
641	

.

[0014] In certain embodiments, when the compound is according to Formula (**LVII**), (**LVIII**), (**LIX**), (**LX**), or (**LXII**), L^1 is selected from the group consisting of -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -OCH_2(cyclopropyl)-, -O-CH_2-CH_2-, -CH_2-O-CH_2-, -CH_2-O-C((CH_3)$_2$), -$NHCH_2$-, -N(Me)CH_2-, and -SO_2NH-.

[0015] In one aspect, provided is a compound according to Formula **LXIII** or a pharmaceutically acceptable salt, or stereoisomer thereof:



(**LXIII**) ,

wherein:

D^1 is -CH-or -N-;

D^2 is -CH-, -N-, -C(CH_3)-;

D^4 is -CH- or -N-;

W is N, CR^{14}, or C; when **W** is CR^{14}, the adjacent dashed line indicates a single bond; when **W** is C, the adjacent dashed line indicates a double bond or L^2 is -C(H)=;

$\mathbf{L^1}$ is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -$NHCH_2$-, -CH_2NH-, -N(Me)CH_2-, and -SO_2NH-;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

$\mathbf{L^3}$ is -CH_2-, -C(O)-, or -$CH(CH_3)$-;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^3}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

$\mathbf{R^4}$ is selected from the group consisting of: (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, , , , , , , , , , , , , , and ;

$\mathbf{R^5}$ is selected from the group consisting of -H, -CH_2OH, -COOH, -CH_2COOH, -$(CH_2)_2COOH$, -$COCF_3$, -C(OH)CF_3, -CONHCN, -CONHOH, CONHOMe, -$CONHSO_2N(Me)_2$, -PO_3H_2, -PO(Me)(OH), -SO_3H, -SO_2NH_2, -SO_2NHMe, -$B(OH)_2$, , , , , , tetrazolyl, and ;

$\mathbf{R^7}$ is -CH_2F or -CHF_2;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

$\mathbf{R^{14}}$ is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0016] In one aspect, provided is a compound according to Formula **LXIV** or a pharmaceutically acceptable salt, or stereoisomer thereof:



(**LXIV**)

wherein:

$\mathbf{D^1}$ is -CH-or -N-;

$\mathbf{D^2}$ is -CH-, -N-, -$C(CH_3)$-;

$\mathbf{D^4}$ is -CH- or -N-;

W is N, $C\mathbf{R^{14}}$, or C; when **W** is $C\mathbf{R^{14}}$, the adjacent dashed line indicates a single bond; when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=;

$\mathbf{L^1}$ is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -$NHCH_2$-, -CH_2NH-, -$N(Me)CH_2$-, and -SO_2NH-;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

$\mathbf{L^3}$ is -CH_2-, -C(O)-, or -$CH(CH_3)$-;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^3}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

$\mathbf{R^4}$ is alkyl, substituted alkyl, unsubstituted arylalkylene, substituted arylalkylene, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkylene, substituted heteroarylalkylene, unsubstituted heterocycloalkyl, or substituted heterocycloalkyl;

$\mathbf{R^5}$ is selected from the group consisting of H, CH_2OH, -CH_2COOH, -$(CH_2)_2COOH$, , , and ;

$\mathbf{R^7}$ is -CH_2F or -CHF_2;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

R^{14} is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0017] In certain aspects, the compounds are useful in methods of treatment and prevention of metabolic diseases, and conditions, methods of detection of metabolic diseases, and conditions, and methods of diagnosis of metabolic diseases, and conditions.

[0018] In another aspect, provided are compositions comprising a compound of Formula **(LVII) - (LXIV)**. In some embodiments, the compositions are pharmaceutical compositions. Any suitable pharmaceutical composition may be used. In a further aspect, provided herein is a kit comprising the compound of Formula **(LVII) - (LXIV)**, or embodiments thereof, or a pharmaceutical composition thereof.

[0019] In another aspect, provided herein are methods of using the compounds or the compositions described herein. In some embodiments, the methods are for treatment. In some embodiments, the methods are diagnostic methods. In some embodiments, the methods are analytical methods. In some embodiments, the compounds, or compositions described herein are used to treat a disease, or condition. In some aspects, the disease, or condition is selected from metabolic diseases, or conditions. In certain embodiments, the disease is type 2 diabetes.

[0020] Also provided herein is the use of compounds described herein, and compositions thereof, for the treatment of a metabolic disease, or condition. Also provided herein is the use of compounds described herein, and compositions thereof, for the treatment of type 2 diabetes.

DEATILED DESCRIPTION

[0021] Described herein are GLP-1 receptor compounds useful for treating metabolic diseases or conditions, such as type 2 diabetes.

Definitions

[0022] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this disclosure pertains. In some cases, terms with commonly understood meanings are defined herein for clarity, and/or ready reference. The techniques and procedures described or referenced herein are generally well understood, and are commonly employed using conventional methodologies by those skilled in the art. As appropriate, procedures involving the use of commercially available kits, and reagents are generally carried out in accordance with manufacturer-defined protocols, and conditions unless otherwise noted.

[0023] As used herein, the singular forms "a," "an," and "the" include the plural referents unless the context clearly indicates otherwise.

[0024] The term "about" indicates and encompasses an indicated value, and a range above and below that value. In certain embodiments, the term "about" indicates the designated value ± 10%, ± 5%, or ± 1%. In certain embodiments, the term "about" indicates the designated value ± one standard deviation of that value. In certain embodiments, for example, logarithmic scales (e.g., pH), the term "about" indicates the designated value ± 0.3, ± 0.2, or ± 0.1.

[0025] When referring to the compounds provided herein, the following terms have the following meanings unless indicated otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[0026] "Alkoxy" and "alkoxyl," refer to the group –O**R″** where **R″** is alkyl or cycloalkyl. Alkoxy groups include, in certain embodiments, methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, *tert*-butoxy, *sec*-butoxy, *n*-pentoxy, *n*-hexoxy, 1,2-dimethylbutoxy, and the like.

[0027] The term "alkoxyamine," as used herein, refers to the group -alkylene-O-NH_2, wherein alkylene is as defined herein. In some embodiments, alkoxyamine groups can react with aldehydes to form oxime residues. Examples of alkoxyamine groups include -CH_2CH_2-O-NH_2 and -CH_2-O-NH_2.

[0028] The term "alkyl," as used herein, unless otherwise specified, refers to a saturated straight, or branched hydrocarbon. In certain embodiments, the alkyl group is a primary, secondary, or tertiary hydrocarbon. In certain embodiments, the alkyl group includes one to ten carbon atoms (i.e., C_1 to C_{10} alkyl). In certain embodiments, the alkyl is a lower alkyl, for

example, C_{1-6} alkyl, and the like. In certain embodiments, the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, *t*-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. In certain embodiments, "substituted alkyl" refers to an alkyl substituted with one, two, or three groups independently selected from a halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, alkoxy, aryl, heteroaryl, cycloalkyl, cyano, oxo, alkyne, and heterocycloalkylalkylene. In some embodiments, alkyl is unsubstituted.

[0029] The term "alkylene," as used herein, unless otherwise specified, refers to a divalent alkyl group, as defined herein. "Substituted alkylene" refers to an alkylene group substituted as described herein for alkyl. In some embodiments, alkylene is unsubstituted.

[0030] "Alkenyl" refers to an olefinically unsaturated hydrocarbon group, in certain embodiments, having up to about eleven carbon atoms, or from two to six carbon atoms (e.g., "lower alkenyl"), which can be straight-chained or branched, and having at least one, or from one to two sites of olefinic unsaturation. "Substituted alkenyl" refers to an alkenyl group substituted as described herein for alkyl.

[0031] "Alkenylene" refers to a divalent alkenyl as defined herein. Lower alkenylene is, for example, C_2-C_6-alkenylene.

[0032] "Alkynyl" refers to acetylenically unsaturated hydrocarbon groups, in certain embodiments, having up to about eleven carbon atoms, or from two to six carbon atoms (e.g., "lower alkynyl"), which can be straight-chained or branched, and having at least one, or from one to two sites of acetylenic unsaturation. Non-limiting examples of alkynyl groups include acetylene (-C≡CH), propargyl (-CH_2C≡CH), and the like. "Substituted alkynyl" refers to an alkynyl group substituted as described herein for alkyl.

[0033] "Alkynylene" refers to a divalent alkynyl as defined herein. Lower alkynylene is, for example, C_2-C_6-alkynylene.

[0034] "Amino" refers to -NH_2.

[0035] The term "alkylamino," as used herein, and unless otherwise specified, refers to the group –NH**R″** where **R″** is, for example, C_{1-10}alkyl, as defined herein. In certain embodiments, alkylamino is C_{1-6}alkylamino.

[0036] The term "dialkylamino," as used herein, and unless otherwise specified, refers to the group –N**R″R″** where, each **R″** is independently C_{1-10}alkyl, as defined herein. In certain embodiments, dialkylamino is di-C_{1-6}alkylamino.

[0037] The term "aryl," as used herein, and unless otherwise specified, refers to phenyl, biphenyl, or naphthyl. The term includes both substituted and unsubstituted moieties. An aryl group can be substituted with any described moiety including, but not limited to, one or more moieties (e.g., in some embodiments one, two, or three moieties) selected from the group consisting of halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate, wherein each moiety is independently either unprotected, or protected as necessary, as would be appreciated by those skilled in the art (e.g., Greene, et al., *Protective Groups in Organic Synthesis*, John Wiley and Sons, Second Edition, 1991); and wherein the aryl in the arylamino and aryloxy substituents are not further substituted.

[0038] The term "arylamino," as used herein, and unless otherwise specified, refers to an -N**R′R″** group where **R′** is hydrogen, or C_1-C_6-alkyl; and **R″** is aryl, as defined herein.

[0039] The term "arylene," as used herein, and unless otherwise specified, refers to a divalent aryl group, as defined herein.

[0040] The term "aryloxy," as used herein, and unless otherwise specified, refers to an -O**R** group where **R** is aryl, as defined herein.

[0041] "Alkarylene" refers to an arylene group, as defined herein, wherein the aryl ring is substituted with one or two alkyl groups. "Substituted alkarylene" refers to an alkarylene, as defined herein, where the arylene group is further substituted, as defined herein for aryl.

[0042] "Aralkylene" refers to an -alkyl-arylene- or arylene-alkyl, for instance, a -C_1-C_2 alkyl-arylene-, -arylene-C_1-C_2 alkyl-, or - C_1-C_2 alkyl-arylene-C_1-C_2 alkyl- group, where arylene is as defined herein. "Substituted aralkylene" refers to an aralkylene, as defined herein, where the aralkylene group is substituted, as defined herein for aryl. "Substituted C_1-C_2 alkyl" refers to a C_1-C_2 alkyl group that is substituted as defined herein for an alkyl.

[0043] "Arylalkylene" refers to -alkyl-arylene- or arylene-alkyl, for instance, a -C_1-C_2 alkyl-arylene-, -arylene-C_1-C_2 alkyl-, or -C_1-C_2 alkyl-arylene-C_1-C_2 alkyl- group, where arylene is as defined herein. "Substituted arylalkylene" refers to an arylalkylene, as defined herein, where the arylalkylene group is substituted, as defined herein for aryl. "Substituted C_1-C_2 alkyl" refers to a C_1-C_2 alkyl group that is substituted as defined herein for an alkyl.

[0044] "Carboxyl" or "carboxy" refers to -C(O)OH or -COOH.

[0045] The term "cycloalkyl," as used herein, unless otherwise specified, refers to a saturated cyclic hydrocarbon. In certain embodiments, the cycloalkyl group may be a saturated, and/or bridged, and/or non-bridged, and/or a fused bicyclic group. In certain

embodiments, the cycloalkyl group includes three to ten carbon atoms (i.e., C_3 to C_{10} cycloalkyl). In some embodiments, the cycloalkyl has from three to fifteen carbons (C_{3-15}), from three to ten carbons (C_{3-10}), from three to seven carbons (C_{3-7}), or from three to six carbons (C_3-C_6) (i.e., "lower cycloalkyl"). In certain embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, decalinyl, or adamantyl.

[0046] The term "cycloalkylene," as used herein refers to a divalent cycloalkyl group, as defined herein. In certain embodiments, the cycloalkylene group is cyclopropylene , cyclobutylene , cyclopentylene , cyclohexylene , cycloheptylene , and the like. Lower cycloalkylene refers to a C_3-C_6-cycloalkylene.

[0047] The term "cycloalkylalkyl," as used herein, unless otherwise specified, refers to an alkyl group, as defined herein, substituted with one or two cycloalkyl, as defined herein.

[0048] The term "ester," as used herein, refers to -C(O)O**R**, or –COO**R**, where **R** is alkyl, as defined herein.

[0049] The term "haloalkyl" refers to an alkyl group, as defined herein, substituted with one, or more halogen atoms (e.g., in some embodiments one, two, three, four, or five) which are independently selected.

[0050] The term "heteroalkyl" refers to an alkyl, as defined herein, in which one or more carbon atoms are replaced by heteroatoms. As used herein, "heteroalkenyl" refers to an alkenyl, as defined herein, in which one, or more carbon atoms are replaced by heteroatoms. As used herein, "heteroalkynyl" refers to an alkynyl, as defined herein, in which one, or more carbon atoms are replaced by heteroatoms. Suitable heteroatoms include, but are not limited to, nitrogen (N), oxygen (O), and sulfur (S) atoms. Heteroalkyl, heteroalkenyl, and heteroalkynyl are optionally substituted. Examples of heteroalkyl moieties include, but are not limited to, aminoalkyl, sulfonylalkyl, and sulfinylalkyl. Examples of heteroalkyl moieties also include, but are not limited to, methylamino, methylsulfonyl, and methylsulfinyl. "Substituted heteroalkyl" refers to heteroalkyl substituted with one, two, or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, a heteroalkyl group may comprise one, two, three, or four heteroatoms. Those of skill in the art

will recognize that a 4-membered heteroalkyl may generally comprise one, or two heteroatoms, a 5- or 6-membered heteroalkyl may generally comprise one, two, or three heteroatoms, and a 7- to 10-membered heteroalkyl may generally comprise one, two, three, or four heteroatoms.

[0051] The term "heteroalkylene," as used herein, refers to a divalent heteroalkyl, as defined herein. "Substituted heteroalkylene" refers to a divalent heteroalkyl, as defined herein, substituted as described for heteroalkyl.

[0052] The term "heterocycloalkyl" refers to a monovalent, monocyclic, or multicyclic non-aromatic ring system, wherein one, or more of the ring atoms are heteroatoms independently selected from oxygen (O), sulfur (S), and nitrogen (N) (e.g., where the nitrogen, or sulfur atoms may be optionally oxidized, and the nitrogen atoms may be optionally quaternized) and the remaining ring atoms of the non-aromatic ring are carbon atoms. In certain embodiments, heterocycloalkyl is a monovalent, monocyclic, or multicyclic fully-saturated ring system. In certain embodiments, the heterocycloalkyl group has from three to twenty, from three to fifteen, from three to ten, from three to eight, from four to seven, from four to eleven, or from five to six ring atoms. The heterocycloalkyl may be attached to a core structure at any heteroatom or carbon atom which results in the creation of a stable compound. In certain embodiments, the heterocycloalkyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused or bridged ring system and in which the nitrogen or sulfur atoms may be optionally oxidized, and/or the nitrogen atoms may be optionally quaternized. In some embodiments, heterocycloalkyl radicals include, but are not limited to, 2,5-diazabicyclo[2.2.2]octanyl, decahydroisoquinolinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. In certain embodiments, heterocycloalkyl may also be optionally substituted as described herein. In certain embodiments, heterocycloalkyl is substituted with one, two, or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, oxo, cyano, and alkoxy. In some embodiments, a heterocycloalkyl group may comprise one, two, three, or

four heteroatoms. Those of skill in the art will recognize that a 4-membered heterocycloalkyl may generally comprise one or two heteroatoms, a 5 or 6-membered heterocycloalkyl may generally comprise one, two, or three heteroatoms, and a 7- to 10-membered heterocycloalkyl may generally comprise one, two, three, or four heteroatoms.

[0053] "Heterocycloalkylene" refers to a divalent heterocycloalkyl as defined herein.

[0054] The term "heteroaryl" refers to a monovalent monocyclic aromatic group, and/or multicyclic aromatic group, wherein at least one aromatic ring contains one, or more heteroatoms independently selected from oxygen, sulfur, and nitrogen in the ring. Each ring of a heteroaryl group can contain one, or two oxygen atoms, one, or two sulfur atoms, and/or one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four, or less and each ring contains at least one carbon atom. In certain embodiments, the heteroaryl has from five to twenty, from five to fifteen, or from five to ten ring atoms. A heteroaryl may be attached to the rest of the molecule via a nitrogen or a carbon atom. In some embodiments, monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, triazolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidyl, and thienopyridyl. Examples of tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, heteroaryl may also be optionally substituted as described herein. "Substituted heteroaryl" is a heteroaryl substituted as defined for aryl.

[0055] The term "heteroarylene" refers to a divalent heteroaryl group, as defined herein. "Substituted heteroarylene" is a heteroarylene substituted as defined for aryl.

[0056] The term "heteroarylalkylene" refers to -alkyl-heteroarylene- or -heteroarylene-alkyl, for instance, a a -C_1-C_2 alkyl-heteroarylene-, -heteroarylene-C_1-C_2 alkyl-, or -C_1-C_2 alkyl-heteroarylene-C_1-C_2 alkyl- group, where heteroarylene is as defined herein. "Substituted heteroarylalkylene" refers to a heteroarylalkylene, as defined herein, where the

heteroarylalkylene group is substituted, as defined herein for aryl. "Substituted C_1-C_2 alkyl" refers to a C_1-C_2 alkyl group that is substituted as defined herein for an alkyl.

[0057] As used herein, an "oxo" refers to =O.

[0058] The term "protecting group," as used herein, and unless otherwise specified, refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction, or for other purposes. A wide variety of oxygen, and nitrogen protecting groups are known to those skilled in the art of organic synthesis. (See, e.g., Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Fourth Edition, 2006, which is incorporated herein by reference).

[0059] "Pharmaceutically acceptable salt" refers to any salt of a compound provided herein which retains its biological properties, and which is not toxic or otherwise undesirable for pharmaceutical use. Such salts may be derived from a variety of organic, and inorganic counter-ions well known in the art. Such salts include, but are not limited to (1) acid addition salts formed with organic, or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic, glucoheptonic, 3-phenylpropionic, trimethylacetic, *tert*-butylacetic, lauryl sulfuric, gluconic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either (a) is replaced by a metal ion, for example, an alkali metal ion, an alkaline earth ion, or an aluminum ion, or alkali metal, or alkaline earth metal hydroxides, such as sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide, or ammonia; or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, including, without limitation, ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, *N*,*N*'-dibenzylethylene-diamine, chloroprocaine, procaine, *N*-benzylphenethylamine, *N*-methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like.

[0060] Pharmaceutically acceptable salts further include, by way of example and without limitation, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium

salts, and the like, and when the compound contains a basic functionality, salts of non-toxic organic, or inorganic acids, such as hydrohalides, for example, hydrochloride and hydrobromide, sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate, fumarate, tartarate, citrate, benzoate, 3-(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane-disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylate, glucoheptonate, 3-phenylpropionate, trimethylacetate, *tert*-butylacetate, lauryl sulfate, gluconate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, muconate, and the like.

[0061] The term "substantially free of" or "substantially in the absence of" with respect to a composition refers to a composition that includes at least 85%, or 90% by weight, in certain embodiments 95%, 98 %, 99%, or 100% by weight; or in certain embodiments, 95%, 98%, 99%, or 100% of the designated enantiomer or diastereomer of a compound. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of one of two enantiomers. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of one of two diastereomers. In certain embodiments, in the methods, and compounds provided herein, the compounds are substantially free of enantiomers (i.e., a racemic, or 50:50 mixture of compounds).

[0062] Similarly, the term "isolated" with respect to a composition refers to a composition that includes at least 85%, 90%, 95%, 98%, or 99% to 100% by weight, of the compound, the remainder comprising other chemical species, enantiomers or diastereomers.

[0063] "Solvate" refers to a compound provided herein, or a salt thereof, that further includes a stoichiometric, or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.

[0064] "Isotopic composition" refers to the amount of each isotope present for a given atom, and "natural isotopic composition" refers to the naturally occurring isotopic composition, or abundance for a given atom. Atoms containing their natural isotopic composition may also be referred to herein as "non-enriched" atoms. Unless otherwise designated, the atoms of the compounds recited herein are meant to represent any stable isotope of that atom. For example, unless otherwise stated, when a position is designated

specifically as hydrogen (H), the position is understood to have hydrogen at its natural isotopic composition.

[0065] "Isotopic enrichment" refers to the percentage of incorporation of an amount of a specific isotope at a given atom in a molecule in the place of that atom's natural isotopic abundance. For example, deuterium (D) enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. The isotopic enrichment of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0066] "Isotopically enriched" refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. "Isotopically enriched" may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom.

[0067] As used herein, "alkyl," "alkylene," "alkylamino," "dialkylamino," "cycloalkyl," "aryl," "arylene," "alkoxy," "amino," "carboxyl," "heterocycloalkyl," "heteroaryl," "heteroarylene," "carboxyl," and "amino acid" groups optionally comprise deuterium (D) at one, or more positions where hydrogen (H) atoms are present, and wherein the deuterium composition of the atom or atoms is other than the natural isotopic composition.

[0068] Also as used herein, "alkyl," "alkylene," "alkylamino," "dialkylamino," "cycloalkyl," "aryl," "arylene," "alkoxy," "amino," "carboxyl," "heterocycloalkyl," "heteroaryl," "heteroarylene," "carboxyl," and "amino acid" groups optionally comprise carbon-13 (^{13}C) at an amount other than the natural isotopic composition.

[0069] As used herein, term "EC_{50}" refers to a dosage, concentration, or amount of a particular test compound that elicits a dose-dependent response at 50% of maximal expression of a particular response that is induced, provoked, or potentiated by the particular test compound.

[0070] As used herein, and unless otherwise specified, the term "IC_{50}" refers to an amount, concentration, or dosage of a particular test compound that achieves a 50% inhibition of a maximal response in an assay that measures such response.

[0071] As used herein, the terms "subject", and "patient" are used interchangeably. The terms "subject", and "subjects" refer to an animal, such as a mammal including a non-primate (e.g., a cow, pig, horse, cat, dog, rat, and mouse), and a primate (e.g., a monkey, such as a

cynomolgous monkey, a chimpanzee, and a human), and in certain embodiments, a human. In certain embodiments, the subject is a farm animal (e.g., a horse, a cow, a pig, etc.), or a pet (e.g., a dog or a cat). In certain embodiments, the subject is a human.

[0072] As used herein, the terms "therapeutic agent", and "therapeutic agents" refer to any agent(s) which can be used in the treatment, or prevention of a disorder, or one or more symptoms thereof. In certain embodiments, the term "therapeutic agent" includes a compound provided herein. In certain embodiments, a therapeutic agent is an agent which is known to be useful for, or has been, or is currently being used for the treatment, or prevention of a disorder, or one, or more symptoms thereof.

[0073] "Therapeutically effective amount" refers to an amount of a compound, or composition that, when administered to a subject for treating a condition, is sufficient to effect such treatment for the condition. A "therapeutically effective amount" can vary depending on, *inter alia*, the compound, the disease or disorder, and its severity, and the age, weight, *etc.*, of the subject to be treated.

[0074] "Treating" or "treatment" of any disease, or disorder refers, in certain embodiments, to ameliorating a disease, or disorder that exists in a subject. In another embodiment, "treating", or "treatment" includes ameliorating at least one physical parameter, which may be indiscernible by the subject. In yet another embodiment, "treating", or "treatment" includes modulating the disease, or disorder, either physically (e.g., stabilization of a discernible symptom), or physiologically (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treating", or "treatment" includes delaying, or preventing the onset of the disease, or disorder, or delaying, or preventing recurrence of the disease, or disorder. In yet another embodiment, "treating", or "treatment" includes the reduction or elimination of either the disease, or disorder, or retarding the progression of the disease, or disorder, or of one, or more symptoms of the disease, or disorder, or reducing the severity of the disease, or disorder, or of one, or more symptoms of the disease, or disorder.

[0075] As used herein, the terms "prophylactic agent", and "prophylactic agents" as used refer to any agent(s) which can be used in the prevention of a disorder, or one or more symptoms thereof. In certain embodiments, the term "prophylactic agent" includes a compound provided herein. In certain other embodiments, the term "prophylactic agent" does not refer a compound provided herein. For example, a prophylactic agent is an agent which is known to be useful for, or has been or is currently being used to prevent, or impede the onset, development, progression, and/or severity of a disorder.

[0076] As used herein, the phrase "prophylactically effective amount" refers to the

amount of a therapy (e.g., prophylactic agent) which is sufficient to result in the prevention, or reduction of the development, recurrence, or onset of one or more symptoms associated with a disorder, or to enhance or improve the prophylactic effect(s) of another therapy (e.g., another prophylactic agent).

Compounds of Formulae (LVII)-(LXIV)

[0077] Herein are GLP-1 receptor compounds useful for modulating one, or more properties of GLP-1 receptor. The compounds can be prepared as described herein and used for therapy, or diagnosis. In certain embodiments, the therapy is the treatment of a metabolic disease or condition. In certain embodiments, the therapy is the treatment of type 2 diabetes.

[0078] The embodiments described herein include the recited compounds as well as pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, tautomers, and/or mixtures thereof.

[0079] In certain embodiments provided herein is a compound of Formula (**LVII**), or a pharmaceutically acceptable salt, or stereoisomer thereof:



LVII

wherein:

$\mathbf{B^4}$ is -CH-, -C($\mathbf{R^2}$)-, or -N-;

$\mathbf{D^1}$ is -CH- or -N-;

$\mathbf{D^2}$ is -CH-, -N-, or -C(CH_3)-;

$\mathbf{D^4}$ is -CH- or -N;

W is N, C$\mathbf{R^{14}}$, or C;

when **W** is C$\mathbf{R^{14}}$, the adjacent dashed line indicates a single bond;

when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^1}$ is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -CH_2NH-, -NHCH_2-, -N(Me)CH_2-, and -SO_2NH-;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

$\mathbf{L^3}$ is -CH_2-, -C(O)-, or -$CH(CH_3)$-;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^3}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

$\mathbf{R^4}$ is selected from the group consisting of alkyl, substituted alkyl, unsubstituted arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl;

$\mathbf{R^5}$ is selected from the group consisting of -H, -CH_2OH, -COOH, -CH_2COOH, -$(CH_2)_2COOH$, -$COCF_3$, -$C(OH)CF_3$, -CONHCN, -CONHOH, CONHOMe, -$CONHSO_2N(Me)_2$, -PO_3H_2, -PO(Me)(OH), -SO_3H, -SO_2NH_2, -SO_2NHMe, -$B(OH)_2$,






tetrazolyl, and

;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

R^{14} is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0080] In certain embodiments, the compound of Formula (**LVII**) is selected from compounds 554, 566, 567, 595, 597, 602-611, 613, 615-617, 619, 620, 622, 624-632, and 634-636 in Table 2.

[0081] In certain embodiments provided herein is a compound of Formula (**LVIII**), or a pharmaceutically acceptable salt, or stereoisomer thereof:



LVIII

wherein:

$\mathbf{B^4}$ is -CH-, -C($\mathbf{R^2}$)-, or -N-;

$\mathbf{D^1}$ is -CH- or -N-;

$\mathbf{D^2}$ is -CH-, -N-, or -C(CH_3)-;

$\mathbf{D^4}$ is -CH- or -N;

W is N, C$\mathbf{R^{14}}$, or C;

when **W** is C$\mathbf{R^{14}}$, the adjacent dashed line indicates a single bond;

when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^1}$ is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -CH_2NH-, -$NHCH_2$-, -N(Me)CH_2-, and -SO_2NH-;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

$\mathbf{L^3}$ is -CH_2-, -C(O)-, or -$CH(CH_3)$-;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-; each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^3}$ is independently selected from the group consisting of -CH_2CH_3, -CH_2F, -CH_2CN, and -CF_3;

$\mathbf{R^4}$ is selected from the group consisting of alkyl, substituted alkyl, unsubstituted arylalkylene, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl;

$\mathbf{R^5}$ is selected from the group consisting of -H, -CH_2OH, -COOH, -CH_2COOH, -$(CH_2)_2COOH$, -$COCF_3$, -C(OH)CF_3, -CONHCN, -CONHOH, CONHOMe, -$CONHSO_2N(Me)_2$, -PO_3H_2, -PO(Me)(OH), -SO_3H, -SO_2NH_2, -SO_2NHMe, -$B(OH)_2$,






, tetrazolyl, and

;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

$\mathbf{R^{14}}$ is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0082] In certain embodiments, when $\mathbf{B^4}$ is -C- and $\mathbf{R^3}$ is $-CH_2F$, then the compound



accordingly to Formula **(LVIII)** is not .

[0083] In certain embodiments, when $\mathbf{B^4}$ is -N- and $\mathbf{R^3}$ is $-CH_2F$, then the compound



accordingly to Formula **(LVIII)** is not .

[0084] In certain embodiments, the compound of Formula **(LVIII)** is selected from compounds 555, 557, 586, 587, and 599 in Table 2.

[0085] In certain embodiments provided herein is a compound of Formula **(LIX)**, or a pharmaceutically acceptable salt, or stereoisomer thereof:



(LXI)

LIX

wherein:

D^{1} is -CH- or -N-;

D^{2} is -CH-, -N-, or -C(CH_3)-;

D^{4} is -CH- or -N-;

L^{1} is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -CH_2NH-, -$NHCH_2$-, -N(Me)CH_2-, and -SO_2NH-;

L^{2} is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

each **R**^{1} is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and **R**^{11}**R**^{12}NCO-;

each **R**^{2} is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and **R**^{11}**R**^{12}NCO-;

each **R**^{3} is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and **R**^{11}**R**^{12}NCO-;

R^{4} is selected from the group consisting of alkyl, substituted alkyl, unsubstituted arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl;

R^{5} is selected from the group consisting of -H, -CH_2OH,-COOH, -CH_2COOH, -$(CH_2)_2$COOH, -$COCF_3$, -C(OH)CF_3, -CONHCN, -CONHOH, CONHOMe, -$CONHSO_2N(Me)_2$, -PO_3H_2, -PO(Me)(OH), -SO_3H, -SO_2NH_2, -SO_2NHMe, -$B(OH)_2$, , tetrazolyl, and ;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

$\mathbf{R^{14}}$ is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0086] In certain embodiments, the compound of Formula (**LIX**) is compound 571 in Table 2.

[0087] In certain embodiments provided herein is a compound of Formula (**LX**), or a pharmaceutically acceptable salt, or stereoisomer thereof:



LX

wherein:

$\mathbf{D^1}$ is -CH- or -N-;

$\mathbf{D^2}$ is -CH-, -N-, or -C(CH_3)-;

$\mathbf{D^4}$ is -CH- or -N-;

W is N,

C$\mathbf{R^{14}}$, or C;

when **W** is C$\mathbf{R^{14}}$, the adjacent dashed line indicates a single bond;

when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=;

$\mathbf{L^1}$ is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -$NHCH_2$-, -CH_2NH-, -N(Me)CH_2-, and -SO_2NH-;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and  ; $\mathbf{L^3}$ is -CH_2-, -C(O)-, or -CH(CH_3)-;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

R^3 is independently selected from the group consisting of $-CH_2CH_3$, $-CH_2F$, and $-CH_2CN$;

R^4 isselected from the group consisting of (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, , , , , , , , , , , , , , , , and ;

R^5 is selected from the group consisting of -H, $-CH_2OH$, -COOH, $-CH_2COOH$, $-(CH_2)_2COOH$, $-COCF_3$, $-C(OH)CF_3$, -CONHCN, -CONHOH, CONHOMe, $-CONHSO_2N(Me)_2$, $-PO_3H_2$, -PO(Me)(OH), $-SO_3H$, $-SO_2NH_2$, $-SO_2NHMe$, $-B(OH)_2$, , , , , , tetrazolyl, and ;

R^7 is $-CH_2F$ or $-CHF_2$; each

R^{11} is hydrogen, or alkyl; each

R^{12} is hydrogen, or alkyl;

R^{13} is hydrogen, alkyl, or -cyclopropyl;

R^{14} is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0088] In certain embodiments, the compound of Formula (**LX**) is selected from compounds 570, 575, 579, 582, 583, 584, 588, 589-592, 600, 601, 612, 618, and 621 in Table 2.

[0089] In certain embodiments provided herein is a compound of Formula (**LXIII**), or a pharmaceutically acceptable salt, or stereoisomer thereof:



LXI

wherein

D^{1} is -CH- or -N-;

D^{2} is -CH-, -N-, or -C(CH_3)-;

D^{4} is -CH- or -N-;

L^{2} is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

L^{3} is -CH_2-, -C(O)-, or -CH(CH_3)-;

each **R**^{1} is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and **R**^{11}**R**^{12}NCO-;

each **R**^{2} is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and **R**^{11}**R**^{12}NCO-;

each **R**^{3} is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and **R**^{11}**R**^{12}NCO-;

R^{4} is selected from the group consisting of alkyl, substituted alkyl, unsubstituted arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl;

R^{5} is selected from the group consisting of -H, -CH_2OH, -COOH, -CH_2COOH, -$(CH_2)_2$COOH, -$COCF_3$, -C(OH)CF_3, -CONHCN, -CONHOH, CONHOMe, -$CONHSO_2N(Me)_2$, -PO_3H_2, -PO(Me)(OH), -SO_3H, -SO_2NH_2, -SO_2NHMe, -$B(OH)_2$, , tetrazolyl, and ;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

$\mathbf{R^{14}}$ is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0090] In certain embodiments, the compound of Formula (**LXI**) is compound 614 in Table 2.

[0091] In certain embodiments provided herein is a compound of Formula (**LXII**), or a pharmaceutically acceptable salt, or stereoisomer thereof:



LXII

wherein:

$\mathbf{D^1}$ is -CH- or -N-;

$\mathbf{D^2}$ is -CH-, -N-, or -C(CH_3)-;

$\mathbf{D^4}$ is -CH- or -N-;

W is N, C$\mathbf{R^{14}}$, or C;

when **W** is C$\mathbf{R^{14}}$, the adjacent dashed line indicates a single bond;

when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=;

$\mathbf{L^1}$ is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H,Me)-, -CH_2O-, -NHCH_2-, -CH_2NH-, -N(Me)CH_2-, and -SO_2NH-; $\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

$\mathbf{L^3}$ is -CH_2-, -C(O)-, or -$CH(CH_3)$-;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each R^3 is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $R^{11}R^{12}NCO$-;

R^4 is selected from the group consisting of alkyl, substituted alkyl, unsubstituted arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl;

R^5 is selected from the group consisting of -H, -CH_2OH -COOH, -CH_2COOH, -$(CH_2)_2COOH$, -$COCF_3$, -$C(OH)CF_3$, -CONHCN, -CONHOH, CONHOMe, -$CONHSO_2N(Me)_2$, -PO_3H_2, -PO(Me)(OH), -SO_3H, -SO_2NH_2, -SO_2NHMe, -$B(OH)_2$,






, tetrazolyl, and

;

each R^{11} is hydrogen, or alkyl;

each R^{12} is hydrogen, or alkyl;

R^{13} is hydrogen, alkyl, or -cyclopropyl;

R^{14} is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

[0092] In certain embodiments, a compound of Formula (**LXII**) is option (a), (b), (c), (d), or (e). In certain embodiments, option (a), when D^1 is -N- and D^2 and D^4 are -CH-, then the compound is not one of the following compounds.

Compound No.	Structure
486	

Compound No.	Structure
512	 , and
513	

[0093] In certain embodiments, option (b), D^1 and D^4 are -CH- and D^2 is -N-. In certain embodiments, option (c), D^1 and D^4 are -CH- and D^2 is -C(CH_3). In certain embodiments, option (d), D^1, D^2, and D^4 are -CH- and R^5 is selected from group consisting of:-H, -CH_2OH -CH_2COOH, -$(CH_2)_2$COOH,  ,  , and  , wherein R^{13} is -CH_3 or -cyclopropyl. In certain embodiments, option (e), D^1, D^2, and D^4 are -CH- and L^3 is -C(H)CH_3-. In certain emboditments, option (e), zero or one of D^1, D^2, and D^4 is -N- and L^3 is -C(H)CH_3-.In certain embodiments, the compound of Formula (**LXII**) is selected from compounds 556, 559, 560, 563-565, 568, 569, 574, 580, 585, 623, 633, and 637-639 in Table 2.

[0094] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein each R^2 and R^3 is H, or F.

[0095] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein **m** is 0; and **o** is 0.

[0096] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein **W** is N, or CH.

[0097] In certain embodiments, provided is a compound of any of Formulas (**LVII**, **LVIII**, **LX**, and **LXII**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein **W** is C.

[0098] In certain embodiments, provided is a compound of any of Formulas (**LVII**, **LVIII**, **LX**, and **LXII**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein **W** is CH.

[0099] In certain embodiments, provided is a compound of any of Formulas (**LVII**, **LVIII**, **LX**, and **LXII**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein **W** is N.

[00100] In certain embodiments, provided is a compound of any of Formulas (**LVII**, **LVIII**, **LX**, and **LXII**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein **W** is CR^{14}.

[00101] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein R^4 is selected from the group consisting of azetidine-3-yl-methyl, (3*R*)-azetidine-3-yl-methyl, (3*S*)-azetidine-3-yl-methyl, (S)-buta-4-yl-1,3-diol, butan-1-yl-one, 1-(cyanomethyl)-cycloprop-1-yl-methyl, 3-(difluoromethyl)oxetan-3-yl-methyl, (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, (1-ethyl-1H-imidazol-5-yl)-methyl, 1-(Fluoromethyl)-cycloprop-1-yl-methyl, 3-fluorooxetan-3-yl-methyl, 1-hydroxyl-cycloprop-1-yl-methyl, isoxazol-5-yl-methyl, (3R,4R)-4-methoxytetrahydrofuran-3-yl , (1-methyl-1H-imidazol-5-yl)-methyl, 1-methoxy-cycloprop-1yl-methyl, methoxyethan-2-yl, 1-(2-methoxyethyl)-cycloprop-1-yl-methyl, {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, oxetan-2-yl-methyl, (2*S*)-oxetan-2-yl-methyl, oxelan-3-yl-methyl, (3*R*)-oxelan-3-yl-methyl, 1,3-oxazol-2-yl-methyl, (*S*)-1,3-oxazol-2-yl-methyl, (*R*)-1,3-oxazol-2-yl-methyl, 2-oxabicyclo[2.1.1]hexa-1-yl-methyl, 1-cyclobutylmethyl, (R)-2-cyclopropoxypropyl, (S)-2-cyclopropoxypropyl, (2R)-2-(difluoromethoxy)propyl, (2S)-2-(difluoromethoxy)propyl, (2S)-oxolan-2-yl-methyl, (1-methoxycyclobutyl)methyl, (2R)-2-(2,2,2-trifluoroethoxy)propyl, (2S)-2-(2,2,2-trifluoroethoxy)propyl, and 2-(2,2,2-trifluoroethoxy)ethyl.

[00102] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein R^4 is selected from the group consisting of oxetan-2-yl-methyl, (1-ethyl-1H-imidazol-5-yl)-methyl, oxelan-3-yl-methyl and 1,3-oxazol-2-yl-methyl.

[00103] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is selected from the group consisting of oxetan-2-yl-methyl, and (1-ethyl-1H-imidazol-5-yl)-methyl.

[00104] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is oxetan-2-yl-methyl.

[00105] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl.

[00106] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl.

[00107] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is selected from the group consisting of (S)-buta-4-yl-1,3-diol, butan-1-yl-one, 1-(cyanomethyl)-cycloprop-1-yl-methyl, (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, 1-(Fluoromethyl)-cycloprop-1-yl-methyl, 1-hydroxyl-cycloprop-1-yl-methyl, isoxazol-5-yl-methyl, (1-methyl-1H-imidazol-5-yl)-methyl, 1-methoxy-cycloprop-1yl-methyl, methoxyethan-2-yl, 1-(2-methoxyethyl)-cycloprop-1-yl-methyl, 2-oxabicyclo[2.1.1]hexa-1-yl-methyl, 1-cyclobutylmethyl, (R)-2-cyclopropoxypropyl, (S)-2-cyclopropoxypropyl, (2R)-2-(difluoromethoxy)propyl, (2S)-2-(difluoromethoxy)propyl, (2S)-oxolan-2-yl-methyl, (1-methoxycyclobutyl)methyl, (2R)-2-(2,2,2-trifluoroethoxy)propyl, (2S)-2-(2,2,2-trifluoroethoxy)propyl, and 2-(2,2,2-trifluoroethoxy)ethyl.

[00108] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol.

[00109] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl.

[00110] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl.

[00111] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl.

[00112] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is 3-fluorooxetan-3-yl-methyl.

[00113] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl.

[00114] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl.

[00115] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl.

[00116] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is (*R*)-1,3-oxazol-2-yl-methyl.

[00117] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl.

[00118] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is –COOH, or -COOMe.

[00119] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is -COOH.

[00120] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is $-CH_2COOH$.

[00121] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is $-(CH_2)_2COOH$.

[00122] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is tetrazolyl.

[00123] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is 1H-1,2,3,4-tetrazol-5-yl.

[00124] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is .

[00125] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is , wherein $\mathbf{R^{13}}$ is $-CH_3$ or -cyclopropyl. In certain embodiments, $\mathbf{R^{13}}$ is $-CH_3$. In certain embodiments, $\mathbf{R^{13}}$ is -cyclopropyl.

[00126] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is -H.

[00127] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is $-CH_2OH$.

[00128] In certain embodiments, provided is a compound of any of Formulas (**LVII - LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{R^5}$ is .

[00129] In certain embodiments, when the compound is according to Formula (**LVII**), (**LVIII**), (**LIX**), (**LX**), or (**LXII**), $\mathbf{L^1}$ is selected from the group consisting of -NH-, -N(Me)-, -N(Et)-, $-OCH_2-$, -OC(H,Me)-, $-CH_2O-$, $-OCH_2$(cyclopropyl)-, $-O-CH_2-CH_2-$, $-CH_2-O-CH_2-$, $-CH_2-O-C((CH_3)_2)$, $-NHCH_2-$, $-CH_2NH-$, $-N(Me)CH_2-$, and $-SO_2NH-$.

[00130] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^2}$ is $-CH_2-$, -C(O)-, or $-SO_2-$.

[00131] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^2}$ is a bond, -C(O)-, $-CH_2-$, -C(H)=, $-SO_2-$, -O-, $-CF_2-$. -CHF-, or -CH(OH)-.

[00132] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^2}$ is -O-.

[00133] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^2}$ is $-CH_2-$.

[00134] In certain embodiments, provided is a compound of Formula (**LXII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^2}$ is -O-.

[00135] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^3}$ is -C(O)-.

[00136] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^3}$ is $-CH_2-$.

[00137] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^3}$ is $-CH(CH_3)-$.

[00138] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-CH_2O-$; and $\mathbf{L^2}$ is $-CH_2-$ or -CO-.

[00139] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-CH_2O-$; and $\mathbf{L^3}$ is -C(O)-.

[00140] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-OCH_2-$ and $\mathbf{L^2}$ is -O-.

[00141] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-CH_2O-$ and $\mathbf{L^2}$ is -O-.

[00142] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-CH_2O-$; and $\mathbf{L^3}$ is $-CH_2-$.

[00143] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-CH_2O-$; and $\mathbf{L^3}$ is $-CH(CH_3)-$.

[00144] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-O-CH_2-$; $\mathbf{L^2}$ is -O-; and $\mathbf{L^3}$ is $-CH_2-$.

[00145] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-O-CH_2-$; $\mathbf{L^2}$ is -O-; and $\mathbf{L^3}$ is $-CH(CH_3)-$.

[00146] In certain embodiments, provided is a compound of any of Formula (**LXIII**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-O-CH_2-$; $\mathbf{L^2}$ is -O-; and $\mathbf{L^3}$ is $-CH_2-$.

[00147] In certain embodiments, provided is a compound of Formula (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-O-CH_2-$.

[00148] In certain embodiments, provided is a compound of Formula (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -O-.

[00149] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-CH_2-$.

[00150] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-OCH_2-$.

[00151] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-CH_2O-$.

[00152] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is $-OCH_2$(cyclopropyl).

[00153] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -CH_2-O-CH_2-.

[00154] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -NH-.

[00155] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -N(Me)-.

[00156] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -N(Et)-.

[00157] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -OC(H,Me)-.

[00158] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -NHCH_2-.

[00159] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -N(Me)CH_2-.

[00160] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -SO_2NH-.

[00161] In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^1}$ is -CH_2NH-.

[00162] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; and $\mathbf{L^2}$ is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; and $\mathbf{L^2}$ is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; and $\mathbf{L^2}$ is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; and $\mathbf{L^2}$ is -SO_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; and $\mathbf{L^2}$ is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; and $\mathbf{L^2}$ is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; $\mathbf{L^2}$ is -C(O)-; and $\mathbf{L^3}$

is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas ((**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVIII**) - (**LXII**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is L^1 -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas ((**LVII**) - (**LXII**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -O-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00163] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; and

L^2 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; and L^2 is -SO_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH--; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)- -; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-

1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is $-SO_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is $-CH_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is $-SO_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is $-CH_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is $-SO_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2*S*)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*,4*R*)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or

mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00164] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is $-SO_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -C(O)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-CH_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -C(H)=; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-SO_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -NH-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -N(Me)- ; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -C(O)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-CH_2-$; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -C(H)=; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-SO_2-$; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -NH-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -N(Me)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-SO_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In

certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*,4*R*)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00165] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH- and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH- and L^2 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; and L^2 is -SO_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1

is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*,4*R*)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-

cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00166] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)- and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)- and L^2 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)- and L^2 is $-SO_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is $-CH_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is $-SO_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is $-CH_2-$; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is $-SO_2-$; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is $-CH_2-$; and

$\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas(**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-;

L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -N(Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-

imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (*S*)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-

yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*,4*R*)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00167] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIII**),), L^1 is -N(Et)-; and L^2 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -SO_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -N(Et)-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -N(Et)-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -N(Et)-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-;

and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIII**),), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-mehyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl;

and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*,4*R*)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00168] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; and L^2 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; and L^2 is -SO_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), is -$NHCH_2$-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -$NHCH_2$-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(H)=; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; L^3 is -CH_2-;

R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -

$NHCH_2$-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is $-SO_2$-; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is $-CH_2$-; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is $-SO_2$-; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas ((**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl.

In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas ((**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas ((**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt,

tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00169] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; and L^2 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; and L^2 is -SO_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -CH_2NH-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -CH_2NH-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-

imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is-CH_2NH-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; -; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ -CH_2NH-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any

embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas ((**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas ((**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas ((**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00170] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -SO_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=;

L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is

(1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)CH_2-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)CH_2-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)CH_2-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)CH_2-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)CH_2-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**)

- (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00171] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; and L^2 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)- and L^2 is $-SO_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; and L^2 is -NH-. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**)

- (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl;

and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-

(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments, provided is a compound of any of

Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00172] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -C(O)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -C(H)=. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -SO_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3

is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH.

In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from

H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-cyclobutylmethyl. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00173] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is $-SO_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is $-SO_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl;

and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; $\mathbf{L^2}$ is $-CH_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; $\mathbf{L^2}$ is $-SO_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -O-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-

yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00174] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-

oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-CH_2O-$; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 1-cyclobutylmethyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (*R*)-1,3-oxazol-2-yl-methyl.

[00175] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is $-CH_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H;

and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -C(O)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; ; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CH_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -C(H)=; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -SO_2-; $\mathbf{L^3}$ is -CH_2-;

R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In

certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any

of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00176] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-;

R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for

instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00177] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is $-CH_2-$; L^3 is $-CH_2-$;

R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-;

L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and

R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00178] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is $-SO_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is $-SO_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In

certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2

and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a

pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00179] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is $-SO_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is $-SO_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is $-SO_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-NHCH_2-$; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is

oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -SO_2-; L^3 is -CH_2-;

$\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 3-

fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00180] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-

oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-

1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-

methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4

is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00181] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**),

L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. . In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. . In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(O)-

; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**),

R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00182] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is $-CH_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is $-CH_2-$; R^2 and R^3 are each

H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH.

In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance

1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, **R¹** can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **R⁴** is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00183] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**)

- (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-;

R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(O)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -C(H)=; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -SO_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl.In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a

pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00184] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; and L^2 is -CF_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; and L^2 is –NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -

CH_2-; **R²** and **R³** are each H; and **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CF_2-; **L³** is -CH_2-; **R²** and **R³** are each H; and **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CHF-; **L³** is -CH_2-; **R²** and **R³** are each H; and **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CH(OH)-; **L³** is -CH_2-; **R²** and **R³** are each H; and **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -NH-; **L³** is -CH_2-; **R²** and **R³** are each H; and **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -N(Me)-; **L³** is -CH_2-; **R²** and **R³** are each H; and **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -O-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (2*S*)-oxetan-2-yl-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CF_2-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (2*S*)-oxetan-2-yl-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CHF-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (2*S*)-oxetan-2-yl-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CH(OH)-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (2*S*)-oxetan-2-yl-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -NH-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (2*S*)-oxetan-2-yl-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -N(Me)-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (2*S*)-oxetan-2-yl-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -O-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CF_2-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CHF-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -CH(OH)-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -NH-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -N(Me)-; **L³** is -CH_2-; **R²** and **R³** are each H; **R⁴** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R⁵** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L¹** is -O-; **L²** is -O-;

L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In

certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-

methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00185] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; and L^2 is $-CF_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -O-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is $-CF_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -CHF-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -CH(OH)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -O-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is $-CF_2-$; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -CHF-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -CH(OH)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -NH-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -N(Me)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-CH_2O-$; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-

imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is

(*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00186] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is $-CF_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-CF_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -CHF-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -CH(OH)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -NH-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -N(Me)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-CF_2-$; L^3 is $-CH_2-$;

and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl.

In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00187] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH- and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH- and L^2 is $-CF_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; and L^2 is -

N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CF_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CF_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -

CH_2-; **R^2** and **R^3** are each H; and **R^4** is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -N(Me)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; and **R^4** is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -O-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CF_2-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CHF-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CH(OH)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -NH-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -N(Me)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -O-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CF_2-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CHF-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CH(OH)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -NH-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -N(Me)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (1-ethyl-1H-imidazol-5-yl)-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -O-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CF_2-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CHF-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -NH-; **L^2** is -CH(OH)-; **L^3**

is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -NH-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -NH-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -NH-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -NH-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-methoxy-

cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a

pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00188] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)- and L^2 is -O-. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)- and L^2 is $-CF_2-$. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)- and L^2 is -CHF-. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)- and L^2 is -CH(OH)-. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)- and L^2 is -NH-. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)- and L^2 is -N(Me)-. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -O-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is $-CF_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -CHF-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -CH(OH)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -NH-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -N(Me)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -O-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -CHF-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -NH-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is $-CH_2-$

; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**)

- (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00189] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is $-CF_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is $-CF_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(ME)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -

N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -

N(Et)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Et)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Et)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$

is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00190] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; and L^2 is $-CF_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; L^2 is -O-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; L^2 is $-CF_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; L^2 is -CHF-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-NHCH_2-$; L^2 is -CH(OH)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1

is -$NHCH_2$-; $\mathbf{L^2}$ is -NH-; and $\mathbf{L^3}$ is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; and $\mathbf{L^3}$ is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. n certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. n certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-

yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In

certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-

oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00191] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -CF_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In

certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00192] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; and L^2 is $-CF_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)- and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)- and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)- and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -O-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is $-CF_2-$; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH(Me)-; and L^3 is $-CH_2-$. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -O-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3

is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; and $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-

methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OC(H,Me)-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-

1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00193] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -O-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -CF_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -CHF-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -CH(OH)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -NH-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; and L^2 is -N(Me)-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -O-; and L^3 is -CH_2-. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CF_2-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CHF-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH(OH)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; and L^3 is -CH_2-. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -O-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CF_2-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CHF-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; and R^2 and R^3 are each H. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (2*S*)-oxetan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H;

and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; ; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH(OH)-;

L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any

of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In

certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00194] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of

Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00195] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-

methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2O-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-

methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -CH_2O-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{R^4}$ is 1-hydroxyl-

cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00196] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -CH(OH)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -CH(OH)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -CH(OH)-; L^3 is -

CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -NH-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -N(Me)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -O-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is 1,3-oxazol-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -CF_2-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is 1,3-oxazol-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -CHF-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is 1,3-oxazol-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -CH(OH)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is 1,3-oxazol-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -NH-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is 1,3-oxazol-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -N(Me)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is 1,3-oxazol-2-yl-methyl; and **R^5** is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -O-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -CF_2-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -CHF-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -CH(OH)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -NH-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -N(Me)-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is oxelan-3-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -O-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is 1,3-oxazol-2-yl-methyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -CF_2-; **L^3** is -CH_2-; **R^2** and **R^3** are each H; **R^4** is 1,3-oxazol-2-yl-methyl; and **R^5**

is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is azetidine-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is butan-1-yl-one. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is methoxyethan-2-yl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas

(**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00197] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-;

L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-

methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00198] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4

is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is $-CF_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is $-CF_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is $-CF_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -N(Me)-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -

N(Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is -N(Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is butan-1-yl-one. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas **(LVII)** -

(**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00199] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of

any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Et)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is

isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a

compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^2}$ is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein $\mathbf{L^2}$ is -N(Me)-.

[00200] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is $-CF_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is $-CF_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is $-CF_2-$; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -$NHCH_2$-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments

of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00201] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In

certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH.

In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -N(Me)CH_2-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain

embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00202] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each

H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; ; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance

1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OC(H,Me)-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2S)-1-(1,2-

oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00203] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-SO_2NH-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-SO_2NH-$; L^2 is $-CF_2-$; L^3 is $-CH_2-$; R^2 and R^3 are each H; and R^4 is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-SO_2NH-$; L^2 is -CHF-; L^3 is $-CH_2-$; R^2 and R^3 are each H;

and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is oxelan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; and $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -NH-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -N(Me)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxelan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; ; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CF_2-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CHF-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -SO_2NH-; $\mathbf{L^2}$ is -CH(OH)-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -

COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is -COOH. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxelan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CF_2-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CHF-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -CH(OH)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -NH-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -SO_2NH-; L^2 is -N(Me)-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In certain embodiments of any of Formulas (**LVII**) -

(**LXIV**), R^4 is azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*R*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3*S*)-azetidine-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is butan-1-yl-one. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(cyanomethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(Fluoromethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-hydroxyl-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is isoxazol-5-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methyl-1H-imidazol-5-yl)-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-methoxy-cycloprop-1yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is methoxyethan-2-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-(2-methoxyethyl)-cycloprop-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is{[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-buta-4-yl-1,3-diol. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 3-fluorooxetan-3-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is ((S)-1,1-dioxidothietan-2-yl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*S*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (*R*)-1,3-oxazol-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 1-cyclobutylmethyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (R)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (S)-2-cyclopropoxypropyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(difluoromethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(difluoromethoxy)propyl. In

certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-oxolan-2-yl-methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (1-methoxycyclobutyl)methyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2R)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl. In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), R^4 is 2-(2,2,2-trifluoroethoxy)ethyl. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -NH-. In certain embodiments, provided is a compound of any of Formulas (**LVII**) - (**LXIV**), or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof, wherein L^2 is -N(Me)-.

[00204] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00205] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is $-CH_2COOH$. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00206] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is $-(CH_2)_2COOH$. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00207] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can

be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00208] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00209] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00210] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00211] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment

according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00212] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00213] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00214] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00215] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00216] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl; and $\mathbf{R^5}$

is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00217] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00218] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00219] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00220] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H,

Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00221] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00222] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00223] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00224] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any

embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00225] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00226] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-fluorooxetan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00227] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-fluorooxetan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00228] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-fluorooxetan-3-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00229] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00230] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00231] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and R^5 is -COOH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00232] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00233] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and

$\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00234] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00235] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00236] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00237] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and

cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00238] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00239] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00240] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*R*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00241] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00242] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00243] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00244] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00245] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is -COOH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00246] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00247] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00248] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00249] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is

. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00250] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00251] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00252] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is

. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00253] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is

. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H,

Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00254] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -O-; **L^3** is -$CH(CH_3)$-; **R^2** and **R^3** are each H; **R^4** is (2*S*)-oxetan-2-yl-methyl; and **R^5** is . In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00255] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -O-; **L^3** is -$CH(CH_3)$-; **R^2** and **R^3** are each H; **R^4** is (S)-buta-4-yl-1,3-diol; and **R^5** is -COOH. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00256] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -O-; **L^3** is -$CH(CH_3)$-; **R^2** and **R^3** are each H; **R^4** is (S)-buta-4-yl-1,3-diol; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00257] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH_2-; **L^2** is -O-; **L^3** is -$CH(CH_3)$-; **R^2** and **R^3** are each H; **R^4** is (S)-buta-4-yl-1,3-diol; and **R^5** is . In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any

embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00258] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00259] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00260] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is-$CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00261] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is-$CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00262] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00263] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00264] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is 3-(difluoromethyl)oxetan-3-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00265] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -COOH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00266] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00267] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00268] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00269] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00270] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH(CH_3)-$; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is -COOH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00271] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH(CH_3)-$; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00272] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH(CH_3)-$; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00273] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH(CH_3)-$; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00274] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH(CH_3)-$; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is

. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00275] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00276] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00277] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00278] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected

from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00279] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH(CH_3)-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00280] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH(CH_3)-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00281] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH(CH_3)-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00282] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH(CH_3)-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any

embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00283] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00284] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00285] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*R*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00286] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*R*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00287] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00288] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00289] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00290] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is -COOH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00291] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00292] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00293] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00294] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00295] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is -COOH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00296] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00297] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00298] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00299] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -CH_2NH-; L^2 is -O-; L^3 is -$CH(CH_3)$-; R^2 and R^3 are each H; R^4 is (2*S*)-oxetan-2-yl-methyl; and R^5 is

. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00300] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -COOH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00301] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00302] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is

. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00303] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is $-NHCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH(CH_3)-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected

from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00304] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -$NHCH_2$-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -$CH(CH_3)$-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00305] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*R*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00306] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*R*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is -CH_2COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00307] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*R*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is -$(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be

selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00308] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*R*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00309] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*R*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00310] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*R*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00311] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*S*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be

selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00312] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*S*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is $-CH_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00313] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*S*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is $-(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00314] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*S*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00315] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((*S*)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00316] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is ((*S*)-1,1-dioxidothietan-2-yl)methyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00317] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1-cyclobutylmethyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00318] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1-cyclobutylmethyl; and R^5 is -CH_2COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00319] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1-cyclobutylmethyl; and R^5 is -$(CH_2)_2$COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00320] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1-cyclobutylmethyl; and R^5 is . In

any embodiment according to this paragraph, **R**^{1} can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R**^{2} can be selected from H and -OMe. In any embodiment according to this paragraph, **R**^{3} can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00321] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L**^{1} is -OCH_2-; **L**^{2} is -O-; **L**^{3} is -CH_2-; **R**^{2} and **R**^{3} are each H; **R**^{4} is 1-cyclobutylmethyl; and **R**^{5} is . In any embodiment according to this paragraph, **R**^{1} can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R**^{2} can be selected from H and -OMe. In any embodiment according to this paragraph, **R**^{3} can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00322] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L**^{1} is -OCH_2-; **L**^{2} is -O-; **L**^{3} is -CH_2-; **R**^{2} and **R**^{3} are each H; **R**^{4} is 1-cyclobutylmethyl; and **R**^{5} is . In any embodiment according to this paragraph, **R**^{1} can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R**^{2} can be selected from H and -OMe. In any embodiment according to this paragraph, **R**^{3} can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00323] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L**^{1} is -OCH_2-; **L**^{2} is -O-; **L**^{3} is -CH_2-; **R**^{2} and **R**^{3} are each H; **R**^{4} is 1-cyclobutylmethyl; and **R**^{5} is -H. In any embodiment according to this paragraph, **R**^{1} can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R**^{2} can be selected from H and -OMe. In any embodiment according to this paragraph, **R**^{3} can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00324] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L**^{1} is -OCH_2-; **L**^{2} is -O-; **L**^{3} is -CH_2-; **R**^{2} and **R**^{3} are each H; **R**^{4} is 1-cyclobutylmethyl; and **R**^{5} is -CH_2OH. In any embodiment according to this paragraph, **R**^{1} can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R**^{2} can be selected from H and -OMe. In any embodiment according to this paragraph, **R**^{3} can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00325] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 1-cyclobutylmethyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00326] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (R)-2-cyclopropoxypropyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00327] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (R)-2-cyclopropoxypropyl; and R^5 is -CH_2COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00328] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (R)-2-cyclopropoxypropyl; and R^5 is -$(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00329] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (R)-2-cyclopropoxypropyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl,

F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00330] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (R)-2-cyclopropoxypropyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00331] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (R)-2-cyclopropoxypropyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00332] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (R)-2-cyclopropoxypropyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00333] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (R)-2-cyclopropoxypropyl; and $\mathbf{R^5}$ is -CH_2OH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00334] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (R)-2-cyclopropoxypropyl; and R^5 is -. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00335] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (S)-2-cyclopropoxypropyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00336] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (S)-2-cyclopropoxypropyl; and R^5 is -CH_2COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00337] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (S)-2-cyclopropoxypropyl; and R^5 is -$(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00338] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (S)-2-cyclopropoxypropyl; and R^5 is

. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00339] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-2-cyclopropoxypropyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00340] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-2-cyclopropoxypropyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00341] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-2-cyclopropoxypropyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00342] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-2-cyclopropoxypropyl; and $\mathbf{R^5}$ is -CH_2OH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -

OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00343] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH$_2$-; **L^2** is -O-; **L^3** is -CH$_2$-; **R^2** and **R^3** are each H; **R^4** is (S)-2-cyclopropoxypropyl; and **R^5** is -. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF$_3$, -OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00344] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH$_2$-; **L^2** is -O-; **L^3** is -CH$_2$-; **R^2** and **R^3** are each H; **R^4** is (2R)-2-(difluoromethoxy)propyl; and **R^5** is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF$_3$, -OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00345] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH$_2$-; **L^2** is -O-; **L^3** is -CH$_2$-; **R^2** and **R^3** are each H; **R^4** is (2R)-2-(difluoromethoxy)propyl; and **R^5** is -CH$_2$COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF$_3$, -OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00346] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH$_2$-; **L^2** is -O-; **L^3** is -CH$_2$-; **R^2** and **R^3** are each H; **R^4** is (2R)-2-(difluoromethoxy)propyl; and **R^5** is -(CH$_2$)$_2$COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF$_3$, -OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00347] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2R)-2-(difluoromethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00348] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2R)-2-(difluoromethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00349] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2R)-2-(difluoromethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00350] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2R)-2-(difluoromethoxy)propyl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00351] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2R)-2-(difluoromethoxy)propyl; and R^5 is -

CH_2OH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00352] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(difluoromethoxy)propyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00353] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-2-(difluoromethoxy)propyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00354] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-2-(difluoromethoxy)propyl; and $\mathbf{R^5}$ is $-CH_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00355] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-2-(difluoromethoxy)propyl; and $\mathbf{R^5}$ is $-(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be

selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00356] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (2S)-2-(difluoromethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00357] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (2S)-2-(difluoromethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00358] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (2S)-2-(difluoromethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00359] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is (2R)-2-(difluoromethoxy)propyl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00360] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(difluoromethoxy)propyl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00361] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(difluoromethoxy)propyl; and R^5 is -. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00362] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-oxolan-2-yl-methyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00363] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-oxolan-2-yl-methyl; and R^5 is -CH_2COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00364] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-oxolan-2-yl-methyl; and R^5 is -$(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl,

propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00365] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-oxolan-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00366] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-oxolan-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00367] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-oxolan-2-yl-methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00368] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-oxolan-2-yl-methyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to

this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00369] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-oxolan-2-yl-methyl; and $\mathbf{R^5}$ is $-CH_2OH$. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00370] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-oxolan-2-yl-methyl; and $\mathbf{R^5}$ is -. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00371] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00372] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is $-CH_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00373] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is $-(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this

paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00374] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00375] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00376] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00377] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment

according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00378] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is $-CH_2OH$. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00379] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00380] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00381] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is $-CH_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00382] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is

-$(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00383] In certain embodiments of any of Formulas **(LVII) - (LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00384] In certain embodiments of any of Formulas **(LVII) - (LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00385] In certain embodiments of any of Formulas **(LVII) - (LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00386] In certain embodiments of any of Formulas **(LVII) - (LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is

-H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00387] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is -CH_2OH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00388] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is -. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00389] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00390] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and $\mathbf{R^5}$ is -CH_2COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00391] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and R^5 is -$(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00392] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00393] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00394] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -$C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00395] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00396] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00397] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (2S)-2-(2,2,2-trifluoroethoxy)propyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00398] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 2-(2,2,2-trifluoroethoxy)ethyl; and R^5 is tetrazolyl, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00399] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 2-(2,2,2-trifluoroethoxy)ethyl; and R^5 is -CH_2COOH, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be

selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00400] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is 2-(2,2,2-trifluoroethoxy)ethyl; and R^5 is $-(CH_2)_2COOH$, for instance 1H-1,2,3,4-tetrazol-5-yl. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00401] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is 2-(2,2,2-trifluoroethoxy)ethyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00402] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is 2-(2,2,2-trifluoroethoxy)ethyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00403] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, L^1 is $-OCH_2-$; L^2 is -O-; L^3 is $-CH_2-$; R^2 and R^3 are each H; R^4 is 2-(2,2,2-trifluoroethoxy)ethyl; and R^5 is . In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any

embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00404] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 2-(2,2,2-trifluoroethoxy)ethyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00405] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 2-(2,2,2-trifluoroethoxy)ethyl; and $\mathbf{R^5}$ is $-CH_2OH$. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00406] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 2-(2,2,2-trifluoroethoxy)ethyl; and $\mathbf{R^5}$ is -. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00407] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00408] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol; and $\mathbf{R^5}$ is $-CH_2OH$. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -

OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00409] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH$_2$-; **L^2** is -O-; **L^3** is -CH$_2$-; **R^2** and **R^3** are each H; **R^4** is (S)-buta-4-yl-1,3-diol; and **R^5** is -. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF$_3$, -OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00410] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH$_2$-; **L^2** is -O-; **L^3** is -CH$_2$-; **R^2** and **R^3** are each H; **R^4** is 3-(difluoromethyl)oxetan-3-yl-methyl; and **R^5** is -H. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF$_3$, -OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00411] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH$_2$-; **L^2** is -O-; **L^3** is -CH$_2$-; **R^2** and **R^3** are each H; **R^4** is 3-(difluoromethyl)oxetan-3-yl-methyl; and **R^5** is -CH$_2$OH. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF$_3$, -OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00412] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), **L^1** is -OCH$_2$-; **L^2** is -O-; **L^3** is -CH$_2$-; **R^2** and **R^3** are each H; **R^4** is 3-(difluoromethyl)oxetan-3-yl-methyl; and **R^5** is -. In any embodiment according to this paragraph, **R^1** can be selected from H, Cl, F, Me, -CF$_3$, -OMe, -CN, -C(O)NMe$_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, **R^2** can be selected from H and -OMe. In any embodiment according to this paragraph, **R^3** can be selected from H, F, Me, -CH$_2$CH$_3$, -CH$_2$CN, and -CF$_3$.

[00413] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1,1-dioxidothietan-2-yl)methyl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00414] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1,1-dioxidothietan-2-yl)methyl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00415] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1,1-dioxidothietan-2-yl)methyl; and R^5 is -. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00416] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00417] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is ((R)-1,1-dioxidothietan-2-yl)methyl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any

embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00418] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is -. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00419] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00420] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is -CH_2OH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00421] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl; and $\mathbf{R^5}$ is -. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00422] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00423] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00424] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (1-ethyl-1H-imidazol-5-yl)-methyl; and R^5 is -. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00425] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00426] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00427] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is 3-fluorooxetan-3-yl-methyl; and R^5 is -. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00428] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00429] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00430] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (3R,4R)-4-methoxytetrahydrofuran-3-yl; and R^5 is -. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00431] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is oxetan-2-yl-methyl; and R^5 is -H. In any

embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00432] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxetan-2-yl-methyl; and $\mathbf{R^5}$ is $-CH_2OH$. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00433] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -  . In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00434] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00435] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is $-CH_2OH$. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, $-CF_3$, -OMe, -CN, $-C(O)NMe_2$, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, $-CH_2CH_3$, $-CH_2CN$, and $-CF_3$.

[00436] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is $-OCH_2-$; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is $-CH_2-$; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl; and $\mathbf{R^5}$ is -


. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00437] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00438] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -CH_2OH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00439] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -


. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00440] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00441] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*S*)-1,3-oxazol-2-yl-methyl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00442] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*S*)-1,3-oxazol-2-yl-methyl; and R^5 is -



. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00443] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is -H. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00444] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is -CH_2OH. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any embodiment according to this paragraph, R^3 can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00445] In certain embodiments of any of Formulas (**LVII**) - (**LXIV**), L^1 is -OCH_2-; L^2 is -O-; L^3 is -CH_2-; R^2 and R^3 are each H; R^4 is (*R*)-1,3-oxazol-2-yl-methyl; and R^5 is -



. In any embodiment according to this paragraph, R^1 can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, R^2 can be selected from H and -OMe. In any

embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00446] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and $\mathbf{R^5}$ is -H. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00447] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and $\mathbf{R^5}$ is -CH_2OH. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00448] In certain embodiments of any of Formulas **(LVII)** - **(LXIV)**, $\mathbf{L^1}$ is -OCH_2-; $\mathbf{L^2}$ is -O-; $\mathbf{L^3}$ is -CH_2-; $\mathbf{R^2}$ and $\mathbf{R^3}$ are each H; $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl; and $\mathbf{R^5}$ is -. In any embodiment according to this paragraph, $\mathbf{R^1}$ can be selected from H, Cl, F, Me, -CF_3, -OMe, -CN, -C(O)NMe_2, alkyl, propyl, isopropyl, and cyclopropyl. In any embodiment according to this paragraph, $\mathbf{R^2}$ can be selected from H and -OMe. In any embodiment according to this paragraph, $\mathbf{R^3}$ can be selected from H, F, Me, -CH_2CH_3, -CH_2CN, and -CF_3.

[00449] In certain embodiments, provided is a compound of Table 1 below, or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof.

Table 1

Compound No.	Structure	IUPAC Name
552		2-{[(3R,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-3-fluoropiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
553		2-{[(3S,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-3-fluoropiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
558		2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(3R)-oxolan-3-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
561		2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2R)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
562		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2R)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
572		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-5-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
573		2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-7-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
576		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
578		2-{[(2S,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(3S)-oxolan-3-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
581		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]-5-fluoropyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
640	 , and	1-{[(2S)-oxetan-2-yl]methyl}-2-{[(1r,4r)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)cyclohexyl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
641		1-{[(2S)-oxetan-2-yl]methyl}-2-{[(1s,4s)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)cyclohexyl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

[00450] In certain embodiments, provided is a compound of Table 2 below, or a pharmaceutically salt, tautomer, stereoisomer, and/or mixture of stereoisomers thereof.

Table 2

Compound No.	Structure	IUPAC Name
554		2-{[(2S,4S)-4-[(2-{[(5-chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
555		2-{[(2R,4S)-4-({2-[(4-chloro-2-fluorophenoxy)methyl]pyridin-4-yl}oxy)-2-(fluoromethyl)piperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
556		2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-imidazo[4,5-b]pyridine-6-carboxylic acid
557		2-{[(2S,4S)-4-({2-[(2-chloro-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-(cyanomethyl)piperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
559		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-N-hydroxy-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxamide

Compound No.	Structure	IUPAC Name
560		2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-N-hydroxy-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxamide
563		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-N-methanesulfonyl-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxamide
564		N-(cyclopropanesulfonyl)-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxamide
565		2-{1-[4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)piperidin-1-yl]ethyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
566		2-{[(2S,4S)-4-[(2-{[(3,5-difluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
567		2-{[(2S,4S)-4-[(2-{[(5-cyanopyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
568		2-{1-[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]ethyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
569		2-{1-[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]ethyl}-1-[(2S)-2,4-dihydroxybutyl]-1H-1,3-benzodiazole-6-carboxylic acid
570		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-({2-oxabicyclo[2.1.1]hexan-1-yl}methyl)-1H-1,3-benzodiazole-6-carboxylic acid
571		2-[6-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)spiro[2.5]octan-1-yl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
574		2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-imidazo[4,5-c]pyridine-6-carboxylic acid
575		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(3R)-oxolan-3-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
577		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(3R,4R)-4-methoxyoxolan-3-yl]-1H-1,3-benzodiazole-6-carboxylic acid
579		2-{[(2S,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxolan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
580		2-{[4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)piperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-imidazo[4,5-c]pyridine-6-carboxylic acid
582		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(3-fluorooxetan-3-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid
583		1-{[3-(difluoromethyl)oxetan-3-yl]methyl}-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
584		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(3S)-oxolan-3-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
585		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-5-methyl-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
586		2-{[(2R,4R)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-ethylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
587		2-{[(2S,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-ethylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
588		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid
589		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxolan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
590		1-(cyclobutylmethyl)-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
591		1-[(2S)-2-(difluoromethoxy)propyl]-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
592		1-[(2R)-2-(difluoromethoxy)propyl]-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
594		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(2R)-2-(2,2,2-trifluoroethoxy)propyl]-1H-1,3-benzodiazole-6-carboxylic acid
595		2-{[(2S,4S)-4-[(2-{[(5-chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid
596		2-{[(2S,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid
597		2-{[(2S,4S)-4-[(2-{[(5-chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
598		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(2S)-2-(2,2,2-trifluoroethoxy)propyl]-1H-1,3-benzodiazole-6-carboxylic acid
599		2-{[(2R,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-(trifluoromethyl)piperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
600		2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(1-methoxycyclobutyl)methyl]-1H-

Compound No.	Structure	IUPAC Name
		1,3-benzodiazole-6-carboxylic acid
601		2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid
602		2-{[(2S,4S)-4-[(2-{[(5-chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-[(2R)-2-(difluoromethoxy)propyl]-1H-1,3-benzodiazole-6-carboxylic acid
603		2-{[(2S,4S)-4-[(2-{[(5-chloropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
604		2-{[(2S,4S)-4-[(2-{[(5-cyanopyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
605		2-({4-[(2-{[(5-chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
606		2-{[(2S,4S)-4-[(2-{[(3,5-difluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-[(oxetan-2-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid

Compound No.	Structure	IUPAC Name
607		2-{[(2S,4S)-4-[(2-{[(5-cyano-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-[(oxetan-2-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid
608		2-{[(2S,4S)-4-[(2-{[(5-chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-ethylpiperidin-1-yl]methyl}-1-[(oxetan-2-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid
609		2-{[(2R,4R)-4-[(2-{[(5-chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-ethylpiperidin-1-yl]methyl}-1-[(oxetan-2-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid
610		2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((R)-1,1-dioxidothietan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
611		2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-1,1-dioxidothietan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
612		1-((S)-2-cyclopropoxypropyl)-2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
613		(S)-2-((4-((2-(((5-chloro-3-fluoropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-

Compound No.	Structure	IUPAC Name
		1H-benzo[d]imidazole-6-carboxylic acid
614		2-(((2S,4S)-4-((2-((2,4-difluorobenzyl)amino)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
615		2-(((2S,4S)-4-((2-(((5-chloro-3-fluoropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
616		2-(((2S,4S)-4-((2-(((5-chloropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
617		1-((R)-2-(difluoromethoxy)propyl)-2-(((2S,4S)-4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
618		1-((R)-2-cyclopropoxypropyl)-2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
619		2-(((2S,4S)-4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-

Compound No.	Structure	IUPAC Name
		benzo[d]imidazole-6-carboxylic acid
620		1-((R)-2-(difluoromethoxy)propyl)-2-(((2S,4S)-4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid
621		2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
622		2-(((2S,4S)-4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
623		3-(2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazol-6-yl)propanoic acid
624		2-(((2S,4S)-4-((2-(((3-chloro-5-fluoropyridin-2-yl)amino)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
625		2-(((2S,4S)-4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-

Compound No.	Structure	IUPAC Name
		benzo[d]imidazole-6-carboxylic acid
626		2-(((2S,4S)-4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-((R)-2-(difluoromethoxy)propyl)-1H-benzo[d]imidazole-6-carboxylic acid
627		2-(((2S,4S)-4-((2-(((3-cyano-5-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-((R)-2-(difluoromethoxy)propyl)-1H-benzo[d]imidazole-6-carboxylic acid
628		(S)-2-((4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
629		2-(((2S,4S)-4-((2-(((3-cyano-5-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
630		2-(((2S,4S)-4-((2-(((3-cyano-5-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
631		2-(((2S,4S)-4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-tetrahydrofuran-2-yl)methyl)-

Compound No.	Structure	IUPAC Name
		1H-benzo[d]imidazole-6-carboxylic acid
632		2-(((2S,4S)-4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
633		2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole
634		(S)-2-((4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
635		2-(((2S,4S)-4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzo[d]imidazole-6-carboxylic acid
636		2-(((2S,4S)-4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzo[d]imidazole-6-carboxylic acid
637		2-(2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazol-6-yl)acetic acid

Compound No.	Structure	IUPAC Name
638		2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-N-(pyridin-3-yl)-1H-benzo[d]imidazole-6-carboxamide
639		(2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazol-6-yl)methanol
640		1-{[(2S)-oxetan-2-yl]methyl}-2-{[(1r,4r)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)cyclohexyl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid
641		1-{[(2S)-oxetan-2-yl]methyl}-2-{[(1s,4s)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)cyclohexyl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid

Optically Active Compounds

[00451] In certain embodiments, compounds provided herein may have several chiral centers and may exist in and be isolated in optically active and racemic forms. In certain embodiments, some compounds may exhibit polymorphism. A person of skill in the art will appreciate that compounds provided herein can exist in any racemic, optically-active, diastereomeric, polymorphic, or stereoisomeric form, and/or mixtures thereof. A person of skill in the art will also appreciate that such compounds described herein that possess the useful properties also described herein is within the scope of this disclosure. A person of skill in the art will further appreciate how to prepare optically active forms of the compounds described herein, for example, by resolution of racemic forms via recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase. In addition, most amino acids are chiral (i.e., designated as L- or D-, wherein the L- enantiomer is the naturally occurring configuration) and can exist as separate enantiomers.

[00452] Examples of methods to obtain optically active materials are known in the art, and include at least the following:

i) physical separation of crystals - a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist (i.e., the material is a conglomerate, and the crystals are visually distinct);

ii) simultaneous crystallization - a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, only if the latter is a conglomerate in the solid state;

iii) enzymatic resolutions - a technique wherein partial, or complete separation of a racemate is accomplished by virtue of different rates of reaction of the enantiomers in the presence of an enzyme;

iv) enzymatic asymmetric synthesis - a synthetic technique wherein at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure, or enriched synthetic precursor of the desired enantiomer;

v) chemical asymmetric synthesis - a synthetic technique wherein the desired enantiomer is synthesized from an achiral precursor using chiral catalysts, or chiral auxiliaries to produce asymmetry (i.e., chirality) in the product;

vi) diastereomer separations - a technique wherein a racemic compound is treated with an enantiomerically pure reagent (a chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography, or crystallization by virtue of their now more distinct diastereomeric differences, and then the chiral auxiliary is removed to obtain each enantiomer;

vii) first- and second-order asymmetric transformations - a technique wherein diastereomers of the racemate equilibrate in solution to yield a preponderance of a diastereomer of the desired enantiomer, or where kinetic, or thermodynamic crystallization of the diastereomer of the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer of the desired enantiomer. The desired enantiomer is then derived from the diastereomer;

viii) kinetic resolutions - this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved

compound) by virtue of unequal reaction rates of the enantiomers with a chiral, or non-racemic reagent, or catalyst under kinetic conditions;

ix) enantiospecific synthesis from non-racemic precursors - a synthetic technique wherein the desired enantiomer is obtained from chiral starting materials, and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;

x) chiral liquid chromatography - a technique wherein the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their different interactions with a stationary phase. The stationary phase can be made of chiral material, or the mobile phase can contain an additional chiral material to provoke the different interactions;

xi) chiral gas chromatography - a technique wherein the racemate is volatilized and enantiomers are separated by virtue of their different interactions in the gaseous mobile phase with a column containing a fixed non-racemic adsorbent phase;

xii) extraction with chiral solvents - a technique wherein the enantiomers are separated by virtue of kinetic or thermodynamic dissolution of one enantiomer into a particular chiral solvent;

xiii) transport across chiral membranes - a technique wherein a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as a concentration, or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic nature of the membrane which allows only one enantiomer of the racemate to pass through.

[00453] In some embodiments, provided herein are compositions of compounds of any of Formulas **(LVII)** - **(LXIV)**, that are substantially free of a designated stereoisomer of that compound. In certain embodiments, in the methods and compounds of this disclosure, the compounds are substantially free of other stereoisomers. In some embodiments, the composition includes a compound that is at least 85%, 90%, 95%, 98%, or 99% to 100% by weight of the compound, the remainder comprising other chemical species, or enantiomers. In some embodiments, provided herein are compositions of compounds of any of Formulas **(LVII)** - **(LXIV)**.

[00454] that are substantially free of a designated enantiomer of that compound. In certain embodiments, in the methods and compounds of this disclosure, the compounds are substantially free of other enantiomers. In some embodiments, the composition includes a

compound that is at least 85%, 90%, 95%, 98%, or 99% to 100% by weight of the compound, the remainder comprising other chemical species or enantiomers.

Isotopically Enriched Compounds

[00455] Also provided herein are isotopically enriched compounds including, but not limited to, isotopically enriched compounds of any of Formulas (**LVII**) - (**LXIV**).

[00456] Isotopic enrichment (for example, deuteration) of pharmaceuticals to improve pharmacokinetics ("PK"), pharmacodynamics ("PD"), and/or toxicity profiles, has been previously demonstrated within some classes of drugs. See, for example, Lijinsky et al., Food Cosmet. Toxicol., 20: 393 (1982); Lijinsky et al., J. Nat. Cancer Inst., 69: 1127 (1982); Mangold et al., Mutation Res. 308: 33 (1994); Gordon et al., Drug Metab. Dispos., 15: 589 (1987); Zello et al., Metabolism, 43: 487 (1994); Gately et al., J. Nucl. Med., 27: 388 (1986); Wade D, Chem. Biol. Interact. 117: 191 (1999).

[00457] Isotopic enrichment of a drug can be used, for example, to (1) reduce or eliminate unwanted metabolites; (2) increase the half-life of the parent drug; (3) decrease the number of doses needed to achieve a desired effect; (4) decrease the amount of a dose necessary to achieve a desired effect; (5) increase the formation of active metabolites if any are formed; and/or (6) decrease the production of deleterious metabolites in specific tissues. Isotopic enrichment of a drug can also be used to create a more effective and/or safer drug for combination therapy, whether the combination therapy is intentional or not.

[00458] Replacement of an atom for one of its isotopes often will result in a change in the reaction rate of a chemical reaction. This phenomenon is known as the Kinetic Isotope Effect ("KIE"). For example, if a C–H bond is broken during a rate-determining step in a chemical reaction (i.e., the step with the highest transition state energy), substitution of a (heavier) isotope for that reactive hydrogen will cause a decrease in the reaction rate. The Deuterium Kinetic Isotope Effect ("DKIE") is the most common form of KIE. (*See, e.g.,* Foster et al., Adv. Drug Res., vol. 14, pp. 1-36 (1985); Kushner et al., Can. J. Physiol. Pharmacol., vol. 77, pp. 79-88 (1999)).

[00459] The magnitude of the DKIE can be expressed as the ratio between the rates of a given reaction in which a C–H bond is broken, and the same reaction where deuterium is substituted for hydrogen and the C–D bond is broken. The DKIE can range from about one (no isotope effect) to very large numbers, such as 50, or more, meaning that the reaction can be fifty, or more, times slower when deuterium has been substituted for hydrogen.

[00460] Substitution of tritium ("T") for hydrogen results in yet a stronger bond than deuterium and gives numerically larger isotope effects. Similarly, substitution of isotopes for

other elements including, but not limited to, ^{13}C, or ^{14}C for carbon; ^{33}S, ^{34}S, or ^{36}S for sulfur; ^{15}N for nitrogen; and ^{17}O, or ^{18}O for oxygen may lead to a similar kinetic isotope effect.

[00461] The animal body expresses a variety of enzymes for the purpose of eliminating foreign substances, such as therapeutic agents, from its circulation system. Examples of such enzymes include the cytochrome P450 enzymes ("CYPs"), esterases, proteases, reductases, dehydrogenases, and monoamine oxidases to react with and convert these foreign substances to more polar intermediates, or metabolites for renal excretion. Some of the most common metabolic reactions of pharmaceutical compounds involve the oxidation of a carbon-hydrogen (C–H) bond to either a carbon-oxygen (C–O), or carbon-carbon (C=C) pi-bond. The resultant metabolites may be stable, or unstable under physiological conditions, and can have substantially different PK/PD, and acute, and long-term toxicity profiles relative to the parent compounds. For many drugs, such oxidations are rapid. Therefore, these drugs often require the administration of multiple or high daily doses.

[00462] Therefore, isotopic enrichment at certain positions of a compound provided herein will produce a detectable KIE that will affect the pharmacologic, PK, PD, and/or toxicological profiles of a compound provided herein in comparison with a similar compound having a natural isotopic composition.

Pharmaceutical Compositions and Methods of Administration

[00463] The compounds provided herein can be formulated into pharmaceutical compositions using methods available in the art and those disclosed herein. Any of the compounds provided herein can be provided in the appropriate pharmaceutical composition and be administered by a suitable route of administration.

[00464] The methods provided herein encompass administering pharmaceutical compositions comprising at least one compound provided herein and one or more compatible and pharmaceutically acceptable carriers. In this context, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal, or state government, or listed in the U.S. Pharmacopeia, or other generally recognized pharmacopeia for use in animals, and in certain embodiments in humans. The term "carrier" includes a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete)), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils including petroleum, animal, vegetable, or oils of synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water can be used as a carrier when the pharmaceutical composition is administered intravenously. Saline solutions, and

aqueous dextrose, and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Examples of suitable pharmaceutical carriers are described in Martin, E.W., *Remington's Pharmaceutical Sciences*.

[00465] In clinical practice the pharmaceutical compositions, or compounds provided herein may be administered by any route known in the art. Exemplary routes of administration include, but are not limited to, inhalation, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary, and subcutaneous routes. In some embodiments, a pharmaceutical composition or compound provided herein is administered parenterally.

[00466] The compositions for parenteral administration can be emulsions or sterile solutions. Parenteral compositions may include, for example, propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters (e.g., ethyl oleate). These compositions can also contain wetting, isotonizing, emulsifying, dispersing, and stabilizing agents. Sterilization can be carried out in several ways, for example, using a bacteriological filter, via radiation, or via heating. Parenteral compositions can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water, or any other injectable sterile medium.

[00467] In some embodiments, a composition provided herein is a pharmaceutical composition, or a single unit dosage form. Pharmaceutical compositions, and single unit dosage forms provided herein comprise a prophylactically, or therapeutically effective amount of one, or more prophylactic, or therapeutic compounds.

[00468] The pharmaceutical composition may comprise one, or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, wherein a person of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Non-limiting examples of suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition, or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a subject and the specific compound in the dosage form. The composition, or single unit dosage form, if desired, can also contain minor amounts of wetting, or emulsifying agents, or pH buffering agents. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the *Handbook*

of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference herein in its entirety.

[00469] In some embodiments, the pharmaceutical composition comprises an anti-foaming agent. Any suitable anti-foaming agent may be used. In some aspects, the anti-foaming agent is selected from an alcohol, an ether, an oil, a wax, a silicone, a surfactant, and combinations thereof. In some aspects, the anti-foaming agent is selected from a mineral oil, a vegetable oil, ethylene bis stearamide, a paraffin wax, an ester wax, a fatty alcohol wax, a long-chain fatty alcohol, a fatty acid soap, a fatty acid ester, a silicon glycol, a fluorosilicone, a polyethylene glycol-polypropylene glycol copolymer, polydimethylsiloxane-silicon dioxide, ether, octyl alcohol, capryl alcohol, sorbitan trioleate, ethyl alcohol, 2-ethyl-hexanol, dimethicone, oleyl alcohol, simethicone, and combinations thereof.

[00470] In some embodiments, the pharmaceutical composition comprises a co-solvent. Illustrative examples of co-solvents include, ethanol, poly(ethylene) glycol, butylene glycol, dimethylacetamide, glycerin, and propylene glycol.

[00471] In some embodiments, the pharmaceutical composition comprises a buffer. Illustrative examples of buffers include, acetate, borate, carbonate, lactate, malate, phosphate, citrate, hydroxide, diethanolamine, monoethanolamine, glycine, methionine, guar gum, and monosodium glutamate.

[00472] In some embodiments, the pharmaceutical composition comprises a carrier, or filler. Illustrative examples of carriers, or fillers include, lactose, maltodextrin, mannitol, sorbitol, chitosan, stearic acid, xanthan gum, and guar gum.

[00473] In some embodiments, the pharmaceutical composition comprises a surfactant. Illustrative examples of surfactants, include *d*-alpha tocopherol, benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, docusate sodium, glyceryl behenate, glyceryl monooleate, lauric acid, macrogol 15 hydroxystearate, myristyl alcohol, phospholipids, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, sodium lauryl sulfate, sorbitan esters, and vitamin E polyethylene(glycol) succinate.

[00474] In some embodiments, the pharmaceutical composition comprises an anti-caking agent. Illustrative examples of anti-caking agents include, calcium phosphate (tribasic), hydroxymethyl cellulose, hydroxypropyl cellulose, and magnesium oxide.

[00475] Other excipients that may be used with the pharmaceutical compositions include, for example, albumin, antioxidants, antibacterial agents, antifungal agents, bioabsorbable polymers, chelating agents, controlled release agents, diluents, dispersing agents, dissolution

enhancers, emulsifying agents, gelling agents, ointment bases, penetration enhancers, preservatives, solubilizing agents, solvents, stabilizing agents, and sugars. Specific examples of each of these agents are described, for example, in the *Handbook of Pharmaceutical Excipients*, Rowe et al. (Eds.) 6th Ed. (2009), The Pharmaceutical Press, incorporated by reference herein in its entirety.

[00476] In some embodiments, the pharmaceutical composition comprises a solvent. In some aspects, the solvent is saline solution, such as a sterile isotonic saline solution, or dextrose solution. In some aspects, the solvent is water for injection.

[00477] In some embodiments, the pharmaceutical compositions are in a particulate form, such as a microparticle or a nanoparticle. Microparticles, and nanoparticles may be formed from any suitable material, such as a polymer, or a lipid. In some aspects, the microparticles, or nanoparticles are micelles, liposomes, or polymersomes.

[00478] Further provided herein are anhydrous pharmaceutical compositions, and dosage forms comprising a compound, since, in some embodiments, water can facilitate the degradation of some compounds.

[00479] Anhydrous pharmaceutical compositions, and dosage forms provided herein can be prepared using anhydrous, or low moisture containing ingredients, and low moisture, or low humidity conditions. Pharmaceutical compositions, and dosage forms that comprise lactose, and at least one active ingredient that comprises a primary, or secondary amine can be anhydrous if substantial contact with moisture, and/or humidity during manufacturing, packaging, and/or storage is expected.

[00480] An anhydrous pharmaceutical composition can be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.

[00481] Lactose-free compositions provided herein can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmocopeia (USP) SP (XXI)/NF (XVI). In general, lactose-free compositions comprise an active ingredient, a binder/filler, and a lubricant in pharmaceutically compatible, and pharmaceutically acceptable amounts. Exemplary lactose-free dosage forms comprise an active ingredient, microcrystalline cellulose, pre gelatinized starch, and magnesium stearate.

[00482] Also provided are pharmaceutical compositions, and dosage forms that comprise one, or more excipients that reduce the rate by which a compound will decompose. Such

excipients, which are referred to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.

Parenteral Dosage Forms

[00483] In certain embodiments, provided are parenteral dosage forms. Parenteral dosage forms can be administered to subjects by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses subjects' natural defenses against contaminants, parenteral dosage forms are typically sterile, or capable of being sterilized prior to administration to a subject. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.

[00484] Suitable vehicles that can be used to provide parenteral dosage forms are well known to those skilled in the art. Examples include, but are not limited to Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose, and Sodium Chloride Injection, and Lactated Ringer's Injection; water miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[00485] Excipients that increase the solubility of one, or more of the antibodies disclosed herein can also be incorporated into the parenteral dosage forms.

Dosage and Unit Dosage Forms

[00486] In human therapeutics, the doctor will determine the posology which he considers most appropriate according to a preventive, or curative treatment, and according to the age, weight, condition, and other factors specific to the subject to be treated.

[00487] In certain embodiments, a composition provided herein is a pharmaceutical composition, or a single unit dosage form. Pharmaceutical compositions, and single unit dosage forms provided herein comprise a prophylactically, or therapeutically effective amount of one, or more prophylactic, or therapeutic antibodies, or antigen binding fragments thereof.

[00488] The amount of the compound, or composition which will be effective in the prevention, or treatment of a disorder, or one, or more symptoms thereof will vary with the nature, and severity of the disease, or condition, and the route by which the compound is

administered. The frequency and dosage will also vary according to factors specific for each subject depending on the specific therapy (e.g., therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the subject. Effective doses may be extrapolated from dose-response curves derived from *in vitro*, or animal model test systems.

[00489] In certain embodiments, exemplary doses of a composition include milligram, or microgram amounts of the compound per kilogram of subject, or sample weight (e.g., about 10 micrograms per kilogram to about 50 milligrams per kilogram, about 100 micrograms per kilogram to about 25 milligrams per kilogram, or about 100 microgram per kilogram to about 10 milligrams per kilogram). In certain embodiments, the dosage of the compound provided herein, based on weight of the compound, administered to prevent, treat, manage, or ameliorate a disorder, or one, or more symptoms thereof in a subject is 0.1 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 10 mg/kg, or 15 mg/kg or more of a subject's body weight. In another embodiment, the dosage of the composition, or a composition provided herein administered to prevent, treat, manage, or ameliorate a disorder, or one, or more symptoms thereof in a subject is 0.1 mg to 200 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 0.1 mg to 20 mg, 0.1 mg to 15 mg, 0.1 mg to 10 mg, 0.1 mg to 7.5 mg, 0.1 mg to 5 mg, 0.1 to 2.5 mg, 0.25 mg to 20 mg, 0.25 to 15 mg, 0.25 to 12 mg, 0.25 to 10 mg, 0.25 mg to 7.5 mg, 0.25 mg to 5 mg, 0.25 mg to 2.5 mg, 0.5 mg to 20 mg, 0.5 to 15 mg, 0.5 to 12 mg, 0.5 to 10 mg, 0.5 mg to 7.5 mg, 0.5 mg to 5 mg, 0.5 mg to 2.5 mg, 1 mg to 20 mg, 1 mg to 15 mg, 1 mg to 12 mg, 1 mg to 10 mg, 1 mg to 7.5 mg, 1 mg to 5 mg, or 1 mg to 2.5 mg.

[00490] The dose can be administered according to a suitable schedule, for example, once, two times, three times, or four times weekly. It may be necessary to use dosages of the compound outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician, or treating physician will know how, and when to interrupt, adjust, or terminate therapy in conjunction with subject response.

[00491] Different therapeutically effective amounts may be applicable for different diseases, and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to prevent, manage, treat, or ameliorate such disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with the antibodies, or antigen binding fragments thereof provided herein are also encompassed by the described

dosage amounts, and dose frequency schedules herein. Further, when a subject is administered multiple dosages of a composition provided herein, not all of the dosages need be the same. For example, the dosage administered to the subject may be increased to improve the prophylactic, or therapeutic effect of the composition, or it may be decreased to reduce one, or more side effects that a particular subject is experiencing.

[00492] In certain embodiments, treatment, or prevention can be initiated with one, or more loading doses of a compound, or composition provided herein followed by one, or more maintenance doses.

[00493] In certain embodiments, a dose of a compound, or composition provided herein can be administered to achieve a steady-state concentration of the compound in blood, or serum of the subject. The steady-state concentration can be determined by measurement according to techniques available to those of skill or can be based on the physical characteristics of the subject such as height, weight, and age.

[00494] In certain embodiments, administration of the same composition may be repeated and the administrations may be separated by at least one day, two days, three days, five days, ten days, fifteen days, thirty days, forty-five days, two months, seventy-five days, three months, or six months. In other embodiments, administration of the same prophylactic, or therapeutic agent may be repeated, and the administration may be separated by at least one day, two days, three days, five days, ten days, fifteen days, thirty days, forty-five days, two months, seventy-five days, three months, or six months.

Therapeutic Applications

For therapeutic applications, the compounds are administered to a mammal, in certain embodiments, a human, in a pharmaceutically acceptable dosage suitable for admisntration form such as those known in the art, and those discussed herein, intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, or intratumoral routes. The compounds also are suitably administered by peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. In certain embodiments, the compounds are administered to a mammal, in certain embodiments, a human, in a pharmaceutically acceptable dosage suitable for oral admisntration form such as those known in the art, and those discussed herein. For example, the compounds of this disclosure may be administered orally to a human as a liquid, or solid form. Solid dosage forms include, capsules, tablets, pills, powders, and granules. In such solid dosage forms, the chemical entity is mixed with one or more pharmaceutically acceptable excipients, such as sodium citrate or

dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[00495] The compounds provided herein may be useful for the treatment of any disease, or condition described herein (e.g., a metabolic disease or condition). In certain embodiments, the disease, or condition is any disease, or condition that benefits from modulation of GLP-1 receptor activity. In certain embodiments, the disease, or condition is any disease, or condition that benefits from agonizing GLP-1 receptor activity. In certain embodiments, the methods reduce blood glucose levels. In certain embodiments, the methods promote insulin synthesis, stimulate insulin secretion, increase the mass of β-cells, modulate gastric acid secretion, modulate gastric emptying, and/or decrease glucagon production. In certain embodiments, the disease, or condition is type 2 diabetes.

[00496] In certain embodiments, the disease, or condition is obesity, or one, or more diseases, or conditions associated with obesity. Non-limiting examples of obesity, and obesity related conditions include, symptomatic obesity, simple obesity, childhood obesity, morbid obesity, and abdominal obesity (central obesity characterized by abdominal adiposity). Non-limiting examples of symptomatic obesity include, endocrine obesity (e.g., Cushing syndrome, hypothyroidism, insulinoma, obese type II diabetes, pseudohypoparathyroidism, hypogonadism), hypothalamic obesity, hereditary obesity (e.g., Prader-Willi syndrome, Laurence-Moon-Biedl syndrome), and drug-induced obesity (e.g., steroid, phenothiazine, insulin, sulfonylurea agent, or β-blocker-induced obesity).

[00497] Examples of such diseases, and conditions associated with obesity include, without limitation, glucose tolerance disorders, diabetes (e.g., type 2 diabetes, obese diabetes), lipid metabolism abnormality, hyperlipidemia, hypertension, cardiac failure,

hyperuricemia, gout, fatty liver (including non-alcoholic steatohepatitis (NASH)), coronary heart disease (e.g., myocardial infarction, angina pectoris), cerebral infarction (e.g., brain thrombosis, transient cerebral ischemic attack), bone, or articular disease (e.g., knee osteoarthritis, hip osteoarthritis, spondylitis deformans, lumbago), sleep apnea syndrome, obesity hypoventilation syndrome (Pickwickian syndrome), menstrual disorder (e.g., abnormal menstrual cycle, abnormality of menstrual flow and cycle, amenorrhea, abnormal catamenial symptom), visceral obesity syndrome, and metabolic syndrome. In certain embodiments, the compounds described herein can be used to treat subjects exhibiting symptoms of both obesity, and insulin deficiency.

[00498] In some embodiments, the disease, or condition is diabetes. Non-limiting examples of diabetes include, type 1 diabetes, type 2 diabetes (e.g., diet-treated type 2-diabetes, sulfonylurea-treated type 2-diabetes, a far-advanced stage type 2-diabetes, long-term insulin-treated type 2-diabetes), diabetes mellitus (e.g., non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus), gestational diabetes, obese diabetes, autoimmune diabetes, and borderline type diabetes.

[00499] In some embodiments, the disease, or condition is associated with diabetes (e.g., a complication of diabetes). Non-limiting examples of disorders associated with diabetes include, obesity, obesity-related disorders, metabolic syndrome, neuropathy, nephropathy (e.g., diabetic nephropathy), retinopathy, diabetic cardiomyopathy, cataract, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious disease (e.g., respiratory infection, urinary tract infection, gastrointestinal infection, dermal soft tissue infections, inferior limb infection), diabetic gangrene, xerostomia, hypacusis, cerebrovascular disorder, diabetic cachexia, delayed wound healing, diabetic dyslipidemia peripheral blood circulation disorder, cardiovascular risk factors, (e.g., coronary artery disease, peripheral artery disease, cerebrovascular disease, hypertension, and risk factors related to unmanaged cholesterol, and/or lipid levels, and/or inflammation), NASH, bone fracture, and cognitive dysfunction

[00500] Other non-limiting examples of diseases, or conditions related to diabetes include, pre-diabetes, hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, high LDL-cholesterolemia, low HDL-cholesterolemia, postprandial hyperlipemia), metabolic syndrome (e.g., metabolic disorder where activation of GLP-1R is beneficial, metabolic syndrome X), hypertension, impaired glucose tolerance (IGT), insulin resistance, and sarcopenia.

[00501] In some embodiments, the disease, or condition is diabetes, and obesity (diabesity). In certain embodiments, the compounds described herein are useful in improving the therapeutic effectiveness of metformin.

[00502] In some embodiments, the disease or condition is a disorder of a metabolically important tissue.

[00503] In some embodiments, the disease, or condition is a fatty liver disease. Fatty liver diseases include, but are not limited to, non-alcoholic fatty acid liver disease (NAFLD), steatohepatitis, non-alcoholic steatohepatitis (NASH), fatty liver disease resulting from hepatitis, fatty liver disease resulting from obesity, fatty liver disease resulting from diabetes, fatty liver disease resulting from insulin resistance, fatty liver disease resulting from hypertriglyceridemia, Abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolmans disease, acute fatty liver of pregnancy, and lipodystrophy.

[00504] Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease occurring in the absence of alcohol abuse, and is typically characterized by the presence of steatosis (fat in the liver). NAFLDis believed to be linked to a variety of conditions, e.g., metabolic syndrome (including obesity, diabetes, and hypertriglyceridemia), and insulin resistance. It can cause liver disease in adults and children, and may ultimately lead to cirrhosis (Skelly et al., J Hepatol 2001; 35: 195-9; Chitturi et al., Hepatology 2002; 35(2):373-9). The severity of NAFLD ranges from the relatively benign isolated predominantly macrovesicular steatosis (i.e., nonalcoholic fatty liver or NAFL) to non-alcoholic steatohepatitis (NASH) (Angulo et al., J Gastroenterol Hepatol 2002; 17 SuppkS 186-90). In certain embodiments, the subject is a pediactric subject (e.g., 6-16 years old; or 6-12 years old; or 6-10 years old). In certain embodiments, the subject is an adult subject.

[00505] Other non-limiting examples of diseases, or conditions in metabolically important tissues include, joint disorders (e.g., osteoarthritis, secondary osteoarthritis), steatosis (e.g. in the liver); gall stones; gallbladder disorders; gastroesophageal reflux; sleep apnea; hepatitis; fatty liver; bone disorder characterized by altered bone metabolism, such as osteoporosis, including post-menopausal osteoporosis, poor bone strength, osteopenia, Paget's disease, osteolytic metastasis in cancer patients, osteodistrophy in liver disease, and the altered bone metabolism caused by renal failure, or haemodialysis, bone fracture, bone surgery, aging, pregnancy, protection against bone fractures, and malnutritionpolycystic ovary syndrome; renal disease (e.g., chronic renal failure, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal disease); muscular dystrophy, angina pectoris, acute, or chronic diarrhea, testicular dysfunction, respiratory dysfunction,

frailty, sexual dysfunction (e.g., erectile dysfunction), and geriatric syndrome. In certain embodiments, the chemical entities described herein can be used for treating surgical trauma by improving recovery after surgery, and/or by preventing the catabolic reaction caused by surgical trauma.

[00506] In some embodiments, the disease, or condition is a cardiovascular disease. Non-limiting examples of cardiovascular disease include, congestive heart failure, atherosclerosis, arteriosclerosis, coronary heart disease, or peripheral artery disease, stroke, coronary artery disease, congestive heart failure, coronary heart disease, hypertension, cardiac failure, cerebrovascular disorder (e.g., cerebral infarction), vascular dysfunction, myocardial infarction, elevated blood pressure (e.g., 130/85 mm Hg or higher), and prothrombotic state (exemplified by high fibrinogen, or plasminogen activator inhibitor in the blood).

[00507] In some embodiments, the disease, or condition is a neurological disorder (e.g., neurodegenerative disorder), or a psychiatric disorder. Non-limiting examples of neurological disorders include, brain insulin resistance, mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), anxiety, dementia (e.g., senile dementia), traumatic brain injury, Huntington's chores, tardive dyskinesia, hyperkinesia, mania, Morbus Parkinson, steel-Richard syndrome, Down's syndrome, myasthenia gravis, nerve trauma, brain trauma, vascular amyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation, Friedrich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis (ALS), glaucoma, and apoptosis-mediated degenerative diseases of the central nervous system (e.g., Creutzfeld-Jakob Disease, bovine spongiform encephalopathy (mad cow disease), chronic wasting syndrome). See, e.g., US20060275288A1.

[00508] Non-limiting examples of psychiatric disorders include, drug dependence/addiction (narcotics, amphetamines, and attention deficit/hyperactivity disorder (ADHD). The chemical entities described herein can be useful in improving behavioral response to addictive drugs, decreasing drug dependence, prevention drug abuse relapse, and relieving anxiety caused by the absence of a given addictive substance. See, e.g., US20120021979A1.

[00509] In certain embodiments, the chemical entities described herein are useful in improving learning, and memory by enhancing neuronal plasticity, and facilitation of cellular differentiation, and also in preserving dopamine neurons, and motor function in Morbus Parkinson.

[00510] In some embodiments, the disease, or condition is impaired fasting glucose (IFG), impaired fasting glycemia (IFG), hyperglycemia, insulin resistance (impaired glucose

homeostasis), hyperinsulinemia, elevated blood levels of fatty acids, or glycerol, a hypoglycemic condition, insulin resistant syndrome, paresthesia caused by hyperinsulinemia, hyperlipidaemia, hypercholesteremia, impaired wound healing, leptin resistance, glucose intolerance, increased fasting glucose, dyslipidemia (e.g., hyperlipidemia, atherogenic dyslipidemia characterized by high triglycerides and low HDL cholesterol), glucagonoma, hyperuricacidemia, hypoglycemia (e.g., nighttime hypoglycemia), and concomitant comatose endpoint associated with insulin.

[00511] In certain embodiments, the compounds described herein can reduce, or slow down the progression of borderline type, impaired fasting glucose, or impaired fasting glycemia into diabetes.

[00512] In some embodiments, the disease, or condition is an autoimmune disorder. Non-limiting examples of autoimmune disorders include, multiple sclerosis, experimental autoimmune encephalomyelitis, autoimmune disorder is associated with immune rejection, graft versus host disease, uveitis, optic neuropathies, optic neuritis, transverse myelitis, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, myasthenia gravis, and Graves disease. See, e.g., US20120148586A1.

[00513] In some embodiments, the disease, or condition is a stomach, or intestine related disorder. Non-limiting examples of these disorders include, ulcers of any etiology (e.g. peptic ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, ulcers related to infections, or other pathogens), digestion disorders, malabsorption, short bowel syndrome, cul-de-sac syndrome, inflammatory bowel diseases (Crohn's disease, and ulcerative colitis), celiac sprue, hypogammaglobulinemic sprue, chemotherapy, and/or radiation therapy-induced mucositis, and diarrhea, gastrointestinal inflammation, short bowel syndrome, colitis ulcerosa, gastric mucosal injury (e.g., gastric mucosal injury caused by aspirin), small intestinal mucosal injury, and cachexia (e.g., cancerous cachexia, tuberculous cachexia, cachexia associated with blood disease, cachexia associated with endocrine disease, cachexia associated with infectious disease, cachexia caused by acquired immunodeficiency syndrome).

[00514] In some embodiments, the compounds described herein can be used to reduce body weight (e.g., excess body weight), prevent body weight gain, induce weight loss, decrease body fat, or reduce food intake in a subject (e.g., a subject in need thereof). In certain embodiments, the weight increase in a subject may be attributed to excessive ingestion of food, or unbalanced diets, or may be weight increase derived from a concomitant drug (e.g., insulin sensitizers having a PPARγ agonist-like action, such as troglitazone, rosiglitazone, englitazone, ciglitazone, pioglitazone, and the like). Alternatively, the weight

increase may be weight increase before reaching obesity, or may be weight increase in an obese subject. The weight increase may also be medication-induced weight gain, or weight gain subsequent to cessation of smoking.

[00515] In some embodiments, the condition, disease, or disorder is an eating disorder, such as hyperphagia, binge eating, bulimia, or compulsive eating.

[00516] In some embodiments, the disease, or condition is an inflammatory disorder. Non-limiting examples of inflammatory disorders include, chronic rheumatoid arthritis, spondylitis deformans, arthritis deformans, lumbago, gout, post-operational or post-traumatic inflammation, bloating, neuralgia, laryngopharyngitis, cystitis, pneumonia, pancreatitis, enteritis, inflammatory bowel disease (including inflammatory large bowel disease), inflammation in metabolically important tissues including liver, fat, pancreas, kidney, and gut, and a proinflammatory state (e.g., elevated levels of proinflammatory cytokines or, markers of inflammation-like C-reactive protein in the blood).

[00517] In some embodiments, the disease, or condition is cancer. Suitable examples of cancer include, breast cancer (e.g., invasive ductal breast cancer, noninvasive ductal breast cancer, inflammatory breast cancer), prostate cancer (e.g., hormone-dependent prostate cancer, hormone-independent prostate cancer), pancreatic cancer (e.g., ductal pancreatic cancer), gastric cancer (e.g., papillary adenocarcinoma, mucous adenocarcinoma, adenosquamous carcinoma), lung cancer (e.g., non-small cell lung cancer, small-cell lung cancer, malignant mesothelioma), colon cancer (e.g., gastrointestinal stromal tumor), rectal cancer (e.g., gastrointestinal stromal tumor), colorectal cancer (e.g., familial colorectal cancer, hereditary non-polyposis colorectal cancer, gastrointestinal stromal tumor), small intestinal cancer (e.g., non-Hodgkin's lymphoma, gastrointestinal stromal tumor), esophageal cancer, duodenal cancer, tongue cancer, pharyngeal cancer (e.g., nasopharyngeal cancer, oropharynx cancer, hypopharyngeal cancer), salivary gland cancer, brain tumor (e.g., pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma), neurilemmoma, liver cancer (e.g., primary liver cancer, extrahepatic bile duct cancer), renal cancer (e.g., renal cell cancer, transitional cell cancer of the renal pelvis and ureter), bile duct cancer, endometrial cancer, uterine cervical cancer, ovarian cancer (e.g., epithelial ovarian cancer, extragonadal germ cell tumor, ovarian germ cell tumor, ovarian tumor of low malignant potential), bladder cancer, urethral cancer, skin cancer (e.g., intraocular (ocular) melanoma, Merkel cell carcinoma), hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer (e.g., medullary thyroid cancer), parathyroid cancer, nasal cavity cancer, sinus cancer, bone tumor (e.g., osteosarcoma, Ewing tumor, uterine sarcoma, soft

tissue sarcoma), angiofibroma, sarcoma of the retina, penis cancer, testicular tumor, pediatric solid tumor (e.g., Wilms' tumor, childhood kidney tumor), Kaposi's sarcoma, Kaposi's sarcoma caused by AIDS, tumor of maxillary sinus, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, and leukemia (e.g., acute myeloid leukemia, acute lymphoblastic leukemia).

[00518] In certain embodiments, provided herein are methods for the treatment that include, the administration of an effective amount of compounds provided herein, or a pharmaceutically acceptable salt thereof. In certain embodiments, the methods encompass the step of administering to the subject in need thereof an amount of a compound described herein effective for the treatment of disease, or condition in combination with a second agent effective for the treatment, or prevention of the disease, or condition. In certain embodiments, the compound is in the form of a pharmaceutical composition, or dosage form, as described elsewhere herein.

[00519] In certain embodiments, the subject is a treatment naïve subject. In further embodiments, the subject has previously received therapy. For instance, in certain embodiments, the subject has not responded to a single agent treatment regimen.

[00520] In certain embodiments, the subject is a subject that discontinued some other therapy because of one or more adverse events associated with the other therapy. In certain embodiments, the subject has received some other therapy and discontinued that therapy prior to administration of a method provided herein. In further embodiments, the subject has received therapy and continues to receive that therapy along with administration of a compound provided herein. The compounds described herein can be co-administered with other therapy for treatment of the disease or condition according to the judgment of one of skill in the art. In certain embodiments, the methods or compositions provided herein can be co-administered with a reduced dose of the other therapy for the treatment of the disease or condition.

Diagnostic Applications

[00521] In some embodiments, the compounds provided herein are used in diagnostic applications. These applications may be useful, for example, in making a diagnosis, and/or prognosis for a disease, or condition, such as a metabolic disease, or condition.

[00522] In some diagnostic and prognostic applications or embodiments, the compound may be labeled with a detectable moiety. Suitable detectable moieties include, but are not limited to, radioisotopes, fluorescent labels, and enzyme-substrate labels. In another embodiment, the compound need not be labeled, and the presence of the compound can be

detected using a labeled antibody, or antigen binding fragment thereof which specifically binds to the compound.

Kits

[00523] In some embodiments, a compound provided herein is provided in the form of a kit (i.e., a packaged combination of reagents in predetermined amounts with instructions for performing a procedure). In some embodiments, the procedure is a diagnostic assay. In certain embodiments, the procedure is a therapeutic procedure.

[00524] In some embodiments, the kit further comprises a solvent for the reconstitution of the compound. In some embodiments, the compound is provided in the form of a pharmaceutical composition.

[00525] In some embodiments, the kits can include a compound, or composition provided herein, an optional second agent, or composition, and instructions providing information to a health care provider regarding usage for treating the disorder. Instructions may be provided in printed form, or in the form of an electronic medium such as a floppy disc, CD, or DVD, or in the form of a website address where such instructions may be obtained. A unit dose of a compound, or a composition provided herein, or a second agent, or composition, can include a dosage such that when administered to a subject, a therapeutically, or prophylactically effective plasma level of the compound, or composition can be maintained in the subject for at least one day. In some embodiments, a compound, or composition can be included as a sterile aqueous pharmaceutical composition, or dry powder (e.g., lyophilized) composition.

[00526] In some embodiments, suitable packaging is provided. As used herein, "packaging" includes a solid matrix, or material customarily used in a system, and capable of holding within fixed limits a compound provided herein, and/or a second agent suitable for administration to a subject. Such materials include, glass, and plastic (e.g., polyethylene, polypropylene, and polycarbonate) bottles, vials, paper, plastic, plastic-foil laminated envelopes, and the like. If e-beam sterilization techniques are employed, the packaging should have sufficiently low density to permit sterilization of the contents.

Preparation and Synthetic Procedures

[00527] In some embodiments, the compounds described herein are prepared as outlined in **Schemes 1-4**. The synthesis of the compounds in this application is not limited to these general reaction schemes illustrated here. For detailed synthesis of each individual compound, please check the Examples section.

Scheme 1



[00528] **Scheme 1.** (zero, one, or two of B^1, B^2, B^3, and B^4 are N, and the rest are CH). Alcohol **8a′** can be used to synthesize **8b′** through Mitsunobu reaction with an alcohol (e.g., phenol), or converted to a mesylate followed by alkylation with a phenol, or coupling with aryl halide through Buchwald reaction to form **8b′**. Reduction of the ester group in **8b′** to afford alcohol **8c′**. Then through Mitsunobu reaction with a phenol or mesylate formation of **8c′** followed by alkylation with a phenol to provide **8d′**. Deprotection of the Boc group with TFA, followed by coupling with **1h** (methyl 2-(chloromethyl)-3-[[(2S)-oxetan -2-yl] methyl] benzimidazole-5-carboxylate)and hydrolysis to afford **8e′**.

Scheme 2



[00529] **Scheme 2.** **9a′** can be synthesized from **8a′** through alkylation. Palladium-catalyzed carbonylation would afford ester **9b′**, which can be reduced to provide alcohol **9c′**. Mesylation formation of alcohol **9c′** followed by alkylation with a phenol can provide **9d′**. Deprotection of the Boc group with TFA, followed by coupling with **1h** and hydrolysis to afford **9e′**.

Scheme 3



[00530] **Scheme 3.** (zero, one, or two of B^1, B^2, B^3, and B^4 are N, and the rest are CH).

Reduction of compound **10a'** resulted in an alcohol **10b'**, which can be coupled with a phenol through alkylation of a mesylate intermediate of **10b'**, a Mitusnobu reaction or alkylation of **10b'** with an alpha-halopyridine to generate **10c'**. Then **10d'** can be synthesized from **10c'** through a Buchwald reaction of Boc-protected piperidine alcohol (when X= Cl or Br) or alkylation through a mesylate intermediate of the alcohol or a Mitsunobu reaction (X = OR, after deprotection). After removal of the Boc group in **10d'** with TFA or HCl, coupling with ester **1h** or its analogs followed by hydrolysis led to final product **10e'**.

Scheme 4



[00531] **Scheme 4.** (zero, one, or two of B^1, B^2, B^3, and B^4 are N, and the rest are CH). Sometimes compounds can be made from **11a'**. HATU or T_3P-mediated coupling of **11a'** with **1g** or its analogs results in **11b'**. Heating of **11b'** in acetic acid cyclizes **11b'** into a benzimidazole ester intermediate which was hydrolyzed with LiOH to afford **11c'**.

EXAMPLES

[00532] ***Preparation of the Compounds***

[00533] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals, and/or from compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources such as Acros Organics (Pittsburgh, PA), Advanced ChemBlocks, Inc (Burlingame, CA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), AK Scientific (Union City, CA), AstaTech, Inc. (Bristol, PA), Aurum Pharmatech LLC (Franklin Park, NJ), Combi-Blocks, Inc. (San Diego, CA), Enamine (Monmouth Jct., NJ), Fisher Scientific Co. (Pittsburgh, PA), Frontier Scientific (Logan, UT), TCI America (Portland, OR), and VWR

(Radnor, PA). Specific and analogous reactants are optionally identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases.

[00534] Suitable reference books that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe their preparation, include for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; "T. L. Gilchrist, "Heterocyclic Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; and J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New York, 1992; R. C. Larock "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; "Organic Reactions" (1942-2000) John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, in 73 volumes. Some compounds require the application of protecting groups. The need for such protection is within the skill in the art. For a general description of protecting groups and their use, see T.W. Greene, P.G.M. Nuts, and Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1999.

[00535] ***Analytical Methods and Instrumentation***

[00536] Proton nuclear magnetic resonance (NMR) spectra were obtained on either Bruker, or Varian spectrometers at 400, or 600 MHz. NMR spectra are reported relative to residual solvent signals as follows: chemical shift δ (ppm), multiplicity, coupling constant *J* (Hz), and integration. Tetramethylsilane (TMS) was used as an internal standard in some of the cases. Mass spectral data were measured using one of the two following systems: System A: Waters Acquity i-class ultra-performance liquid chromatography (UPLC) system with Acquity Photo Diode Array Detector, Acquity Evaporative Light Scattering Detector (ELSD) and Waters ZQ Mass Spectrometer. Data was acquired using Waters MassLynx 4.1 software and purity characterized by UV wavelength 220 nm, evaporative light scattering detection (ELSD) and electrospray positive ion (ESI) (column: Acquity UPLC BEH C18 1.7 μ ι 2.1 x 50 mm). System B: Agilent LC/MS consisting of a 1200 series LC and 6140 Quadrupole MS detector (column: Agilent USGYL01131, HPH-C18 2.7 μM, 2.1 x 50 mm). Solvents used: acetonitrile/water, containing 0.1% formic acid; flow rate 0.7 mL/min. Preparatory HPLC purifications were conducted with a flow rate of 15 mL/min and detection by UV wavelength 214 nm and 254 nm (Column: Jupiter© 10 μM Proteo 90 Å, 250 x 21.2 mm A, solvent:

acetonitrile/water, containing modifier such as 0.1% trifluoroacetic acid, formic acid or acetic acid). Compound purity was checked on an analytical HPLC (Waters Acquity UPLC H-Class instrument), with a flow rate of 0.5 mL/min (Acquity BEH C18, 50x2.1 mm column).

[00537] Abbreviations *used in the examples include:*

Abbreviation	Name
CH_3CN	acetonitrile
aq.	aqueous
atm	atmospheres
BINAP	(1,1′-binaphthalene-2,2′-diyl)bis(diphenylphosphine)
Boc	*t*-butoxycarbonyl
CCl_4	carbon tetrachloride
$CDCl_3$	deuterated chloroform
CO	carbon monoxide gas
CO_2	carbon dioxide
Cs_2CO_3	cesium carbonate
CuBr	copper(I) bromide
$Cu(OAc)_2$	copper(II) acetate
DCM	dichloromethane
DEAD	diethyl azodicarboxylate
DIPEA	diisopropylethylamine
DMF	*N*,*N*-dimethylformamide
DMSO	dimethylsulfoxide
ESI	electrospray ionization
Et_3N	triethylamine
EtOAc	ethyl acetate
EtOH	ethanol
h	hours
H_2O	water
HATU	1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
HCl	hydrochloric acid
HOAc	acetic acid
K_2CO_3	potassium carbonate
KI	potassium iodide
KOH	potassium hydroxide
KOtBu	potassium *tert*-butoxide
$LiAlH_4$	lithium aluminum hydride
LiOH	lithium hydroxide
MeOH	methanol
min	minutes
N_2	nitrogen
Na_2CO_3	sodium carbonate
Na_2SO_4	sodium sulfate
NaH	sodium hydride
$NaHCO_3$	sodium bicarbonate

Abbreviation	Name
NaN_3	sodium azide
NaOH	sodium hydroxide
NBS	*N*-bromosuccinimide
NH_4Cl	ammonium chloride
NH_4HCO_3	ammonium bicarbonate
NMR	nuclear magnetic resonance
$Pd_2(dba)_3$	tris(dibenzylideneacetone)dipalladium(0)
$Pd(dppf)Cl_2$	[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
Pd/C	palladium on carbon
$Pd(OAc)_2$	palladium(II) acetate
Prep-TLC	preparatory thin layer chromatography
RuPhos-Pd-G2	chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)
sat.	**saturated**
t-BuOH	*tert*-butanol
T_3P	propylphosphonic anhydride
TBD	1,5,7-triazabicyclo[4.4.0]dec-5-ene
TFA	trifluoracetic acid
THF	tetrahydrofuran

[00538] Unless otherwise noted, reagents, and solvents were used as received from commercial suppliers. Anhydrous solvents and oven-dried glassware were used for synthetic transformations sensitive to moisture, and/or oxygen. Reaction times, and yields were not optimized. Example numbers and compound numbers are the same.

Examples

[00539] Example 552. 2-{[(3R,4S)-4-({2-[(4-Cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-3-fluoropiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



552

[00540] Example **552** was synthesized from *tert*-butyl (3*R*,4*S*)-3-fluoro-4-hydroxypiperidine-1-carboxylate as described for **Example 599**.

[00541] Example 553. 2-{[(3S,4S)-4-({2-[(4-Cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-3-fluoropiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



553

[00542] Example **553** was synthesized according to **Example 599**.

[00543] Example 554. 2-(((2S,4S)-4-((2-(((5-Chloro-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylic acid (554).



554

[00544] Step A. *tert*-Butyl (2*S*,4*S*)-4-((2-(((5-chloro-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidine-1-carboxylate (554a).



355c **554a**

[00545] To a stirred solution of **606e** (50 mg, 0.15 mmol) in THF (2 mL) under nitrogen at 0 °C was added NaH (25 mg, 0.62 mmol, 60% dispersion in mineral oil). The reaction was stirred at 0 °C for 1H and 5-chloro-2,3-difluoropyridine (35 mg, 0.23 mmol) was added. After heating at 50 °C for 2H, the reaction was quenched with ice-water (10 mL) and extracted with EtOAc (30 mL x 3). The organic layer was washed with water (15 mL), brine (15 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to provide a crude residue, which was purified by silica gel column chromatography (EtOAc:petroleum ether = 1:4) to afford the title product (**554a**) (56 mg, 76% yield). *m/z* (ESI, +ve ion) = 453.1 $[M+H]^+$.

[00546] Step B. 2-(((5-Chloro-3-fluoropyridin-2-yl)oxy)methyl)-4-(((2*S*,4*S*)-2-methylpiperidin-4-yl)oxy)pyrimidine (554b).



554a 554b

[00547] A solution of **554a** (35 mg, 0.07 mmol) in 4 N HCl in dioxane (2 mL) was stirred at 20 °C for 2H. After completion, the reaction was diluted with H_2O (15 mL) and extracted with EtOAc (20 mL x 3). The organic layer was dried, filtered, and concentrated to afford the title product (**554b**) (crude, 27 mg), which was used in the next step without further purification. *m/z* (ESI, +ve ion) = 353.1 $[M+H]^+$.

Step C. Methyl 2-(((2*S*,4*S*)-4-((2-(((5-chloro-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylate (554c).



554b 554c

[00548] A solution of **554b** (50 mg, 0.14 mmol), methyl 2-(chloromethyl)-3-[[(2S)-oxetan -2-yl] methyl] benzimidazole-5-carboxylate (50 mg, 0.17 mmol), K_2CO_3 (59 mg, 0.43 mmol) and potassium iodide (24 mg, 0.14 mmol) in DMF (2 mL) was stirred at 50 °C for 4 h. The reaction was quenched with ice-water (10 mL) and extracted with EtOAc (30 mL x 3). The combined organic layer was washed with water (15 mL), brine (15 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to provide a crude residue, which was purified by silica gel column chromatography (MeOH:DCM = 1:20) to afford the title product (**554c**) (65 mg, 90% yield). *m/z* (ESI, +ve ion) = 611.2 $[M+H]^+$.

[00549] Step D. 2-(((2S,4S)-4-((2-(((5-Chloro-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylic acid (554).



554c 554

[00550] To a solution of **554c** (45 mg, 0.07 mmol) in MeOH (1 mL) stirred at 20 °C was added a solution of LiOH (35 mg, 1.47 mmol) in H_2O (1 mL). The reaction was stirred at 20 °C for 5 h. After completion, 1 N HCl (about 2.0 mL) was added to the mixture to adjust to pH = 6 in an ice bath. The reaction mixture was then extracted with EtOAc (15 mL x 3). The combined organic layer was dried, filtered, concentrated and purified by silica gel column chromatography (MeOH:DCM = 1:10) afford the title product **(554)** (36 mg, 78% yield). *m/z* (ESI, +ve ion) = 597.2 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ ppm 8.37 (d, 1H), 8.29 (s, 1H), 7.98 (brd, 1H), 7.82 (d, 1H), 7.73 - 7.76 (m, 1H), 7.68 (d, 1H), 6.65 (d, 1H), 5.57 (s, 2H), 5.22 - 5.34 (m, 1H), 4.89 - 4.95 (m, 1H), 4.80 - 4.83 (m, 1H), 4.71 (dd, 1H), 4.57 - 4.64 (m, 2H), 4.30 (dt, 1H), 3.56 (d, 1H), 2.66 - 2.78 (m, 2H), 2.32 - 2.49 (m, 2H), 2.08 - 2.17 (m, 1H), 1.89 - 1.98 (m, 1H), 1,71 - 1.78 (m, 1H), 1.37 - 1.53 (m, 2H), 1.20 (d, 3H).

[00551] Examples 566. 2-{[(2S,4S)-4-[(2-{[(3,5-Difluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid



566; and

[00552] Example 567. 2-{[(2S,4S)-4-[(2-{[(5-Cyanopyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



567

[00553] **Example 566** and **567** were synthesized in similar procedures as described in Example **554**.

[00554] **Examples 573. 2-{[(2S,4S)-4-({2-[(2-Cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-7-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.**



573; and

[00555] **Example 574. 2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-imidazo[4,5-c]pyridine-6-carboxylic acid.**



574

[00556] **Examples 573** and **574** were prepared similarly to to **Example 606**.

[00557] **Example 555. 2-(((2*R*,4*S*)-4-((2-((4-Chloro-2-fluorophenoxy)methyl)pyridin-4-yl)oxy)-2-(fluoromethyl)piperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylic acid (555).**



555

[00558] **Step A. 4-(Benzyloxy)-2-((4-chloro-2-fluorophenoxy)methyl)pyridine (555a).**



555a

[00559] Methyl 4-(benzyloxy)picolinate was first reduced to (4-(benzyloxy)pyridin-2-yl)methanol with sodium borohydride. The title compound **555a** was synthesized from the mesylate of (4-(benzyloxy)pyridin-2-yl)methanol and 4-chloro-2-fluorophenol using K_2CO_3 in the second step. *m/z* (ESI, +ve ion) = 344.1 $[M+H]^+$.

[00560] **Step B. 2-((4-Chloro-2-fluorophenoxy)methyl)pyridin-4-ol (555b).**



555a 555b

[00561] A mixture of **555a** (300 mg, 0.87 mmol) in TFA (10 mL) was stirred at 80 °C for 16 h under N_2. After completion, the mixture was concentrated *in vacuo*. The residue was diluted with EtOAc (30 mL), washed with aq. $NaHCO_3$ (10 mL), H_2O (10 mL), and brine (10 mL). The organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to afford the title product (**555b**) (200 mg, 86% yield). *m/z* (ESI, +ve ion) = 254.2 $[M+H]^+$.

[00562] **Step C. 1-(*tert*-Butyl) 2-methyl (2*R*,4*S*)-4-((2-((4-chloro-2-fluorophenoxy)methyl)pyridin-4-yl)oxy)piperidine-1,2-dicarboxylate (555c).**



555b 555c

[00563] The title compound **555c** was synthesized from the mesylate of 1-*tert*-butyl 2-methyl (2*R*,4*R*)-4-hydroxypiperidine-1,2-dicarboxylate and **555b** using K_2CO_3 in the second step. *m/z* (ESI, +ve ion) = 495.1 $[M+H]^+$.

[00564] **Step D. *tert*-Butyl (2*R*,4*S*)-4-((2-((4-chloro-2-fluorophenoxy)methyl)pyridin-4-yl)oxy)-2-(hydroxymethyl)piperidine-1-carboxylate (555d).**



555c 555d

[00565] To a solution of **555c** (240 mg, 0.48 mmol) in THF (10 mL) was added DIBAL-H (2.4 mL, 2.4 mmol, 1 M in hexanes) at 0 °C. The reaction was stirred at 20 °C for 3H under N_2. After completion, it was quenched with $Na_2SO_4 \cdot 10H_2O$ (1 g), filtered and concentrated *in vacuo* to afford the title product (**555d**) (200 mg, 80% yield) as a colorless oil. *m/z* (ESI, +ve ion) = 467.2 $[M+H]^+$.

[00566] **Step E. ((2*R*,4*S*)-4-((2-((4-Chloro-2-fluorophenoxy)methyl)pyridin-4-yl)oxy)piperidin-2-yl)methanol (555e).**



[00567] To a solution of **555d** (200 mg, 0.43 mmol) in DCM (8 mL) was added TFA (2 mL) at 0 °C. The reaction was stirred at 20 °C for 2H under N_2. After completion, the reaction mixture was concentrated *in vacuo* to afford the title product (**555e**) (160 mg, 92% yield) as a colorless oil. *m/z* (ESI, +ve ion) = 367.1 $[M+H]^+$.

[00568] **Step F. Methyl 2-(((2*R*,4*S*)-4-((2-((4-chloro-2-fluorophenoxy)methyl)pyridin-4-yl)oxy)-2-(hydroxymethyl)piperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylate (555f).**



[00569] To a solution of **555e** (180 mg, 0.49 mmol) and **1h** (144 mg, 0.49 mmol) in CH_3CN (10 mL) was added K_2CO_3 (203 mg, 1.5 mmol) at 20 °C. The mixture was stirred at 50 °C for 16 h under N_2. After completion, the reaction was quenched with H_2O (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layer was washed with H_2O (10 mL), brine (10 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a crude residue, which was purified by silica gel column chromatography (MeOH:DCM = 1:20) to afford the title product (**555f**) (100 mg, 31% yield) as a yellow oil. *m/z* (ESI, +ve ion) = 625.2 $[M+H]^+$.

[00570] **Step G. Methyl 2-(((2*R*,4*S*)-4-((2-((4-Chloro-2-fluorophenoxy)methyl)pyridin-4-yl)oxy)-2-(**fluoromethyl**)piperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylate (555g).**



[00571] To a solution of **555f** (80 mg, 0.13 mmol) in DCM (5 mL) was added DAST (41

mg, 0.26 mmol) at 0 °C. The reaction was stirred at 20 °C for 4 h under N_2. After completion, the mixture was quenched with H_2O (5 mL) and extracted with DCM (5 mL x 3). The combined organic layer was washed with H_2O (5 mL), brine (5 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a crude residue, which was purified by silica gel column chromatography (DCM: MeOH = 20:1) to afford the title product **(555g)** (50 mg, 56% yield) as a colorless oil. *m/z* (ESI, +ve ion) = 627.2 $[M+H]^+$.

[00572] Step H. 2-(((2*R*,4*S*)-4-((2-((4-Chloro-2-fluorophenoxy)methyl)pyridin-4-yl)oxy)-2-(fluoromethyl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[*d*]imidazole-6-carboxylic acid (555).



[00573] To a mixture of **555g** (40 mg, 0.064 mmol) in THF/H_2O (1:1, 4 mL) was added LiOH (7.6 mg, 0.32 mmol) at 20 °C. After stirring at 20 °C for 16 h under N_2, the mixture was adjusted to pH = 7 with 1 N HCl and extracted with EtOAc (5 mL x 3). The combined organic layer was washed with H_2O (5 mL), brine (5 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a crude residue, which was purified by reverse phase HPLC (30% CH_3CN in H_2O, with 0.05% $NH_3{\cdot}H_2O$ as a modifier) to afford the title product **(555)** (10 mg, 25% yield). *m/z* (ESI, +ve ion) = 613.2 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ ppm 8.33 (d, 1H), 8.16 (s, 1H) 7.94 (d, 1H) 7.58 (d, 1H), 7.19 - 7.27 (m, 1H), 7.07 - 7.18 (m, 3H), 6.96 (dd, 1H), 5.24 - 5.33 (m, 1H), 5.16 (s, 2H), 4.89 - 4.96 (m, 1H), 4.56 - 4.74 (m, 4H), 4.32 (dt, 1H), 3.78 (brd, 1H), 2.80 - 2.94 (m, 3H), 2.67 - 2.80 (m, 2H), 2.36 - 2.53 (m, 2H), 2.11 - 2.23 (m, 1H), 1.97 - 2.05 (m, 1H), 1.72 - 1.84 (m, 1H), 1.56 - 1.70 (m, 1H).

[00574] Examples 575. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(3R)-oxolan-3-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



575; and

[00575] Example 584. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(3S)-oxolan-3-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



584

[00576] Examples 575 and **584** were were prepared in a manner similar to **Example 577**.

[00577] Example 580. 2-{[4-({2-[(4-Cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)piperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-imidazo[4,5-c]pyridine-6-carboxylic acid.



580

[00578] Example **580** was synthesized in a manner similar to **Example 606**.

[00579] **Examples 578. 2-{[(2S,4S)-4-({2-[(4-Cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(3S)-oxolan-3-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.**



578; and

[00580] **Example 579. 2-{[(2S,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxolan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.**



579

[00581] Example **578** and **579** were synthesized in similar procedures as described in Example **555**, with NaI added at the second to last step.

[00582] **Example 556. 2-(((2*S*,4*S*)-4-((2-((2-Cyano-4-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-imidazo[4,5-*b*]pyridine-6-carboxylic acid (556).**



556

[00583] **Step A. Methyl 2-(((2*S*,4*S*)-4-((2-((2-cyano-4-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-imidazo[4,5-*b*]pyridine-6-carboxylate (556b).**



556a 556b

[00584] To a mixture of **556a** (synthesized similarly as **Example 599** (18 mg, 0.029 mmol) in DMSO/MeOH (1:1, 3 mL) was added $Pd(dppf)Cl_2$ (2 mg, 0.003 mmol) and triethylamine (9 mg, 0.087 mmol) at 20 °C. The reaction was heated at 80 °C for 12H under CO. After completion, the reaction was quenched with H_2O (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layer was washed with H_2O (10 mL), brine (10

mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford the title product (**556b**) (21 mg, 84% yield) as a brown oil. *m/z* (ESI, +ve ion) = 602.2 $[M+H]^+$.

[00585] Step B. 2-(((2*S*,4*S*)-4-((2-((2-Cyano-4-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-imidazo[4,5-*b*]pyridine-6-carboxylic acid (556).



[00586] To a mixture of **556b** (20 mg, 0.033 mmol) in THF/H_2O (1:1, 2 mL) was added lithium hydroxide (8 mg, 0.332 mmol) at 20 °C. After stirring for 5 h, the mixture was quenched by 1 N HCl (5 mL), adjusted to pH = 6 and extracted with EtOAc (10 mL x 3). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated to afford a crude residue which was purified by reverse phase HPLC (15% CH_3CN in H_2O with 0.1% NH_3H_2O as a modifier) to afford the title product (**556**) (7.7 mg, 39% yield). *m/z* (ESI, +ve ion) = 588.2 $[M+H]^+$. ^1H NMR (400 MHz, CD_3OD) δ ppm 9.06 (d, 1H), 8.49 - 8.58 (m, 1H), 8.41 (d, 1H), 7.52 (dd, 1H), 7.27 - 7.39 (m, 1H), 7.14 (dd, 1H), 6.70 (d, 1H), 5.38 (s, 2H), 5.23 - 5.33 (m, 1H), 4.90 - 5.03 (m, 2H), 4.71 - 4.81 (m, 1H), 4.52 - 4.66 (m, 2H), 4.34 (dt, 1H), 3.66 (d, 1H), 2.69 - 2.84 (m, 2H), 2.39 - 2.53 (m, 2H), 2.20 - 2.31 (m, 1H), 1.93 - 2.02 (m, 1H), 1.84 - 1.93 (m, 1H), 1.52 - 1.65 (m, 1H), 1.39 - 1.52 (m, 1H), 1.20 (d, 3H).

[00587] Example 557. 2-{[(2S,4S)-4-({2-[(2-Chloro-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-(cyanomethyl)piperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



557

[00588] Example **557** was prepared in a manner similar to **Example 555f**, followed by

fluoromethyl to cyanomethyl conversion with NaCN, DMF, 50 °C for 8 h, then Step B in Example **556**.

[00589] Example 558. 2-{[(2S,4S)-4-({2-[(2-Cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(3R)-oxolan-3-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



558

[00590] Example 558 was prepared in a manner similar to **Example 599**.

[00591] Example 559. 2-(((2*S*,4*S*)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-*N*-hydroxy-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxamide (559).



559

[00592] Step A. 2-(((2*S*,4*S*)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-*N*-hydroxy-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxamide (559).



559a **559**

[00593] To a THF (3 mL) solution of **559a** (prepared in a manner similar to **Example 599**)

(30 mg, 0.052 mmol), was added CDI at 0 °C and stirred for 30 min at room temperature. After cooling to 0 °C, hydroxyl amine hydrochloride salt (5.4 mg, 0.052 mmol) was added and the reaction was stirred at room temperature for 3H. 1 mL water was added, followed by addition of 15 mg DMAP and more hydroxyl amine hydrochloride. The reaction was stirred overnight, quenched with brine and extracted with ethyl acetate (3 x). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography with methanol in DCM to provide the title product (**559**) (7 mg, 22.7% yield). *m/z* (ESI, +ve ion) = 595.2 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ ppm 8.41 (d, 1H), 8.01 (s, 1H), 7.69 (d, 1H), 7.54 - 7.56 (m, 1H), 6.85 - 6.96 (m, 2H), 6.71 - 6.75 (m,1H), 6.56 (d, 1H), 5.20 - 5.25 (m, 3H), 5.01 - 5.08 (m, 1H), 4.91 (d, 1H), 4.50 - 4.61 (m, 3H), 4.28 - 4.31 (m,1H), 3.58 (d, 1H), 2.77 - 2.80 (m, 1H), 2.67 - 2.69 (m, 1H), 2.38 - 2.45 (m, 2H), 2.25 (t, 1H), 2.02 - 2.05 (m,1H), 1.89 - 1.92 (m, 1H), 1.55 - 1.59 (m, 1H), 1.42 - 1.51 (m, 1H), 1.20 (d, 3H).

[00594] Example 560. 2-{[(2S,4S)-4-({2-[(2-Cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-N-hydroxy-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxamide.



560

[00595] Example **560** was synthesized in similar procedures as Example **559**, with DIPEA as the base.

[00596] Example 561 2-{[(2S,4S)-4-({2-[(2-Cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2R)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



561; and

[00597] Example 562. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2R)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



562

[00598] Examples **561** and **562** were prepared in a manner similar to **Example 599**.

[00599] Example 563. 2-(((2*S*,4*S*)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-*N*-(methylsulfonyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxamide (563).



563

Step A. 2-(((2*S*,4*S*)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-*N*-(methylsulfonyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxamide (563).



559a **563**

[00600] A solution of **Compound 559a** (prepared as described in **Example 599**)(30 mg, 0.052 mmol) was dissolved in anhydrous DCM. $CH_3SO_2NH_2$ (14.8 mg, 0.16 mmol), DMAP (19.1 mg, 0.16 mmol) and DCC (32 mg, 0.16 mmol) were added to the reaction mixture. After stirring at room temperature overnight, the reaction was quenched with brine and extracted with DCM (3 x). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The crude residue was purified by silica gel

column chromatography with methanol in DCM to provide the title compound (**563**) (23 mg, 68% yield). *m/z* (ESI, +ve ion) = 657.2 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$) δ ppm 8.41 (d, 1H), 8.06 (s, 1H), 7.74 (s, 2H), 6.85 - 6.96 (m, 2H), 6.71 - 6.76 (m, 1H), 6.56 (d, 1H), 5.22 - 5.25 (m, 3H), 5.03 - 5.08 (m, 1H), 4.89 - 4.93 (m, 1H), 4.48 - 4.65 (m, 3H), 4.30 - 4.35 (m, 1H), 3.62 (d, 1H), 3.43 (s, 3H), 2.82 - 2.83 (m, 1H), 2.67 - 2.74 (m, 1H), 2.42 - 2.64 (m, 2H), 2.28 - 2.34 (m, 1H), 2.04 - 2.07 (m, 1H), 1.93 - 1.95 (m, 1H), 1.57 - 1.61 (m, 1H), 1.43 - 1.52 (m, 1H), 1.20 (d, 3H).

[00601] Example 564. N-(Cyclopropanesulfonyl)-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxamide.



564

[00602] Example **564** was synthesized in similar procedures as Example **563**.

[00603] Example 565. 2-(1-(4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)ethyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylic acid (565).



565

[00604] Step A. *tert*-Butyl 2-(4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)propanoate (565b).



565a **565b**

[00605] Example **565a** (22 mg, 0.069 mmol) and *tert*-butyl 2-bromopropanate (21.5 mg, 0.069 mmol) were dissolved in anhydrous DMF. DIPEA (0.036 mL, 0.069 mmol) was added to the reaction mixture. The reaction was heated at 60 °C for 2H, quenched with brine and extracted with EtOAc (3 x). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The crude reaction mixture was purified by silica gel column chromatography with EtOAc in hexanes to provide the title product (**565b**) (20 mg, 65% yield). *m/z* (ESI, +ve ion) = 450.3 $[M+H]^+$.

[00606] **Step B. 2-(4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)propanoic acid (565c).**



[00607] The title compound **565c** was synthesized as Step E in Example **555**. *m/z* (ESI, +ve ion) = 394.4 $[M+H]^+$.

[00608] **Step C. Methyl 4-(2-(4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)propanamido)-3-((((*S*)-oxetan-2-yl)methyl)amino)benzoate (565d).**



[00609] **565c** (19 mg, 0.048 mmol) was dissolved in anhydrous DMF and added DIPEA (0.025 mL, 0.15 mmol). After 5 min, HATU (36.7 mg, 0.097 mmol) was added, followed by dropwise addition of a DMF solution of **1g** (12.6 mg, 0.053 mmol). After stirring at room temperature overnight, the reaction was quenched with water and extracted with EtOAc (5 mL x 3). The combined organic layer was dried over anhydrous Na_2SO_4, filtered,

concentrated and purified by silica gel column chromatography to afford the title product (**565d**) (14 mg, 47% yield). *m/z* (ESI, +ve ion) = 612.3 $[M+H]^+$.

[00610] Step D. Methyl 2-(1-(4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)ethyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylate (565f).



[00611] **565d** (14 mg, 0.023 mmol) was dissolved in acetic acid (1 mL) and heated at 60 °C overnight. The acetic acid in the reaction was removed under reduced pressure. Then the reaction was quenched with sat $NaHCO_3$ and extracted with EtOAc (5 mL x 3). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated to provide the title product (**565f**), which was used in the next step without further purification. *m/z* (ESI, +ve ion) = 594.3 $[M+H]^+$.

[00612] Step E. 2-(1-(4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)ethyl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylic acid (565).



[00613] The title compound (**565**) was synthesized in similar procedures as described in Example **554**, Step D, with THF/MeOH/H2O (6:1:1) as solvent. *m/z* (ESI, +ve ion) = 580.3 $[M+H]^+$.

[00614] Example 568. 2-{1-[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]ethyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



568; and

[00615] Example 569. 2-{1-[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]ethyl}-1-[(2S)-2,4-dihydroxybutyl]-1H-1,3-benzodiazole-6-carboxylic acid.



569

[00616] **Example 568** was synthesized in similar procedures as described in Example **565**. Example **569** was the side product isolated from the last step of making **568**.

[00617] Example 570. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-({2-oxabicyclo[2.1.1]hexan-1-yl}methyl)-1H-1,3-benzodiazole-6-carboxylic acid.



570

[00618] **Example 570** was prepared in a manner similar to **Example 577**.

[00619] Example 571. 2-(6-((2-((4-Cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)spiro[2.5]octan-1-yl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[d]imidazole-6-carboxylic acid (571).



571

[00620] Step A. Methyl 2-(4-((*tert*-butyldiphenylsilyl)oxy)cyclohexylidene)acetate (571a).



571a

[00621] *t*-BuOK (2.27 g, 20.2 mmol) was added to a solution of methyl 2-(diethoxyphosphoryl)acetate (4.26 g, 20.2 mmol) in THF (30 mL) at 0 °C. After stirring at 0 °C for 1H, the reaction was cooled to –50 °C. A solution of 4-[(*tert*-butyldiphenylsilyl)oxy]cyclohexan-1-one (5.5 g, 15.6 mmol) in THF (30 mL) was added dropwise at –50°C, and the reaction mixture was allowed to slowly warm to 20 °C, and stirred for 16 h. After completion, the reaction was quenched with H_2O (50 mL) and extracted with EtOAc (50 mL x 3). The cobmined organic layer was washed with H_2O (50 mL), brine (50 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a crude residue, which was purified by silica gel column chromatography (petroleum ether:EtOAc = 20:1) to afford the title product **(571a)** (4.1 g, 60.9% yield) as a yellow oil. *m/z* (ESI, +ve ion) = 431.1 $[M+Na]^+$.

[00622] Step B. Methyl 6-((*tert*-butyldiphenylsilyl)oxy)spiro[2.5]octane-1-carboxylate (571b).



571a 571b

[00623] A solution of *t*-BuOK (0.48 g, 4.3 mmol) was added to a solution of trimethylsulfoxonium iodide (0.95 g, 4.3 mmol) in DMSO (5 mL). The mixture was stirred at 20 °C for 1H. A solution of **571a** (1.0 g, 2.4 mmol) in DMSO (5 mL) was added at 20 °C, and the reaction was stirred for 23H. After completion, the reaction was diluted with H_2O (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layer was washed with H_2O (30 mL), brine (30 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to provide a crude residue, which was purified by reverse phase HPLC (CH_3CN in

H_2O, with 0.1%TFA as a modifier) to afford the title product (**571b**) (200 mg, 16.7% yield) as a yellow oil. *m/z* (ESI, +ve ion) = 445.1 $[M+Na]^+$.

[00624] Step C. Methyl 6-hydroxyspiro[2.5]octane-1-carboxylate (571c).



[00625] A solution of **571b** (1.2 g, 2.8 mmol) and NH_4F (1.04 g, 28.0 mmol) in MeOH (10 mL) was heated at 70 °C for 16 h. After completion, the reaction was quenched with H_2O (5 mL) and extracted with EtOAc (10 mL x 3). The organic layer was washed with H_2O (10 mL), brine (10 mL), dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* to give a crude residue, which was purified by reverse phase HPLC (CH_3CN in H_2O, with 0.1%TFA as a modifier) to afford the title product (**571c**) (52.3 mg) with some impurity. *m/z* (ESI, +ve ion) = 185.1 $[M+H]^+$.

[00626] Step D. 2-(6-((2-((4-Cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)spiro[2.5]octan-1-yl)-1-(((*S*)-oxetan-2-yl)methyl)-1*H*-benzo[*d*]imidazole-6-carboxylic acid (571).



[00627] The title compound **571** was prepared as a pair of diastereomers from **571c** as described in Example **565**, *m/z* (ESI, +ve ion) = 584.3 $[M+H]^+$.

[00628] Example 590. 1-(Cyclobutylmethyl)-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



590; and

[00629] Example 591. 1-[(2S)-2-(Difluoromethoxy)propyl]-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-

benzodiazole-6-carboxylic acid.



591

[00630] **Examples 590** and **591** were synthesized from methyl 2-(4-hydroxycyclohexyl)acetate in similar procedures as Example **571**and were separated by reverse phase HPLC at the last step.

[00631] **Examples 572. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-5-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.**



572

[00632] **Example 576. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.**



576

[00633] **Example 582. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(3-fluorooxetan-3-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid.**



582

[00634] Example 583. 1-{[3-(difluoromethyl)oxetan-3-yl]methyl}-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



583

[00635] Example 585. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-5-methyl-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



585

[00636] Examples **572-576, 582-583, and 585** were synthesized from 2-((2,4-difluorophenoxy)methyl)-4-(((2*S*,4*S*)-2-methylpiperidin-4-yl)oxy)pyrimidine as described for **Example 606f, Step F,** and corresponding imidazole core was prepared by following synthetic procedure of **577d**.

[00637] Example 581 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]-5-fluoropyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



581

[00638] Example 586. 2-{[(2R,4R)-4-({2-[(4-Cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-ethylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



586

[00639] 2-{[(2S,4S)-4-({2-[(4-Cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-ethylpiperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



587

[00640] Example **581**, Example **586**,and Example **587** were synthesized in similar procedures as described in Example **599**. Examples **586** and **587** were chirally separated at the second to last step through SFC chiral separation.

[00641] Example 577. 2-(((2S,4S)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-((3R,4R)-4-methoxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylic acid (577).



577

[00642] Step A. Methyl 3-(((3R,4R)-4-methoxytetrahydrofuran-3-yl)amino)-4-nitrobenzoate (577b)



577a 577b

[00643] To a solution of **577a** (300 mg, 1.51 mmol) in THF (5.0 mL) was added [cis-4-methoxytetrahydro-3-furanyl]amine hydrochloride (231.0 mg, 1.51 mmol) and triethylamine (1.05 mL, 7.53 mmol) at room temperature. Reaction mixture was allowed to stir at 60 °C for 12H. Upon completion, it was cooled down to room temperature and diluted with EtOAc (20 mL) and water (10 mL). Organic layer was separated. The aqueous layer was extracted with EtOAc (20 mL x 3). The combined organic layer was washed with brine (5 mL), dried over Na_2SO_4, filtered and concentrated and the resulting crude residue was purified by silica gel column chromatography (gradient elution, 0-60% EtOAc/hexanes) to afford the product **577b** (363.0 mg, 81% yield) as a yellow oil. m/z (ESI, +ve ion) = 297.3 $[M+H]^+$.

[00644] Step B. Methyl 4-amino-3-(((3R,4R)-4-methoxytetrahydrofuran-3-yl)amino)benzoate (577c).



577b 577c

[00645] To a solution of **577b** (363.0 mg, 1.23 mmol) in methanol (12.3 mL) was added 10% Pd/C (261.0 mg). Reaction mixture was stirred at room temperature under a balloon of hydrogen for 12H. After completion, Pd/C was removed by filtration. The filtrate was concentrated to afford the crude product (**577c**) (310.0 mg) without further purification. m/z (ESI, +ve ion) = 267.3 $[M+H]^+$.

[00646] Step C. Methyl 2-(chloromethyl)-1-((3R,4R)-4-methoxytetrahydrofuran-3-

yl)-1H-benzo[d]imidazole-6-carboxylate (577d).



577c 577d

[00647] A suspension of **577c** (310.0 mg, 1.16 mmol), 2-chloro-1,1,1-trimethoxyethane (172 µL, 1.28 mmol) and TsOH (22.1 mg, 0.12 mmol) in acetonitrile (3.9 mL) was stirred at 60 °C for 2H. After completion, the reaction solvent was removed under reduced pressure and the resulting residue was purified by silica gel column chromatography (gradient elution, 40-80% EtOAc/hexanes) to afford product **577d** (300.0 mg, 79% yield). m/z (ESI, +ve ion) = 325.3 $[M+H]^+$.

[00648] Step D. Methyl 2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-((3R,4R)-4-methoxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate (577e).



577d 577e

[00649] A solution of **577d** (24.5 mg, 0.075 mmol), 2-[(2,4-difluorophenoxy)methyl]-4-{[(2S,4S)-2-methylpiperidin-4-yl]oxy}pyrimidine (25.3 mg, 0.075 mmol) and DIPEA (39.4 µL, 0.23 mmol) in DMF (0.3 mL) was stirred at 60 °C for 2H. After completion, the reaction mixture was diluted with EtOAc (5 mL). The organic layer was washed with water (3 mL x 2), brine (3 mL), dried over Na_2SO_4, filtered and concentrated and the resulting crude residue was purified by silica gel column chromatography (gradient elution, 0-10% MeOH/DCM) to afford the title product (**577e**) (41.2 mg, 88% yield) as a gummy oil. m/z (ESI, +ve ion) = 624.4 $[M+H]^+$.

[00650] Step E. 2-(((2S,4S)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-((3R,4R)-4-methoxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylic acid (577).



577d 577

[00651] A solution of **577d** (41.2 mg, 0.066 mmol) and LiOH (7.9 mg, 0.33 mmol) in THF: ^{i}PrOH: H_2O = 1:1:1 (0.6 mL) was stirred at 30 °C for 2H. After completion, the reaction solvent was removed under reduced pressure and the resulting residue was diluted with water to 1 mL and purified by reverse phase HPLC (gradient elution, 20-60% CH_3CN in H_2O, with 20 mM NH_4HCO_3 as a modifier) to afford the title product (**577**) (29.4 mg, 73% yield). ^{1}H NMR (400 MHz, DMSO-d_6) δ ppm 12.71 (s, 1H), 8.49 (d, 1H), 8.36 (d, 1H), 7.76 (d, 1H), 7.60 (d, 1H), 7.24 – 7.34 (m, 1H), 7.14 (td, 1H), 6.94 (brt, 1H), 6.80 (d, 1H), 5.42 – 5.77 (m, 1H), 5.30 (s, 2H), 4.82 – 4.93 (m, 1H), 4.52 – 4.68 (m, 1H), 4.05 – 4.38 (m, 4H), 3.94 – 4.03 (m, 1H), 3.76 – 3.91 (m, 1H), 2.88 – 2.97 (m, 3H), 2.55 – 2.78 (m, 1H), 2.26 – 2.47 (m, 1H), 2.00 – 2.11 (m, 1H), 1.79 – 1.99 (m, 1H), 1.26 – 1.54 (m, 2H), 1.07 – 1.24 (m, 3H); m/z (ESI, +ve ion) = 610.3 $[M+H]^+$.

[00652] **Example 588. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid (588)**.



588

[00653] **Step A. Methyl 4-nitro-3-((2-(2,2,2-trifluoroethoxy)ethyl)amino)benzoate (588c)**.



588a 588b 588c

[00654] To a stirred solution of compound **588a** (100 mg, 0.502 mmol) in anhydrous DMF, compound **588b** (108 mg, 0.603 mmol) followed by Et_3N (0.486 ml, 3.52 mmol) was

added under argon atmosphere. The reaction mixture was stirred at room temperature for overnight. The reaction mixture was quenched by addition of water (2 ml), the aqueous layer was extracted by ethyl acetate (3x5 ml). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The crude solid was washed with 20% ethyl acetate in hexane three times. The yellow solid was air dried and carried forward for the next step without further purification (162 mg, 99% yield); m/z (ESI, +ve ion) = 323.1 $[M+H]^+$.

[00655] Step B. Methyl 2-(chloromethyl)-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzo[d]imidazole-6-carboxylate (588e).



[00656] Compound **588c** (160 mg, 0.497) was dissolved in a mixture of solvents, EtOH:THF (5 ml, 1:1) then catalytic amount of Pd/C was added and stirred at room temperature under hydrogen atmosphere for 1.5 h. The reaction mixture was filtered, and solvent was removed under reduced pressure. The crude **588d** (145 mg, 91% yield) was pure enough for the next step; m/z (ESI, +ve ion) = 293.3 $[M+H]^+$. Crude **588d** (130 mg, 0.445 mmol) was dissolved in the anhydrous acetonitrile, 2-chloro-1,1,1, trimethoxyethane (0.066 ml, 0.489 mmol) followed PTSA (3.8 mg, 0.022 mmol) was added to the reaction mixture. The reaction mixture was heated to 60 ^{0}C for 2H. The reaction mixture was concentrated under reduced pressure and crude reaction mixture was purified using silica gel column chromatography to get compound **588e** (153 mg, 76% yield); m/z (ESI, +ve ion) = 351.1 $[M+H]^+$.

[00657] Step C. Methyl 2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzo[d]imidazole-6-carboxylate (588f).



[00658] To a solution of compound **588e** (prepared using a synthetic procedure as described for **599e**) (27 mg, 0.080 mmol) and compound **588d** (37 mg, 0.105) in anhydrous DMF, diisopropylethylamine (0.042 ml, 0.242 mmol) was added. The reaction mixture was heated to 60 ^{0}C for overnight. The reaction mixture was quenched with the addition of water, the aqueous layer was extracted with the ethyl acetate (3*5 ml). The combined organic layer was dried over anhydrous Na_2SO_4, filtered and concentrate under reduced pressure. The crude reaction mixture was purified by silica gel column chromatography to get pure compound **588f** (52 mg, 40% yield); m/z (ESI, +ve ion) = 650.3 $[M+H]^+$.

[00659] **Step D. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid**.



[00660] Compound **588f** (21 mg, 0.032 mmol) was dissolved in a mixture of solvents THF:CH_3OH:H_2O (5 ml, 6:1:1) and LiOH.H_2O (4 mg, 0.162 mmol) was added and stirred for 12H at room temperature. The reaction mixture was quenched with the addition of acetic acid to adjust the pH around 7.0. The reaction mixture was concentrated under reduced pressure and diluted with water. The aqueous layer was extracted with ethyl acetate (4*5 ml), the combined organic layer was dried over anhydrous Na_2SO_4 and concentrated under vacuum. The crude reaction mixture was purified using silica gel column chromatography to get pure **588** (21 mg, 68% yield); ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 8.44 (d, 1H), 8.22 (s, 1H), 8.11 (d, 1H), 7.86 (d, 1H), 6.97-6.85 (m, 2H), 6.76-6.71 (m, 1H), 6.57 (d, 1H), 5.24 (s, 2H), 5.11-4.99 (m, 2H), 4.57-4.51 (m, 2H), 4.07-3.98 (m, 2H), 3.81-3.72 (m, 2H), 3.63 (d, 1H), 2.80-2.77 (m, 1H), 2.52-2.46 (m, 1H), 2.32-2.26 (m, 1H), 2.08 (d, 1H), 1.94 (d, 1H), 1.62-1.45 (m,

2H), 1.27 (d, 3H); m/z (ESI, +ve ion) = 636.5 $[M+H]^+$.

[00661] Example 589. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-{[(2S)-oxolan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (589).



589

[00662] Example **589** was synthesized using the synthetic procedure of Example **579**. ^{1}H NMR (400 MHz, MeOD) δ 8.41 (d, 1H), 8.16 (s, 1H), 7.93 (dd, 1H), 7.56 (d, 1H), 7.10 – 6.97 (m, 2H), 6.85 – 6.78 (m, 1H), 6.71 (d, 1H), 5.25 (s, 2H), 5.07 – 4.99 (m, 1H), 4.86 – 4.69 (m, 1H), 4.56 – 4.45 (m, 2H), 4.42 – 4.32 (m, 1H), 3.86 (dd, 1H), 3.72 (dd, 1H), 3.57 (d, 1H), 2.78 (d, 1H), 2.45 (s, 1H), 2.28 – 2.17 (m, 1H), 2.16 – 2.05 (m, 1H), 2.05 – 1.98 (m, 1H), 1.95 – 1.79 (m, 3H), 1.74 – 1.53 (m, 2H), 1.47 (dd, 1H), 1.23 (d, 3H); m/z (ESI, +ve ion) = 594.2 $[M+H]^+$.

[00663] Example 590. 1-(Cyclobutylmethyl)-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (590).



590

[00664] Step A: Methyl 3-[(cyclobutylmethyl)amino]-4-nitrobenzoate (590c).



590a **590b** **590c**

[00665] To a solution of **590a** (2.34 g, 11.8 mmol) in THF (20 mL) was added **590b** (1.51g,17.7 mmol) and TEA (3.58 g, 35.4 mmol). The reaction was stirred at 20 °C for 16 h.

After completion, the mixture was diluted with H_2O (20 mL), extracted with ethyl acetate (50 mL*3). The combined organic layer was washed with brine (20 mL), dried over anhydrous Na_2SO_4 and filtered. The filtrate was concentrated under reduce pressure to give a residue. The residue was purified by flash column on silica gel (PE/EA =4:1) to afford **590c** (2.8 g, 89.5 % yield) as yellow solid; m/z (ESI, +ve ion) = 265.1 $[M+H]^+$.

[00666] Step B: methyl 4-amino-3-[(cyclobutylmethyl)amino]benzoate (590d).



590c **590d**

[00667] To a solution of **590c** (2.7 g, 10.2 mmol) in MeOH (30 mL) was added Pd/C (0.11 g,1 mol,0.1 eq). The reaction was stirred at 20 °C for 16 h under H_2 atmosphere. After completion, the mixture was filtered, and the filter cake was washed with methanol. The organic layers were concentrated under vacuum to give a residue. The residue was purified by flash column on silica gel (PE/EA =4:1) to afford **590d** (2.07 g, 86.2 % yield) as yellow solid; m/z (ESI, +ve ion) = 235.3 $[M+H]^+$.

[00668] Step C: Methyl 2-(chloromethyl)-3-(cyclobutylmethyl)-1,3-benzodiazole-5-carboxylate (590e).



590d **590e**

[00669] To a solution of **590d** (200 mg, 0.85 mmol) in ACN (2 mL) was added 2-chloro-1,1,1-trimethoxyethane (395.9 mg, 2.56 mmol) and PTSA (14.7 mg, 0.085 mmol). The mixture was stirred at 20 °C for 2H. After completion, the mixture was concentrated in vacuo to give a residue. The residue was purified by flash column on silica gel (PE/EA =2:1) to afford **590e** (245 mg, 98.7 % yield) as yellow solid; m/z (ESI, +ve ion) = 293.3 $[M+H]^+$.

[00670] Step D: Methyl 1-(cyclobutylmethyl)-2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (590f).



590e 590f

[00671] To a solution of compound **588e** (triflate salt which was prepared using the same procedure as **355f** (27 mg, 0.08 mmol), **590e** (24 mg, 0.08 mmol), K_2CO_3 (34 mg, 0.24 mmol) and KI (14 mg, 0.08 mmol) in CH_3CN (4 mL) was stirred at 20 °C for 16 h. After completion, the mixture was diluted with H_2O (10 mL), extracted with EtOAc (10 mL x 3). The organic layer was washed with H_2O (10 mL), brine (10 mL), dried over anhydrous Na_2SO_4, filtrated and concentrated and purified by flash column on silica gel (DCM : MeOH = 20 : 1) to afford product (30 mg, 60% yield) as yellow oil; m/z (ESI, +ve ion) = 592.2 $[M+H]^+$.

[00672] **Step E: 1-(Cyclobutylmethyl)-2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (590).**



590f 590

[00673] A solution of **590f** (30 mg, 0.05 mmol, 1.0 eq) and LiOH (6 mg, 0.25 mmol, 5.0 eq) in THF/H_2O = 1/1 (4 mL) was stirred at 20°C for 16 h. After completion, 1N HCl was added to the mixture to adjust pH to 5 in an ice bath. The reaction mixture was extracted with EtOAc (10 mL x 3). The organic layer was washed with H_2O (5 mL), brine (5 mL), dried over anhydrous Na_2SO_4, filtrated and concentrated in vacuo to give a residue. The residue was purified by Pre-HPLC (Mobile Phase: ACN-H_2O (0.1%NH_4OH)) to afford **590** (13.7 mg, 46% yield). ^1H NMR (400 MHz, DMSO) δ 8.49 (d, 1H), 8.05 (s, 1H), 7.77 (dd, 1H), 7.43 (d, 1H), 7.29 (ddd, 1H), 7.14 (td, 1H), 6.95 (dt, 1H), 6.79 (d, 1H), 5.31 (s, 2H), 4.91 – 4.82 (m, 1H), 4.45 (dd, 1H), 4.36 – 4.26 (m, 2H), 3.41 (s, 1H), 2.90 (dd, 1H), 2.73 – 2.67 (m, 1H), 2.36 (dd, 1H), 2.09 (t, 1H), 1.99 – 1.80 (m, 8H), 1.46 – 1.38 (m, 1H), 1.35 – 1.26 (m, 1H), 1.20 (d, 3H); m/z (ESI, +ve ion) = 578.2 $[M+H]^+$.

[00674] **Example 591. 1-[(2S)-2-(Difluoromethoxy)propyl]-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-**

benzodiazole-6-carboxylic acid (591).



591

[00675] Step A: Benzyl (S)-(2-(difluoromethoxy)propyl)carbamate (591b).



591a 591b

[00676] A mixture of **591a** (7 g, 33.45 mmol) and CuI (1.27 g, 6.69 mmol) in dry CH_3CN (70 mL) was degassed and purged with N_2 for 3 times. The mixture was heated to 65 °C. 2,2-difluoro-2-fluorosulfonyl-acetic acid (8.94 g, 50.18 mmol, 5.20 mL) in CH_3CN (70 mL) was added dropwise over 50 min at 65 °C. The mixture was stirred at 65 °C for another 10 min under N_2. After completion, the mixture was concentrated to give crude product. The crude product was diluted with ethyl acetate (20 mL), and then filtered through a Celite® pad, and the filtrate was concentrated to give crude product. The crude product was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Petroleum ether: Ethyl acetate =1:0~82: 18) to afford desired product **591b** (5.4 g, 62.26% yield) as colorless oil. m/z (ESI, +ve ion) = 260.2 $[M+H]^+$.

[00677] Step B. Methyl (S)-3-((2-(difluoromethoxy)propyl)amino)-4-nitrobenzoate (591c).



591b 591c

[00678] To a solution of **591b** (5 g, 19.29 mmol) in THF (50 mL) was added Pd/C (5 g, 50%w/w) under Ar. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (50 psi) at 40 °C for 5 h. After completion, the mixture was filtered through a Celite® pad, the filter cake was washed with THF (30 mL x 5). The filtrate was used for next step directly without work up. The crude amine was dissolved in THF (~200 mL) was obtained as a colorless liquid.

[00679] A mixture of amine (2.4 g, 19.18 mmol), methyl 3-fluoro-4-nitro-benzoate (3.82

g, 19.18 mmol), K_2CO_3 (7.95 g, 57.55 mmol) in THF (200 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 45 °C for 16 h under N_2 atmosphere. After completion, the mixture was filtered, and the filtrate was concentrated to give crude product. The product was diluted with ethyl acetate (50 mL), H_2O (50 mL) was added. Separated, the organic phase was concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, petroleum ether: ethyl acetate = 1: 0~5: 1) to afford desired product **591c** (3.8 g, 65.11% yield) as a yellow solid. m/z (ESI, +ve ion) = 305.1 $[M+H]^+$.

[00680] Step C: Methyl (S)-2-(chloromethyl)-1-(2-(difluoromethoxy)propyl)-1H-benzo[d]imidazole-6-carboxylate (591d).



[00681] MeOH (40 mL) was added Pd/C (3 g, 50% w/w) under N_2. The suspension was degassed under vacuum and purged with H_2 (19.88 mg, 9.86 mmol) several times. The mixture was stirred under H_2 (15 psi) at 30 °C for 1H. Compound **591c** (3 g, 9.86 mmol) was added under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 30 °C for 2H. After completion, the mixture was filtered through a Celite® pad, the filter cake was washed with MeOH (20 mL x 4). The filtrate was concentrated to afford amine (2.7 g, 99.84% yield) as a colorless oil. m/z (ESI, +ve ion) = 275.2 $[M+H]^+$.

[00682] To a solution of amine (2.7 g, 9.84 mmol) in MeCN (30 mL) was added 4-methylbenzenesulfonic acid;hydrate (187.26 mg, 984.46 umol) and 2-chloro-1,1,1-trimethoxy-ethane (2.28 g, 14.77 mmol, 1.99 mL). The mixture was stirred at 60 °C for 30 min. After completion, the mixture was concentrated to give crude product. The reaction was quenched by sat. $NaHCO_3$ (30 mL) and then extracted with ethyl acetate (30 mL x 2). The combined organic phase was dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, petroleum ether: ethyl acetate = 1: 0~3: 1) to afford desired product **591d** (2.5 g, 76.18% yield). *m/z* (ESI, +ve ion) = 333.0 $[M+H]^+$.

[00683] Step D: Methyl 1-((S)-2-(difluoromethoxy)propyl)-2-(((2S,4S)-4-((2-((2,4-

difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (591e).



591d 591e

[00684] To a solution of **588e** (triflate salt which was prepared using the same procedure as **355f** (0.1 g, 298.20 umol) and **591d** (99.22 mg, 298.20 µmol) in DMF (3 mL) was added DIEA (192.70 mg, 1.49 mmol, 259.70 µL). The mixture was stirred at 80 °C for 16 h under N_2. After completion, the reaction was quenched by H_2O (10 mL) and then extracted with ethyl acetate (10 mL x 2). The combined organic phase was dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by prep- TLC (SiO_2, Petroleum ether: Ethyl acetate = 0: 1, R_f = 0.6) to afford **591e** (100 mg, 53.09% yield). *m/z* (ESI, +ve ion) = 632.2 $[M+H]^+$.

[00685] Step E: 1-((S)-2-(Difluoromethoxy)propyl)-2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (591).



591e 591

[00686] To a solution of **591e** (80 mg, 126.66 umol) in THF (2 mL), MeOH (1 mL) and H_2O (1 mL) was added LiOH.H_2O (26.58 mg, 633.30 umol). The mixture was stirred at 15 °C for 16 hr. After completion, the mixture was concentrated to remove THF and MeOH. The mixture was adjusted to pH ~6 with HCl (1 M, ~0.6 mL) and extracted with DCM (10 mL × 3). The combined organic layers were concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (NH_4HCO_3)-ACN]; B%: 15%-45%, 8 min) to afford compound **591** (60 mg, 76.70% yield). ^{1}H NMR (400 MHz, DMSO-*d6*) δ 8.49 (d, 1H), 8.21 (s, 1H), 7.79 (dd, 1H), 7.63 (d, 1H), 7.28 (ddd, 1H), 7.14 (dt, 1H), 6.98 - 6.89 (m, 1H), 6.79 (d, 1H), 6.74 - 6.31 (m, 1H), 5.30 (s, 2H), 4.94 - 4.84 (m, 1H), 4.83 - 4.75 (m, 1H), 4.66 - 4.52 (m, 2H), 4.26 (d, 1H),

3.67 (d, 1H), 2.80 - 2.68 (m, 1H), 2.46 (brd, 1H), 2.23 (brt, 1H), 1.97 - 1.80 (m, 2H), 1.48 (dq, 1H), 1.32 (d, 4H), 1.10 (d, 3H); *m/z* (ESI, +ve ion) = 618.2 $[M+H]^+$.

[00687] Example 592. 1-[(2R)-2-(Difluoromethoxy)propyl]-2-{[(2S,4S)-4-({2-[(2,4-difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (592).



592

[00688] Example **592** was synthesized by following similar synthetic route starting from opposite enantiomer of **591a**. ^{1}H NMR (400 MHz, DMSO-d6) δ 8.55 - 8.39 (m, 1H), 8.22 (d, 1H), 7.79 (dd, 1H), 7.63 (d, 1H), 7.29 (ddd, 1H), 7.14 (dt, 1H), 6.99 - 6.88 (m, 1H), 6.79 (d, 1H), 6.66 - 6.20 (m, 1H), 5.36 - 5.26 (m, 2H), 4.94 - 4.74 (m, 2H), 4.69 - 4.37 (m, 3H), 3.36 (s, 1H), 2.70 - 2.59 (m, 1H), 2.39 - 2.28 (m, 1H), 2.10 - 1.78 (m, 3H), 1.46 - 1.24 (m, 5H), 1.20 (d, 3H); m/z (ESI, +ve ion) = 618.2 $[M+H]^+$.

[00689] Example 594. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(2R)-2-(2,2,2-trifluoroethoxy)propyl]-1H-1,3-benzodiazole-6-carboxylic acid (594).



594

[00690] Example **594** was synthesized using similar procedure as compound **592**. ^{1}H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (d, 1H), 8.33 (s, 1H), 7.90 (brd, 1H), 7.79 (brd, 1H), 7.27 (ddd, 1H), 7.17 (td, 1H), 6.96 (brt, 1H), 6.88 (d, 1H), 5.30 (s, 2H), 5.03 - 5.19 (m, 2H), 4.74 - 4.88 (m, 1H), 4.01 - 4.16 (m, 4H), 3.38 (brs, 5H), 1.86 - 2.28 (m, 4H), 1.67 (d, 3H), 1.38 (brs, 3H), 1.23 (s, 1H); *m/z* (ESI, +ve ion) = 650.2 $[M+H]^+$.

[00691] Example 595. 2-{[(2S,4S)-4-[(2-{[(5-chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid (595).



595

[00692] Example **595** was synthesized by following the synthetic route A-B for Example **554** followed by C-D of **588**. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 8.39 (d, 1H), 8.19 (s, 1H), 8.08 (d, 1H), 7.84-7.82 (m, 2H), 7.44 (dd, 1H), 6.53 (d, 1H), 5.59 (s, 1H), 5.04-4.89 (m, 2H), 4.57-4.49 (m, 2H), 4.07-3.96 (m, 2H), 3.77 (q, 2H), 3.61-3.58 (m, 1H), 2.76-2.74(m, 1H), 2.42 (bs, 1H), 2.20-2.18 (m, 1H), 2.03-2.00 (m, 2H), 1.87-1.85 (m, 2H), 1.54-1.43 (m, 2H), 1.26 (d, 3H); m/z (ESI, +ve ion) = 654.3 $[M+H]^+$.

[00693] Example 596. 2-{[(2S,4S)-4-({2-[(4-Cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid.



596

[00694] Example **596** was synthesized using similar procedure as described in Example **588**. Compound **596**. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 8.33 (d, 1H), 8.10 (s, 1H), 7.98 (d, 1H), 7.73 (d, 1H), 7.32 (d, 1H), 7.27 (d, 1H), 6.94 (t, 1H), 6.5 (d, 1H), 5.22 (s, 2H), 4.94-4.88 (m, 2H), 4.46-4.40 (m, 2H), 3.98-3.88 (m, 2H), 3.71-3.64 (m, 2H), 3.49 (d, 1H), 2.70-2.67 (m, 1H), 2.38-2.30 (m, 1H), 2.17-2.11 (m, 1H), 1.96-1.93 (m, 1H), 1.84-1.82 (m, 1H), 1.52-1.35 (m, 3H), 1.17 (d, 3H); m/z (ESI, +ve ion) = 643.3 $[M+H]^+$.

[00695] Example 597. 2-{[(2S,4S)-4-[(2-{[(5-Chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (597).



597

[00696] Example **597** was synthesized by following the synthetic route for Example **606**. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 8.30 (d, 1H), 7.95 (s, 1H), 7.73 (d, 1H), 7.63 (d, 1H), 7.37 (d, 1H), 6.44 (d, 1H), 5.5 (s, 2H), 5.18-5.16 (m, 1H), 4.94-4.89 (m, 1H), 4.56-4.42 (m, 3H), 4.23-4.18 (m, 1H), 3.56 (d, 1H), 2.68-2.61 (m, 2H), 2.36-2.27 (m, 2H), 2.16-2.10 (m, 1H), 1.91-1.88 (m, 1H), 1.77-1.75 (m, 1H), 1.49-1.31 (m, 3H), 1.12 (d, 3H); m/z (ESI, +ve ion) = 615.3 $[M+H]^+$.

[00697] Example 598. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(2S)-2-(2,2,2-trifluoroethoxy)propyl]-1H-1,3-benzodiazole-6-carboxylic acid (598).



598

[00698] Example 598 was synthesized using similar procedure as compound **592**. ^{1}H NMR (400 MHz, DMSO-d6) δ ppm 8.48 (d, 1H), 8.20 (s, 1H), 7.80 (brd, 1H), 7.65 (brd, 1H), 7.28 (ddd, 1H), 7.10 - 7.19 (m, 1H), 6.89 - 6.98 (m, 1H), 6.77 (d, 1H), 5.32 - 5.39 (m, 1H), 5.30 (s, 2H), 4.83-4.92 (m, 1H), 4.38 (brd, 1H), 4.15 (brt, 1H), 3.96 - 4.10 (m, 3H), 3.39 - 3.45 (m, 3H), 2.33 (brd, 1H), 2.04 - 2.13 (m, 1H), 1.91 - 1.99 (m, 1H), 1.82 - 1.89 (m, 1H), 1.60 (brd, 3H), 1.38 - 1.49 (m, 1H), 1.26 - 1.36 (m, 1H), 1.17 (brd, 3H); m/z (ESI, +ve ion) = 650.2 $[M+H]^+$.

[00699] Example 599. 2-{[(2R,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-(trifluoromethyl)piperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (599).



599

[00700] Step A: tert-Butyl (2R,4S)-4-((2-chloropyrimidin-4-yl)oxy)-2-(trifluoromethyl)piperidine-1-carboxylate (599b)



599a 599b

[00701] To a solution of 2,4-dichloropyrimidine (180 mg, 1.21 mmol) and **599a** (195.20 mg, 724.94 umol) in DMF (3 mL) was added Cs_2CO_3 (1.18 g, 3.62 mmol). The mixture was stirred at 80 °C for 16 hr. After completion, the reaction mixture was diluted with NH_4Cl water solution (30 mL). The aqueous phase was extracted with ethyl acetate (10 mL*3). The combined organic phase was washed with brine (50 mL*2), dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum. The residue was purified by prep-TLC (PE/EA = 3:1, Rf = 0.3) to afford **599b** (178 mg, 38.59% yield) as a yellow oil; m/z (ESI, +ve ion) = 382.3 $[M+H]^+$.

[00702] Step B: Methyl 4-(((2R,4S)-1-(tert-butoxycarbonyl)-2-(trifluoromethyl)piperidin-4-yl)oxy)pyrimidine-2-carboxylate (599c).



599b 599c

[00703] A mixture of **599b** (178 mg, 466.24 umol), TEA (47.18 mg, 466.24 umol, 64.89 uL) and $Pd(dppf)Cl_2$ (17.06 mg, 23.31 umol) in MeOH (2 mL) and DMSO (2 mL) was degassed and purged with CO for 3 times, and then the mixture was stirred at 65 °C for 12H under CO atmosphere. After completion, the residue was diluted with NH_4Cl water solution (50 mL). The aqueous phase was extracted with ethyl acetate (30 mL*3). The combined organic phase was washed with brine (100 mL*2), dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum. The residue was purified by prep-TLC (PE/EA = 0:1, Rf = 0.3) to afford **599c** (120 mg, 63.49% yield) as a yellow solid. m/z (ESI, +ve ion) = 406.2 $[M+H]^+$.

[00704] Step C: tert-Butyl (2R,4S)-4-((2-(hydroxymethyl)pyrimidin-4-yl)oxy)-2-

(trifluoromethyl)piperidine-1-carboxylate (599d).



599c **599d**

[00705] A mixture of methyl **599c** (120 mg, 296.03 umol) and $CaCl_2$ (19.71 mg, 177.62 umol) in EtOH (2 mL) was degassed and purged with N_2 for 3 times, then $NaBH_4$ (6.72 mg, 177.62 umol) was added, and then the mixture was stirred at 0-20 °C for 1H under N_2 atmosphere. After completion, the reaction mixture was diluted with water (30 mL). The aqueous phase was extracted with ethyl acetate (20 mL*3). The combined organic phase was dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum. The residue was purified by prep-TLC (PE/EA = 1:1, Rf = 0.3) to afford **599d** (80 mg, 71.62% yield). m/z (ESI, +ve ion) = 378.3 $[M+H]^+$.

[00706] **Step D: tert-Butyl (2R,4S)-4-((2-((4-cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-(trifluoromethyl)piperidine-1-carboxylate (599e)**.



599d **599e**

[00707] A mixture of **599d** (75 mg, 198.75 umol) and DIPEA (77.06 mg, 596.25 umol, 103.86 uL) in DCM (1 mL) was degassed and purged with N_2 for 3 times, then MsCl (34.15 mg, 298.13 umol, 23.07 uL) was added, and then the mixture was stirred at 0-20 °C for 2H under N_2 atmosphere. After completion, the reaction mixture was diluted with water (50 mL). The aqueous phase was extracted with DCM (30 mL*3). The combined organic phase was dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum to afford the crude product (90 mg, 99.43% yield) as a yellow oil, which was used in the next step reaction without further purification.

[00708] A mixture of mesyl ester (90 mg, 197.61 umol), 3-fluoro-4-hydroxy-benzonitrile (32.51 mg, 237.13 umol) and K_2CO_3 (81.93 mg, 592.82 umol) in DMF (2 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 35 °C for 14 h under N_2 atmosphere. After completion, the reaction mixture was diluted with NH_4Cl water solution

(20 mL). The aqueous phase was extracted with ethyl acetate (10 mL*3). The combined organic phase was dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum to afford the crude product (110 mg, 94.35% yield) as a yellow oil, which was used in the next step reaction without further purification. m/z (ESI, +ve ion) = 497.2 $[M+H]^+$.

[00709] Step E: Methyl 2-(((2R,4S)-4-((2-((4-cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-(trifluoromethyl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (599f).



[00710] A mixture of **599e** (120 mg, 241.71 umol) and TFA (145 mg, 1.27 mmol, 94.16 uL) in DCM (1 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 15 °C for 3H under N_2 atmosphere. After completion, the reaction mixture was adjusted to pH=8 with $NaHCO_3$ water solution. The aqueous phase was extracted with DCM (30 mL*3). The combined organic phase was dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum to afford the crude product (90 mg, 93.95% yield) as a yellow oil, which was used in the next step reaction without further purification. m/z (ESI, +ve ion) = 397.3 $[M+H]^+$.

[00711] To a solution of amine (70 mg, 176.62 umol) and methyl 2 - (chloromethyl) – 3 - [[(2S) –oxetan – 2 - yl] methyl] benzimidazole – 5 - carboxylate (52.05 mg, 176.62 umol) in ACN (2 mL) was added K_2CO_3 (73.23 mg, 529.85 umol) and KI (29.32 mg, 176.62 umol). The mixture was stirred at 50 °C for 16 h. After completion, the reaction mixture was diluted with NH_4Cl water solution (30 mL). The aqueous phase was extracted with ethyl acetate (30 mL*3). The combined organic phase was washed with brine (100 mL*2), dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum. The residue was purified by prep-TLC (PE/EA = 0:1, Rf = 0.3) to afford **599f** (50 mg, 76.38 umol, 43.25% yield) as a yellow solid; m/z (ESI, +ve ion) = 655.4 $[M+H]^+$.

[00712] Step F: 2-{[(2R,4S)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-(trifluoromethyl)piperidin-1-yl]methyl}-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid.



599f 599

[00713] To a solution of **599f** (40 mg, 61.11 umol) in THF (0.2 mL), MeOH (0.1 mL) and H_2O (0.1 mL) was added $LiOH.H_2O$ (5.13 mg, 122.21 umol). The mixture was stirred at 15 °C for 16 h. After completion, the reaction mixture was adjusted to pH=5 with 1M HCl, extracted with DCM (10 mL *3), The combined organic phase was dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex Luna C18 75 * 30 mm * 3 um; mobile phase: [water (FA)-ACN]; B%: 25%-55%,8min) to afford the desired product **599** (13.13 mg, 20.50 umol, 33.54% yield). ^1H NMR (400 MHz, CD_3OD) δ = 8.46 (d, 1H), 8.33 - 8.29 (m, 1H), 7.98 (d, 1H), 7.69 (dd, 1H), 7.59 (ddd, 1H), 7.47 (d, 1H), 7.24 (t, 1H), 6.76 (dd, 1H), 5.40 (s, 2H), 5.25 - 5.11 (m, 2H), 4.72 - 4.58 (m, 4H), 4.54 - 4.40 (m, 2H), 4.18 - 3.94 (m, 1H), 3.52 - 3.41 (m, 1H), 2.97 - 2.73 (m, 2H), 2.58 - 2.22 (m, 3H), 2.01 - 1.81 (m, 2H), 1.79 - 1.58 (m, 1H); m/z (ESI, +ve ion) = 641.2 $[M+H]^+$.

[00714] **Example 600. 2-{[(2S,4S)-4-({2-[(2,4-Difluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[(1-methoxycyclobutyl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid (600)**.



600

[00715] **Step A: (1-Methoxycyclobutyl)methanamine (600b)**.



600a 600b

[00716] To a solution of **600a** (2 g, 17.22 mmol) in DMF (30 mL) was added NaH (2.76 g, 68.90 mmol, 60% purity) at 0 °C. The mixture was stirred at 15 °C for 2H. MeI (9.78 g, 68.90 mmol, 4.29 mL) was added. The mixture was stirred at 15 °C for 16 h. After completion. The mixture was dropwise added to sat. NH_4Cl (70 mL) and extracted with

MTBE (50 mL x 3). The organic layer was washed with brine (20 mL x 2), dried over Na_2SO_4, filtered and concentrated in vacuo to afford desired ester (2.6 g, crude) as a yellow oil.

[00717] A solution of ester (2.6 g, 18.03 mmol) in THF (10 mL) saturated with $NH_3.H_2O$ (31.55 g, 225.04 mmol, 34.67 mL, 25% purity) was stirred at 75°C for 24 h in a 100 mL of sealed tube. After completion, the reaction was quenched by brine (30 mL) and then extracted with ethyl acetate (60 mL x 3). The combined organic phase was dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo to afford amide (2 g, 85.86% yield). The crude product was used for next step directly without purification.

[00718] To a solution of amide (2 g, 15.49 mmol) in THF (20 mL) was added BH_3.THF (1 M, 46.46 mL) at 15 °C under N_2. The mixture was stirred at 70 °C for 3Hr. After completion, the reaction was quenched by MeOH (20 mL) and brine (30 mL) was added, then extracted with ethyl acetate (50 mL x 5). The combined organic phase was washed with brine (20 mL), dried over anhydrous Na_2SO_4, filtered was diluted with 4 M HCl/dioxane (8 mL), and the mixture was concentrated to afford **600b** (2 g, crude, HCl salt) as colorless oil.

[00719] Example **600** was synthesized using the similar procedure as compounds **590** from amine, **600b**. ^{1}H NMR (400 MHz, DMSO-*d6*) δ 13.02 - 12.49 (m, 1H), 8.52 - 8.44 (m, 1H), 8.30 (s, 1H), 7.79 (brd, 1H), 7.64 (d, 1H), 7.30 - 7.20 (m, 1H), 7.13 (dt, 1H), 6.97 - 6.88 (m, 1H), 6.78 (d, 1H), 5.30 (s, 2H), 4.92 - 4.79 (m, 1H), 4.77 - 4.63 (m, 2H), 4.48 (brd, 1H), 3.58 (brd, 1H), 3.20 (s, 3H), 2.66 (brd, 2H), 2.36 - 2.23 (m, 2H), 2.17 (brt, 1H), 1.96 - 1.89 (m, 1H), 1.86 - 1.75 (m, 4H), 1.72 (brd, 1H), 1.50 - 1.37 (m, 1H), 1.30 (q, 1H), 1.14 (brd, 3H); *m/z* (ESI, +ve ion) = 608.3 $[M+H]^+$.

[00720] **Example 601. 2-{[(2S,4S)-4-({2-[(2-cyano-4-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)-2-methylpiperidin-1-yl]methyl}-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-1,3-benzodiazole-6-carboxylic acid (601)**.



601

[00721] Example **601** was synthesized using similar procedure as described in Example **588**. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 8.31 (d, 1H), 8.09 (s, 1H), 7.96 (d, 1H), 7.71 (d,

1H), 7.23-7.21 (m, 1H), 7.12-7.08 (m, 1H), 6.87-6.84 (m, 1H), 6.49 (d, 1H), 5.21 (s, 2H), 4.99-4.86 (m, 2H), 4.43-4.40 (m, 2H), 3.98-3.87 (m, 2H), 3.72-3.63 (m, 2H), 3.48 (d, 1H), 2.70-2.64 (m, 1H), 2.41-2.34 (m, 1H), 2.18-2.12 (m, 1H), 1.98-1.95 (m, 1H), 1.83-1.80 (m, 1H), 1.42-1.34 (m, 2H), 1.17 (d, 3H); m/z (ESI, +ve ion) = 643.3 $[M+H]^+$.

[00722] Example 602. 2-{[(2S,4S)-4-[(2-{[(5-Chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-1-[(2R)-2-(difluoromethoxy)propyl]-1H-1,3-benzodiazole-6-carboxylic acid (602).



602

[00723] Example **602** was synthesized by following the synthetic route A-B for Example **554** followed by C-D of **588**. ^{1}H NMR (400 MHz, CD_3OD) δ ppm 8.37 (d, 1H), 8.26 (s, 1H), 7.96 (dd, 1H), 7.82 (d, 1H), 7.76 (dd, 1H), 7.66 (d, 1H), 6.66 (d, 1H), 6.15 (t, 1H), 5.57 (s, 2H), 4.89 - 4.98 (m, 2H), 4.72 (dd, 1H), 4.63 (d, 1H), 4.42 (dd, 1H), 3.37 (brd, 2H), 2.57 - 2.67 (m, 1H), 2.26 - 2.34 (m, 1H), 1.93 - 2.06 (m, 2H), 1.69 - 1.78 (m, 1H), 1.47 (d, 3H), 1.42 (brd, 2H), 1.30 (d, 4H); m/z (ESI, +ve ion) = 635.2 $[M+H]^+$.

[00724] Example 603. 2-{[(2S,4S)-4-[(2-{[(5-Chloropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (603).



603

[00725] Compound **603** was synthesized by following the synthetic route A-D for Example **606**. ^{1}H NMR (400 MHz, DMSO-d6) δ 13.20 - 12.76 (m, 1H), 8.43 (d, 1H), 8.14 (d, 1H), 8.10 - 8.07 (m, 1H), 7.83 (dd, 1H), 7.51 (dd, 1H), 7.03 (d, 1H), 6.71 (d, 1H), 5.54 - 5.37 (m, 2H), 5.21 - 5.06 (m, 1H), 4.82 - 4.68 (m, 3H), 4.52 - 4.37 (m, 2H), 4.24 (td, 1H), 3.57 (d, 1H), 2.68 - 2.61 (m, 2H), 2.37 - 2.30 (m, 2H), 2.19 - 2.04 (m, 1H), 1.80 - 1.64 (m, 2H), 1.38 (dq, 1H), 1.29 - 1.18 (m, 1H), 1.07 (d, 3H); m/z (ESI, +ve ion) = 597.2 $[M+H]^+$.

[00726] Example 604. 2-{[(2S,4S)-4-[(2-{[(5-cyanopyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-

benzodiazole-6-carboxylic acid (604).



604

[00727] Example **604** was synthesized by following the synthetic route A-D for Example **606**. ^{1}H NMR (400 MHz, DMSO-d6) δ 8.60 (d, 1H), 8.44 (d, 1H), 8.22 (dd, 1H), 8.12 (d, 1H), 7.51 (dd, 1H), 7.19 (d, 1H), 6.73 (d, 1H), 5.64 - 5.46 (m, 2H), 5.20 - 5.08 (m, 1H), 4.81 - 4.68 (m, 3H), 4.51 - 4.37 (m, 2H), 4.28 - 4.19 (m, 1H), 3.58 (d, 1H), 2.73 - 2.60 (m, 2H), 2.40 - 2.27 (m, 2H), 2.14 (brt, 1H), 1.77 - 1.68 (m, 2H), 1.50 - 1.36 (m, 1H), 1.24 (q, 1H), 1.07 (d, 3H); m/z (ESI, +ve ion) = 588.3 $[M+H]^+$.

[00728] Example 605. 2-({4-[(2-{[(5-Chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-oxetan-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (605).



605

[00729] Example **605** was synthesized by following the synthetic route A-D for Example **606**. ^{1}H NMR (400 MHz, DMSO-d6) δ 8.44 (d, 1H), 8.13 - 8.06 (m, 2H), 7.97 (d, 1H), 7.50 (d, 1H), 6.76 (d, 1H), 5.56 (s, 2H), 5.13 - 5.02 (m, 1H), 4.86 - 4.71 (m, 2H), 4.70 - 4.58 (m, 1H), 4.53 - 4.45 (m, 1H), 4.36 (td, 1H), 3.94 (d, 1H), 3.79 (d, 1H), 2.80 - 2.62 (m, 3H), 2.47 - 2.36 (m, 1H), 2.25 - 2.12 (m, 2H), 1.75 (brdd, 2H), 1.60 - 1.45 (m, 2H); m/z (ESI, +ve ion) = 601.1 $[M+H]^+$.

[00730] Example 606. 2-{[(2S,4S)-4-[(2-{[(3,5-Difluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-[(oxetan-2-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid (606).



606

[00731] Step A: Tert-butyl (2S,4S)-4-((2-chloropyrimidin-4-yl)oxy)-2-methylpiperidine-1-carboxylate (606c).



606a 606b 606c

[00732] To a mixture of TEA (117.19 g, 1.16 mol, 161.20 mL) was added dropwise HCOOH (51.36 g, 1.07 mol) at 25 °C. After that N-[(1S,2S)-2-amino-1,2-diphenyl-ethyl]-4-methyl-benzenesulfonamide;chlororuthenium;1-isopropyl-4-methyl-benzene (1.42 g, 2.23 mmol,) was added to the mixture and stirred at 30 °C for 10 min under N_2. Then tert-butyl (2S)-2-methyl-4-oxo-piperidine-1-carboxylate, **606a** (95 g, 445.44 mmol) was added to the mixture and stirred at 50 °C for 12H. After completion. The mixture was quenched by addition of H_2O (1500 mL) and citric acid (50%, aq. 500 mL), then extracted with EtOAc (600 mL*3). The combined organic layer was washed with $NaHCO_3$ (sat. 200 mL*2), dried with Na_2SO_4 and concentrated under reduce pressure to give a residue. The residue was triturated with n-heptane (20V) at 25 °C for 3H and the mixture was filtered to give (2S,4S)-tert-butyl 4-hydroxy-2-methylpiperidine-1-carboxylate, **606b** (82 g, 380.88 mmol, 85 % yield).

[00733] To a solution of 2,4-dichloropyrimidine (94.11 g, 631.71 mmol) and tert-butyl (2S,4S)-4-hydroxy-2-methyl-piperidine-1-carboxylate, **606b** (80 g, 371.59 mmol) in DMF (900 mL) was added Cs_2CO_3 (363.22 g, 1.11 mol) .The mixture was stirred at 80 °C for 16hr. After completion. The reaction was quenched with ice H_2O (1500 mL), then extracted with PE (1000 mL*3), the organic layer was dried over Na_2SO_4, concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=50/1 to 10/1) to give (2S, 4S)-tert-butyl 4-((2-chloropyrimidin-4-yl)oxy)-2-methylpiperidine-1-carboxylate, **606c** (63.33 g, 49 % yield). *m/z* (ESI, +ve ion) = 328.2 $[M+H]^+$



606c 606d 606e

[00734] Step B: tert-butyl (2S,4S)-4-((2-(hydroxymethyl)pyrimidin-4-yl)oxy)-2-methylpiperidine-1-carboxylate (606e).

[00735] A mixture of tert-butyl (2S,4S)-4-(2-chloropyrimidin-4-yl)oxy-2-methyl-piperidine-1-carboxylate, **606c** (63 g, 192.19 mmol) , TEA (25.28 g, 249.84 mmol, 34.77 mL) ,Pd(dppf)Cl_2 (14.06 g, 19.22 mmol) in MeOH (400 mL) and DMSO (200 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 60°C for 16 h under CO (50 psi) atmosphere. After completion. The reaction was concentrated and added H_2O (800 mL), extracted with EtOAc (500 mL*3), the organic layer was dried over Na_2SO_4, concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=40/1 to 1/1) to give methyl 4-(((2S,4S)-1-(tert-butoxycarbonyl)-2-methylpiperidin-4-yl)oxy)pyrimidine-2-carboxylate, **606d** (35.04 g, 52% yield) as yellow oil. *m/z* (ESI, +ve ion) = 352.3 $[M+H]^+$

[00736] A mixture of **606d** (25 g, 71.14 mmol) ,$CaCl_2$ (4.74 g, 42.69 mmol)in EtOH (300 mL) was degassed and purged with N_2 for 3 times, then $NaBH_4$ (2.15 g, 56.92 mmol) was added, and then the mixture was stirred at 20 °C for 1hr under N_2 atmosphere. After completion, the reaction was quenched by addition of MeOH (300 mL) and concentrated under reduce pressure to give a residue. The residue was diluted with sat. aqueous NH_4Cl (100 mL) and EtOAc (300 mL*3). The combined organic layer was washed with brine (100 mL), concentrated under reduce pressure to give a residue. The residue was triturated with PE (10V) at 50 °C until dissolved and then cooled to 25 °C and precipitated to give (2S,4S)-tert-butyl 4-((2-(hydroxymethyl)pyrimidin-4-yl)oxy)-2-methylpiperidine-1-carboxylate, **606e** (21.05 g, 85% yield). *m/z* (ESI, +ve ion) = 324.2 $[M+H]^+$

[00737] Step C: 2-(((3,5-difluoropyridin-2-yl)oxy)methyl)-4-(((2S,4S)-2-methylpiperidin-4-yl)oxy)pyrimidine (606f).



[00738] To a solution of **606e** (150 mg, 463.84 umol), 2,3,5-trifluoropyridine (94.48 mg, 695.76 umol, 98% purity), NaH (74.21 mg, 1.86 mmol, 60% purity) in THF (6 mL) at 0 °C was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 0-50 °C for 3Hr under N_2 atmosphere. After completion, reaction mixture was quenched with sat. NH_4Cl (5mL), and then was extracted with EA(10mL*3), the combined organic layer was washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered, concentrated and purified by prep-TLC(PE/EA = 1:1, R_f = 0.43) to afford the desired product (154 mg, 76% yield) as a brown oil. *m/z* (ESI, +ve ion) = 437.3 $[M+H]^+$.

[00739] To a solution of tert-butyl (2S,4S)-4-[2-[(3,5-difluoro-2-pyridyl)oxymethyl]pyrimidin-4-yl]oxy-2-methyl-piperidine-1-carboxylate (154 mg, 352.85 umol) in TFA (1 mL) and DCM (1 mL) .The mixture was stirred at 15 °C for 1Hr . After completion, reaction mixture was quenched with H_2O (5mL) and Na_2CO_3, and then was extracted with EA (10mL*3), the combined organic layer was washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered and concentrated, without further purification to afford the desired product, **606f** (118.6 mg, 100% yield). *m/z* (ESI, +ve ion) = 337.3 $[M+H]^+$.

[00740] Step D: Methyl (S)-3-fluoro-4-nitro-5-((oxetan-2-ylmethyl)amino)benzoate (606h).



[00741] A mixture of methyl 3,5-difluoro-4-nitro-benzoate, **606g** (2 g, 9.21 mmol) [(2S)-oxetan-2-yl] methanamine (1.04 g, 11.97 mmol), DIEA (3.57 g, 27.63 mmol, 4.81 mL) and THF (39.7 mL) and DMF (39.7 mL) was stirred at 50°C for 4 h. After completion, the mixture was then quenched with ammonium chloride aqueous solution (100 mL) and extracted with ethyl acetate (100 mL*2). The extract was washed with brine, (60 ml) dried

over sodium sulfate, filtered, and concentrated The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=100/1 to 10/1) to afford the desired product, **606h** (1.7 g, 65% yield) as a yellow solid. m/z (ESI, +ve ion) =285.0 $[M+H]^+$.

[00742] Step E: methyl (S)-2-(chloromethyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (606i).



606h **606i**

[00743] To a solution of **606h** (1.6 g, 5.63 mmol, 1 eq) in THF (100 mL) was added Pd/C (1.6 g, 10% purity) under Ar_2 atmosphere. The suspension was degassed and purged with H_2 for 3 times. The mixture was stirred under H_2(15 Psi) at 25 °C for 2Hr. After completion, the reaction mixture was filtered and concentrated to give the di-amine intermediate (1.5 g, crude). m/z (ESI, +ve ion) =255.0 $[M+H]^+$.

[00744] A mixture of crude methyl 4-amino-3-fluoro-5-[[(2S)-oxetan-2-yl]methylamino]benzoate (2.6 g, 10.23 mmol), ACN (32 mL), 2-chloro-1,1,1-trimethoxy-ethane (1.58 g, 10.23 mmol, 1.37 mL) and PTSA (88.04 mg, 511.29 umol) was stirred at 60°C for 3H.. After completion, the reaction mixture was concentrated. The residue was diluted with H_2O (50 mL) and extracted with EA (50 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give crude product. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=20/1 to 5/1) to afford the desired product, **606i** (1.8 g, 56% yield). ^1H NMR (400 MHz, DMSO-d6) δ = 8.25 (s, 1H), 7.61 (d, 1H), 5.20 - 5.11 (m, 3H), 4.79-4.77 (m, 1H), 4.70-4.69 (m, 1H), 4.48 - 4.47 (m, 1H), 4.34 - 4.32 (m, 1H), 3.90 (s, 3H), 2.72 - 2.68 (m, 1H), 2.40 - 2.35 (m, 1H). m/z (ESI, +ve ion) =172.2$[M+H]^+$.

[00745] Step F: 2-(((2S,4S)-4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (606).



606f 606i 606

[00746] To a solution of 2-[(3,5-difluoro-2-pyridyl)oxymethyl]-4-[[(2S,4S)-2-methyl-4-piperidyl]oxy]pyrimidine, **606f** (118.6 mg, 352.62 umol), methyl 2-(chloromethyl)-7-fluoro-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate, **606i** (110.34 mg, 352.62 umol), DIEA (228.01 mg, 1.76 mmol) in DMF (5 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 80 °C for 3Hr under N_2 atmosphere. After completion, reaction mixture was quenched with H_2O (5mL), and then was extracted with EA (10mL*3), the combined organic layer was washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered, concentrated and purified by prep-TLC (PE/EA = 0:1, R_f = 0.35) to afford the corresponding ester (170 mg, 79% yield). *m/z* (ESI, +ve ion) = 613.2 $[M+H]^+$.

[00747] To a solution of methyl 2-[[(2S,4S)-4-[2-[(3,5-difluoro-2-pyridyl)oxymethyl]pyrimidin-4-yl]oxy-2-methyl-1-piperidyl]methyl]-7-fluoro-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate (170 mg, 277.51 umol), $LiOH.H_2O$ (1.16 mg, 27.75 umol) in THF (0.6 mL), MeOH (0.3 mL), H_2O (0.3 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 15 °C for 16 hr under N_2 atmosphere. After completion, reaction mixture was adjusted to pH-5 with 1M HCl, extracted with EA (50 mL*3), the combined organic phase was washed with brine (100 mL*2), dried with anhydrous Na_2SO_4, filtered, concentrated in vacuum and purified by prep-TLC(PE/EA = 0:1, Rf = 0.40) and prep-HPLC to afford the desired product, **606** (48 mg, 29% yield). ^1H NMR (400 MHz, $CDCl_3$) δ 1.22 (brd, 3H) 1.40 - 1.64 (m, 2H) 1.89 (brd, 1H) 2.01 (brd, 1H) 2.26 (brt, 1H) 2.35 - 2.49 (m, 2H) 2.67 - 2.83 (m, 2H) 3.67 (brd, 1H) 4.30 (dt, 1H) 4.50 - 4.67 (m, 3H) 4.91 - 5.03 (m, 2H) 5.22 - 5.29 (m, 1H) 5.58 (s, 2H) 6.53 (d, 1H) 7.28 - 7.32 (m, 1H) 7.70 - 7.77 (m, 2H) 8.04 (s, 1H) 8.40 (d, 1H); *m/z* (ESI, +ve ion) = 599.2 $[M+H]^+$.

[00748] Example 607. 2-{[(2S,4S)-4-[(2-{[(5-Cyano-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-methylpiperidin-1-yl]methyl}-4-fluoro-1-[(oxetan-2-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid (607).



607

[00749] Example **607** was synthesized by following the synthetic route A-D for Example **606**. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 1.23 (brd, 3H) 1.47 - 1.58 (m, 3H) 1.90 (brd, 1H) 2.01 (brd, 1H) 2.23 - 2.32 (m, 1H) 2.36 - 2.50 (m, 2H) 2.67 - 2.83 (m, 2H) 3.68 (brd, 1H) 4.29 (dt, 1H) 4.48 - 4.67 (m, 3H) 4.90 - 5.04 (m, 2H) 5.20 - 5.31 (m, 1H) 5.64 (d, 2H) 6.55 (d, 1H) 7.65 (brd, 1H) 7.72 (d, 1H) 8.03 (s, 1H) 8.19 (d, 1H) 8.38 (d, 1H); m/z (ESI, +ve ion) = 606.2 $[M+H]^+$.

[00750] Example 608. 2-{[(2S,4S)-4-[(2-{[(5-Chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-ethylpiperidin-1-yl]methyl}-1-[(oxetan-2-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid.



608

[00751] Example 609. 2-{[(2R,4R)-4-[(2-{[(5-Chloro-3-fluoropyridin-2-yl)oxy]methyl}pyrimidin-4-yl)oxy]-2-ethylpiperidin-1-yl]methyl}-1-[(oxetan-2-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid.



609

[00752] Examples **608** and **609** (stereoisomers) were synthesized using a similar procedure as **Example 599** followed by chiral separation by SFC.

[00753] Examples 610 and 611. 2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((R)-

1,1-dioxidothietan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (610) and 2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-1,1-dioxidothietan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (611).



610 611

[00754] Step A: tert-Butyl (2,4-dihydroxybutyl)carbamate (610b).



610a 610b

[00755] To a solution of **610a** (1 g, 8.39 mmol) in H_2O (15 mL) was added NaOH (738.70 mg, 18.47 mmol, 35.09 mL) and $(Boc)_2O$ (2.38 g, 10.91 mmol, 2.51 mL) and dioxane (2.5 mL). The mixture was stirred at 15 °C for 72H. After completion, the reaction was added HCl (1N) till pH = 2-3, then extracted with DCM (80 mL*3), the organic layer was dried over Na_2SO_4, filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 20/1 to 0/1) to afford Boc-protected compound (1.5 g, 81% yield) as a white oil.

[00756] To a solution of Boc-protected compound (12 g, 54.74 mmol) in THF (150 mL) was added BH_3.THF (1 M, 147.79 mL) at 0 °C under N_2 atmosphere. The mixture was stirred at 0 °C for 2H. After completion, the mixture was quenched with 10% AcOH in MeOH (100 ml). Then EtOAc (160 mL*3) was added, and the reaction mixture was washed with sat. $NaHCO_3$ (100 mL), the organic layer was dried over Na_2SO_4. The filtrate was concentrated to afford **610b** (5.6 g, 49.8% yield) as a yellow oil.

[00757] Step B: tert-butyl (thietan-2-ylmethyl)carbamate (610c).



610b 610c

[00758] To a solution of **610b** (5.6 g, 27.28 mmol) in DCM (120 mL) was added TEA (16.56 g, 163.70 mmol) and MsCl (7.19 g, 62.75 mmol) at 0 °C under N_2 atmosphere. The mixture was stirred at 0 °C for 2H. After completion, the reaction mixture was quenched by the addition of the sat. $NaHCO_3$ (200 mL) at 15 °C, and then extracted with DCM (200 mL *

3). The combined organic layers were washed with sat. NH_4Cl (200 mL * 2), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The filtrate was concentrated to afford di mesylated compound (9.17 g, 92.99% yield).

To a solution of di mesylated compound (9.17 g, 25.37 mmol) in MeOH (900 mL) was added $Na_2S.9H_2O$ (30.47 g, 126.86 mmol) under N_2 atmosphere. The mixture was stirred at 40 °C for 16 h. After completion, the mixture was extracted with DCM (20 mL*3), dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum. The filtrate was concentrated to afford **610c** (3.74 g, 72.5% yield) as a white oil.

Step C: 2-(Aminomethyl)thietane 1,1-dioxide (610d).



[00759] To a solution of **610c** (3.34 g, 16.42 mmol) in DCM (60 mL) was added m-CPBA (10.00 g, 49.28 mmol, 85% purity) under N_2 atmosphere. The mixture was stirred at 15 °C for 16 h. After completion, the mixture was washed with the sat. $NaHCO_3$ (60 ml) and extracted with EtOAc (60 mL×3). The combined organic layer was dried over Na_2SO_4 and filtered. The filtrate was concentrated under reduced pressure to give sulfone (2.1 g, 51.32% yield) as a white oil.

[00760] To a solution of sulfone (2.1 g, 8.92 mmol) in DCM (10 mL) was added TFA (15.40 g, 135.06 mmol) under N_2 atmosphere. The mixture was stirred at 15 °C for 4 hr. After completion, the reaction mixture was concentrated under reduced pressure to remove solvent. The filtrate was concentrated to afford amine (2.22 g, crude) as a white oil.

[00761] Final steps:



[00762] Compound **610e** was synthesized from amine **610d** by following the similar procedure as **590a-e**.

[00763] To a solution of **610e** (0.09 g, 140.26 umol) in THF (2.5 mL) MeOH (1.25 mL) and H_2O (1.25 mL) was added $LiOH.H_2O$ (29.43 mg, 701.30 umol). The mixture was stirred at 20 °C for 3H. After completion, the reaction solution was added 1N HCl (701.30 umol),

diluted with H_2O (5 mL) and extracted with DCM/i-PrOH (3/1) (30 mL x 3). The combine organic layer was washed with brine (30 mL x 3), dried over Na_2SO_4, concentrated and the product was purified by SFC (column: DAICEL CHIRALCEL OD (250 mm*30 mm,10 um);mobile phase: [0.1%NH_3/H_2O /IPA];B%: 45%-45%,17 min, P1:Rt=1.481 min, P2: Rt=1.656 min) to afford the desired products.

[00764] Example **610:** ^{1}H NMR (400 MHz, CD_3OD) δ ppm 8.39 - 8.44 (m, 2H), 8.00 (dd, 1H), 7.69 (d, 1H), 6.99 - 7.11 (m, 2H), 6.79 - 6.86 (m, 1H), 6.71 (d, 1H), 5.25 (s, 2H), 5.14 - 5.23 (m, 2H), 4.98 - 5.10 (m, 1H), 4.65 - 4.81 (m, 2H), 4.10 - 4.22 (m, 1H), 3.97 - 4.08 (m, 1H), 3.45 - 3.52 (m, 1H), 2.65 - 2.73 (m, 1H), 2.38 - 2.50 (m, 2H), 2.15 - 2.26 (m, 1H), 2.04 - 2.13 (m, 2H), 1.89 - 2.00 (m, 1H), 1.46 - 1.63 (m, 2H), 1.31 - 1.36 (m, 3H); m/z (ESI, +ve ion) = 628.2 $[M+H]^+$.

[00765] Example **611**: ^{1}H NMR (400 MHz, CD_3OD) δ ppm 8.43 (d, 1H), 8.39 (s, 1H), 8.01 (dd, 1H), 7.70 (d, 1H), 6.99 -7.13 (m, 2H), 6.80 - 6.88 (m, 1H), 6.73 (d, 1H), 5.26 (s, 2H), 5.02 - 5.14 (m, 3H), 4.98 (t, 1H), 4.53 (d, 1H), 4.12 - 4.24 (m, 1H), 4.01 - 4.12 (m, 1H), 3.65 (d, 1H), 2.80 (brd, 1H), 2.40 - 2.56 (m, 2H), 2.27 (brt, 1H), 2.10 - 2.19 (m, 1H), 2.01 - 2.08 (m, 1H), 1.92 - 1.99 (m, 1H), 1.57 - 1.74 (m, 2H), 1.29 (d, 3H); *m/z* (ESI, +ve ion) = 628.2 $[M+H]^+$.

[00766] **Example 612. 1-((S)-2-cyclopropoxypropyl)-2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (612).**



612

[00767] **Step A: (*S*)-N,N-dibenzyl-2-(vinyloxy)propan-1-amine (612b).**



612a 612b

[00768] To a solution of **612a** (7 g, 27.41 mmol) in 1-vinyloxybutane (41.18 g, 411.19 mmol) was added 4,7-diphenyl-1,10-phenanthroline (455.60 mg, 1.37 mmol) and $Pd(OAc)_2$ (307.72 mg, 1.37 mmol) and TEA (1.11 g, 10.97 mmol). The mixture was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 100 °C for 16 h under N_2 atmosphere. After completion, the reaction was filtered and concentrated. 20 mL of H_2O was

added, and then was extracted with EtOAc (10 mL x 3), the combined organic layer was washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered, concentrated and purified by silica gel column (PE: EA = 10:1) to afford the desired product **612b** (4.6 g, 59.63% yield) as a colorless oil. m/z (ESI, +ve ion) = 282.4 $[M+H]^+$.

[00769] Step B: (S)-N,N-dibenzyl-2-cyclopropoxypropan-1-amine (612c).



[00770] To a solution of CH_2I_2 (71.39 g, 266.53 mmol) in DCM (60 mL) was cooled to -65 °C, and $ZnEt_2$ (1 M, 266.53 mL) was added dropwise via syringe. The solution was degassed and purged with N_2 for 3 times. To this solution was added **612b** (5 g, 17.77 mmol) in DCM (30 mL) dropwise via syringe, and the reaction mixture was stirred for 16 h at 15 °C under N_2 atmosphere. After completion, the reaction was quenched with saturated NH_4Cl solution (20 mL), and then was extracted with EtOAc (10 mL x 3), the combined organic layer was washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered and concentrated and purified by prep-HPLC (column: Welch Xtimate C18 250*70mm#10um;mobile phase: [water(NH_4HCO_3)-ACN];B%: 65%-95%, 20min) to afford the desired product **612c** (1.35 g, 25.72% yield) as a colorless oil. m/z (ESI, +ve ion) = 296.2 $[M+H]^+$.

[00771] Step C: (S)-2-cyclopropoxypropan-1-amine (612d).



[00772] To a solution of Pd/C (3.23 g, 50% w/w) in MeOH (10 mL) was added Compound **612c** (900 mg, 3.05 mmol), KOAc (298.99 mg, 3.05 mmol). The solution was degassed and purged with H_2 (15 Psi) for 3 times, and then the mixture was stirred at 30 °C for 16 h under H_2 atmosphere. After completion, the mixture was filtered and concentrated in vacuum, without further purification to afford the crude product **612d** (350 mg, 99.75% yield) as a colorless oil.

[00773] Step d: 1-((S)-2-cyclopropoxypropyl)-2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (612).



612d

[00774] Example **612** was synthesized from **612d** using the same synthetic procedure as Example **588**. ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 8.43 (d, 1H), 8.21 (s, 1H), 8.03 (d, 1H), 7.78 (d, 1H), 6.98 - 6.85 (m, 2H), 6.77 - 6.70 (m, 1H), 6.58 (d, 1H), 5.23 (s, 2H), 5.13 - 5.00 (m, 1H), 4.59 - 4.52 (m, 1H), 4.44 - 4.30 (m, 2H), 4.04 - 3.96 (m, 1H), 3.69 (brd, 1H), 3.18 (brd, 1H), 2.87 - 2.79 (m, 1H), 2.57 - 2.48 (m, 1H), 2.38 - 2.24 (m, 1H), 2.07 - 1.90 (m, 3H), 1.32 (d, 3H), 1.26 (s, 1H), 1.24 - 1.18 (m, 3H), 0.46 - 0.38 (m, 2H), 0.27 - 0.19 (m, 1H), -0.03 - -0.13 (m, 1H); m/z (ESI, +ve ion) = 608.2 $[M+H]^+$.

[00775] Example 613. (S)-2-((4-((2-(((5-Chloro-3-fluoropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (613).



613

[00776] Example **613** was synthesized by following the synthetic route A-D for Example **554**. ^{1}H NMR (400 MHz, DMSO-d6) δ 13.07 (brs, 1H), 8.34 (d, 1H), 8.16 (d, 1H), 8.12 - 8.04 (m, 2H), 7.50 (dd, 1H), 7.03 - 6.92 (m, 2H), 5.41 (s, 2H), 5.14 - 5.01 (m, 1H), 4.88 - 4.75 (m, 1H), 4.71 - 4.62 (m, 1H), 4.61 - 4.52 (m, 1H), 4.52 - 4.46 (m, 1H), 4.40 - 4.32 (m, 1H), 3.96 (d, 1H), 3.81 (d, 1H), 2.83 - 2.65 (m, 3H), 2.46 - 2.33 (m, 3H), 2.01 - 1.90 (m, 2H), 1.71 - 1.55 (m, 2H); m/z (ESI, +ve ion) = 600.0 $[M+H]^+$.

[00777] Example 614. 2-(((2S,4S)-4-((2-((2,4-Difluorobenzyl)amino)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (614).



614

[00778] **Step A: tert-Butyl (2S,4S)-4-((2-chloropyrimidin-4-yl)oxy)-2-**

methylpiperidine-1-carboxylate (614b).



614a 614b

[00779] A mixture of **614a** (1.5 g, 6.97 mmol) in DMF (2 mL) was added Cs_2CO_3 (6.81 g, 20.90 mmol) and 2,4-dichloropyrimidine (2.08 g, 13.93 mmol). The mixture was stirred at 80 °C for 12H. After completion, the residue was poured water (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL*3). The combined organic phase was washed with brine (200 mL*2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The resulting residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 40/1 to 0/1)) to afford the desired product **614b** (1.05 g, 45.97% yield). m/z (ESI, +ve ion) = 328.2 $[M+H]^+$.

[00780] Step B: tert-Butyl (2S,4S)-4-((2-((2,4-difluorobenzyl)amino)pyrimidin-4-yl)oxy)-2-methylpiperidine-1-carboxylate (614c).



614b 614c

[00781] A mixture of **614b** (100mg, 305.06umol), (2,4-difluorophenyl)methanamine (218.32 mg, 1.53mmol), BINAP(19.00 mg, 30.51umol) and Cs_2CO_3 (198.79 mg, 610.12umol) in toluene (2 mL) was degassed and purged with N_2 for 3 times, then $Pd_2(dba)_3$ (13.97 mg, 15.25umol) was added and degassed and purged with N_2 for 3 times, BINAP (19.00 mg, 30.51umol) and then the mixture was stirred at 90 °C for 16 h under N_2 atmosphere. After completion, the residue was poured into water (30 mL). The aqueous phase was extracted with ethyl acetate (50mL*3). The organic layer was dried over Na_2SO_4 and concentrated to afford the crude product **614c** (25 mg, 18.86% yield) as a colorless oil. m/z (ESI, +ve ion) = 328.2 $[M+H]^+$.

[00782] Step D: Methyl 2-(((2S,4S)-4-((2-((2,4-difluorobenzyl)amino)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (614d).



[00783] To a solution of **614c** (100mg, 230.16 umol) in TFA (0.4 mL) and DCM (1.2 mL). The mixture was stirred at 27 °C for 1H. The mixture was adjusted to pH=7 with saturated sodium bicarbonate solution water solution, extracted with DCM (20mL*3), the organic layer was dried over Na_2SO_4 and concentrated to afford the crude amine (75 mg, 97.46% yield) as a colorless oil. m/z (ESI, +ve ion) = 335.3 $[M+H]^+$.

[00784] A mixture of amine (67.87 mg, 230.29 umol) and N-[(2,4-difluorophenyl)methyl]-4-[[(2S,4S)-2-methyl-4-piperidyl]oxy]pyrimidin-2-amine (77mg, 230.29 umol), DIEA (148.82 mg, 1.15 mmol) in DMF (1 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 85 °C for 5 h under N_2 atmosphere. After completion, the residue was poured into water (30mL). The aqueous phase was extracted with ethyl acetate (20 mL*3). dried over Na_2SO_4, concentrated and purified by silica gel column (PE: EA = 1:1) to afford the desired product **614d** (110 mg, 80.60% yield) as a yellow solid, m/z (ESI, +ve ion) = 593.4 $[M+H]^+$.

[00785] Step E: 2-(((2S,4S)-4-((2-((2,4-Difluorobenzyl)amino)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (614).



[00786] To a solution of **614d** (110 mg, 185.61umol) in THF (0.4 mL) MeOH (0.2 mL) and H_2O (0.2 mL) was added $LiOH.H_2O$ (38.94 mg, 928.06umol). The mixture was stirred at 20 °C for 16 h. After completion, the mixture was adjusted to pH=7 with HCl solution, extracted with DCM: IPA (3:1) (20ML*3), dried over Na_2SO_4, filtrated and concentrated in vacuum. The resulting residue was purified by prep-TLC (PE/EA = 1:1) to afford the desired product **614** (24.75 mg, 23.05% yield). ^1H NMR (400 MHz, CD_3OD) δ ppm 1.19 (brd, 3H) 1.36 - 1.58 (m, 2H) 1.96 (brs, 2H) 2.23 (brt, 1H) 2.40 - 2.51 (m, 2H) 2.69 - 2.80 (m, 2H) 3.56 (d, 1H) 4.29 (dt, 1H) 4.47 - 4.64 (m, 4H) 4.49 (s, 1H) 4.71 (dd, 1H) 4.93 (brdd, 2H) 5.24 -

5.33 (m, 1H) 5.97 (d, 1H) 6.82 - 6.98 (m, 2H) 7.29 - 7.40 (m, 1H) 7.65 (d, 1H) 7.88 - 8.02 (m, 2H) 8.25 (s, 1H); m/z (ESI, +ve ion) = 579.2 $[M+H]^+$.

[00787] Example 615. 2-(((2S,4S)-4-((2-(((5-Chloro-3-fluoropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (615).



615

[00788] Example **615** was synthesized by following the synthetic route A-D for Example **554**. ^{1}H NMR (400 MHz, DMSO-d6) δ ppm 12.88 - 12.67 (m, 1H), 8.35 (brd, 1H), 8.27 (brs, 1H), 8.08 (dt, 2H), 7.85 - 7.78 (m, 1H), 7.70 - 7.62 (m, 1H), 7.04 - 6.95 (m, 2H), 5.41 (s, 2H), 5.16 - 5.08 (m, 1H), 4.80 - 4.70 (m, 2H), 4.61 - 4.35 (m, 3H), 4.30 - 4.21 (m, 1H), 3.68 - 3.52 (m, 1H), 2.81 - 2.61 (m, 2H), 2.41 - 2.27 (m, 2H), 2.17 - 1.80 (m, 3H), 1.52 - 1.30 (m, 2H), 1.26 - 1.11 (m, 3H); m/z (ESI, +ve ion) = 596.2 $[M+H]^+$.

[00789] Example 616. 2-(((2S,4S)-4-((2-(((5-Chloropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (616).



616

[00790] Example **616** was synthesized by following the synthetic route A-D for Example **606**. ^{1}H NMR (400 MHz, CD_3OD) δ = 8.30 (d, 1H), 8.17 (s, 1H), 8.09 (d, 1H), 7.72 (dd, 1H), 7.64 (d, 1H), 7.05 (d, 1H), 6.97 - 6.90 (m, 2H), 5.38 (s, 2H), 5.32 - 5.24 (m, 1H), 4.96 (brd, 1H), 4.75 (dd, 1H), 4.66 - 4.51 (m, 3H), 4.32 (td, 1H), 3.67 (d, 1H), 2.90 - 2.81 (m, 1H), 2.80 - 2.70 (m, 1H), 2.69 - 2.59 (m, 1H), 2.51 - 2.35 (m, 2H), 2.11 (brd, 1H), 2.07 - 1.98 (m, 1H), 1.68 - 1.49 (m, 2H), 1.25 (d, 3H); m/z (ESI, +ve ion) = 629.1 $[M+H]^+$.

[00791] Example 617. 1-((R)-2-(Difluoromethoxy)propyl)-2-(((2S,4S)-4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (617).



617

[00792] Example **617** was synthesized by following the synthetic route A-D for Example **554** using **591d**. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.79 (brs, 1H), 8.45 (d, 1H), 8.23 (s, 1H) 8.04 (ddd, 1H), 7.96 (d, 1H), 7.80 (dd, 1H), 7.64 (d, 1H), 6.74 (d, 1H), 6.24 - 6.65 (m, 1H), 5.50 - 5.60 (m, 2H), 4.70 - 4.84 (m, 2H), 4.57 - 4.68 (m, 1H), 4.40 - 4.55 (m, 2H), 2.62 (brd, 1H), 1.91 - 2.06 (m, 1H), 1.84 (brd, 1H), 1.72 - 1.80 (m, 1H), 1.39 (d, 4H), 1.15 - 1.32 (m, 5H); *m/z* (ESI, +ve ion) = 619.3. $[M+H]^+$.

[00793] Example 618. 1-((R)-2-cyclopropoxypropyl)-2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (618).



618

[00794] Example **618** was synthesized using same synthetic procedure as Example **612** from opposite enantiomer of **612a**. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.43 (d, 1H), 8.20 (s, 1H), 8.04 (d, 1H), 7.79 (d, 1H), 7.01 - 6.85 (m, 2H), 6.77 - 6.70 (m, 1H), 6.57 (d, 1H), 5.23 (s, 2H), 5.11 - 5.00 (m, 1H), 4.70 - 4.55 (m, 2H), 4.19 - 4.11 (m, 1H), 4.05 - 3.95 (m, 1H), 3.48 - 3.41 (m, 1H), 3.13 - 3.06 (m, 1H), 2.75 (brdd, 1H), 2.47 - 2.37 (m, 1H), 2.25 - 2.16 (m, 1H), 2.14 - 2.05 (m, 2H), 1.99 - 1.90 (m, 2H), 1.38 (d, 3H), 1.29 (brd, 3H), 0.43 - 0.32 (m, 2H), 0.18 - 0.07 (m, 1H), -0.26 - -0.35 (m, 1H); m/z (ESI, +ve ion) = 608.2 $[M+H]^+$.

[00795] Example 619. 2-(((2S,4S)-4-((2-(((3,5-Difluoropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (619).



619

[00796] Example **619** was synthesized by following the synthetic route A-D for **Example 606**. ^{1}H NMR (400 MHz, DMSO-d6) δ ppm 13.08 (brd, 1H), 8.33 (d, 1H), 8.15 (s, 1H), 7.92 - 8.09 (m, 2H), 7.51 (d, 1H), 6.90 - 7.02 (m, 2H), 5.40 (s, 2H), 5.11 - 5.19 (m, 1H), 4.70 - 4.87 (m, 2H), 4.42 - 4.57 (m, 3H), 4.24 (dt, 1H), 3.61 (brd, 1H), 2.57 - 2.80 (m, 3H), 2.28 - 2.39 (m, 2H), 2.01 - 2.10 (m, 1H), 1.91 - 2.01 (m, 1H), 1.29 - 1.42 (m, 1H), 1.19 - 1.27 (m, 1H), 1.15 (brd, 3H); m/z (ESI, +ve ion) =598.3 $[M+H]^+$.

[00797] Example 620. 1-((R)-2-(difluoromethoxy)propyl)-2-(((2S,4S)-4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (620).



620

[00798] Example **620** was synthesized using similar procedure as Example **592**. ^{1}H NMR (400 MHz, DMSO-*d6*) δ 8.44 (d, 1H), 8.11 (d, 1H), 8.07 - 7.99 (m, 1H), 7.95 (d, 1H), 7.50 (dd, 1H), 6.73 (d, 1H), 6.67 - 6.21 (m, 1H), 5.63 - 5.46 (m, 2H), 4.86 - 4.59 (m, 3H), 4.55 - 4.37 (m, 2H), 3.37 (brd, 1H), 2.61 (brd, 1H), 2.31 - 2.22 (m, 1H), 2.08 - 1.96 (m, 1H), 1.90 - 1.72 (m, 2H), 1.39 (brd, 4H), 1.31 - 1.13 (m, 4H); *m/z* (ESI, +ve ion) = 637.3 $[M+H]^+$.

[00799] Example 621. 2-(((2S,4S)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (621).



621

[00800] Example **621** was prepared in a manner similar to **Example 589**. ^{1}H NMR (400

MHz, CD_3OD) δ ppm 8.43 (d, 1H), 8.14 (d, 1H), 7.59 - 7.67 (m, 1H), 6.98 - 7.11 (m, 2H), 6.78 - 6.87 (m, 1H), 6.72 (d, 1H), 5.25 (s, 2H), 5.03 - 5.13 (m, 1H), 4.81 (d, 1H), 4.45 - 4.60 (m, 2H), 4.27 - 4.36 (m, 1H), 3.84 - 3.92 (m, 1H), 3.69 - 3.81 (m, 2H), 2.86 - 2.97 (m, 1H), 2.59 - 2.73 (m, 1H), 2.33 - 2.49 (m, 1H), 2.12 - 2.20 (m, 1H), 2.04 - 2.12 (m, 1H), 1.95 - 2.02 (m, 1H), 1.85 - 1.94 (m, 2H), 1.63 - 1.73 (m, 2H), 1.48 - 1.59 (m, 1H), 1.25 (d, 3H); *m/z* (ESI, +ve ion) = 612.2. $[M+H]^+$.

[00801] Example 622. 2-(((2S,4S)-4-((2-(((3,5-Difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (622).



622

[00802] Example **622** prepared in a route similar to **Example 606**. ^1H NMR (400 MHz, $CDCl_3$) δ ppm 8.41 (d, 1H), 8.03 (s, 1H), 7.66 - 7.78 (m, 2H), 7.28 - 7.35 (m, 1H), 6.54 (d, 1H), 5.58 (s, 2H), 4.90 - 5.01 (m, 1H), 4.83 (brd, 1H), 4.49 (brd, 1H), 4.39 (brdd, 1H), 4.28 (brdd, 1H), 3.81 - 3.91 (m, 1H), 3.68 - 3.79 (m, 2H), 2.82 (brd, 2H), 2.51 (brs, 2H), 2.31 (brt, 1H), 2.04 - 2.13 (m, 1H), 1.96 - 2.04 (m, 1H), 1.85 - 1.92 (m, 2H), 1.60 (brdd, 2H), 1.42 - 1.54 (m, 1H), 1.23 (brd, 3H); *m/z* (ESI, +ve ion) = 613.2. $[M+H]^+$.

[00803] Example 623. 3-(2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazol-6-yl)propanoic acid (623).



623

[00804] Step A: (2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazol-6-yl)methanol (Compound 639).



639a 639

[00805] Example 639a (0.2 g, 0.337 mmol) (prepared using a similar procedure as **599f**) was dissolved in toluene (3.4 mL) and was cooled to -78°C. DIBAl-H (1.0M in toluene, 0.674 mmol) was added dropwise and the resulting mixture stirred at -78°C. After 1H, DIBAl-H (1.0M in toluene, 0.169 mmol) was added dropwise and the mixture continued to stir at -78°C. Upon completion of the reaction, the mixture was allowed to warm to 0°C. The mixture was quenched with saturated Rochelle's salt, extracted with EtOAc (5 mL x 3), dried with Na_2SO_4, filtered, and concentrated. The crude residue was purified via flash chromatography (0-5% MeOH in DCM) to afford Compound **639** (155 mg, 81% yield). *m/z* (ESI, +ve ion) = 566.4 $[M+H]^+$.

[00806] **Step B: 2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carbaldehyde (623b).**



639 623b

[00807] To a stirring solution of Compound **639** (42.5 mg, 0.0751 mmol) in MeCN:$CHCl_3$ = 1:1 (0.75 mL) was added MnO_2 (32.7 mg, 0.376 mmol). Upon completion of the reaction, the mixture was filtered, and the solid residue was washed with DCM (2 mL x 3). The filtrate was concentrated to afford compound **623b** (42.3 mg, 100% yield) to be used without further purification. (ESI, +ve ion) = 564.4 $[M+H]^+$.

[00808] **Step C: ethyl (E)-3-(2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazol-6-yl)acrylate (623c).**



623b 623c

[00809] Compound **623b** (42.3 mg, 0.0751 mmol) was dissolved in DCM (0.37 mL) and

ethyl (triphenylphosphoranylidene)acetate (39.2 mg, 0.113 mmol) was then added. The resulting mixture was allowed to stir at ambient temperature. Upon completion of the reaction, the mixture was concentrated and purified via flash chromatography (0-100% EtOAc in hexanes) to afford compound **623c** (13.7 mg, 29% yield). (ESI, +ve ion) = 634.3 $[M+H]^+$.

[00810] Step D: 3-(2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazol-6-yl)propanoic acid (623).



[00811] **623c** (13.7 mg, 0.0022 mmol) was dissolved in anhydrous MeOH (1 mL) and the atmosphere was purged. 10% Pd/C (0.23 mg, 0.0002 mmol) was added, and the mixture was stirred under a H_2 atmosphere. Upon completion of the reaction, the mixture was filtered, and the solid residue was washed with MeOH (2 mL x 3). The filtrate was concentrated to afford the reduced product (8.8 mg, 64% yield) to be used without further purification. (ESI, +ve ion) = 636.4 $[M+H]^+$. The reduced product (8.8 mg, 0.0014 mmol) was dissolved in THF:MeOH:H_2O = 4:1:1 (0.6 mL) and lithium hydroxide monohydrate (2.9 mg, 0.0692 mmol) was added. Upon completion of the reaction, the solution was adjusted to pH = 7 via the addition of acetic acid. Volatiles were evaporated and the resulting aqueous solution was extracted with EtOAc (5 mL x 3). The organic layer was dried with Na_2SO_4, filtered, and concentrated. The crude residue was purified via flash chromatography (0-10% MeOH in DCM) to afford compound **523** (3.6 mg, 43% yield). ^1H NMR (400 MHz, $CDCl_3$) δ: 8.41 (d, 1H), 7.65 (d, 1H), 7.28 (s, 1H), 7.12 (d, 1H), 6.85-6.97 (m, 2H), 6.70-6.77 (m, 1H), 6.56 (d, 1H), 5.15-5.26 (m, 3H), 4.99-5.09 (m, 1H), 4.88 (dd, 1H), 4.50-4.61 (m, 2H), 4.37 (dd, 1H), 4.25 (dt, 1H), 3.52 (d, 1H), 3.11 (brt, 2H), 2.69-2.80 (m, 6H), 2.61-2.68 (m, 1H), 2.34-2.49 (m, 2H), 2.22 (brt, 1H), 2.03 (brd, 1H), 1.90 (brd, 1H), 1.40-1.59 (m, 2H), 1.22 (d, 3H); *m/z* (ESI, +ve ion) = 608.4 $[M+H]^+$.

[00812] Example 624. 2-(((2S,4S)-4-((2-(((3-Chloro-5-fluoropyridin-2-yl)amino)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (624).



624

[00813] Step A: tert-Butyl (2S,4S)-4-((2-formylpyrimidin-4-yl)oxy)-2-methylpiperidine-1-carboxylate (624a).



624a 624b

[00814] To a solution of **624a** (300 mg, 927.68 umol) in DCM (2 ml) was added TEMPO (14.59 mg, 92.77 umol) and iodobenzene diacetate (328.68 mg, 1.02 mmol). The mixture was stirred at 25 °C for 16 h. After completion, the residue was poured into Na_2SO_3 (10 ml) and water (20 ml). The aqueous phase was extracted with DCM (20 ml*3). The combined organic layer was dried over Na_2SO_4, concentrated and purified by prep-TLC (PE/EA = 1:1) to afford the desired product **624b** (226 mg, 75.81% yield) as a colorless oil. m/z (ESI, +ve ion) = 340.3 $[M+H]^+$.

[00815] Step B: tert-Butyl (2S,4S)-4-((2-(((3-chloro-5-fluoropyridin-2-yl)amino)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidine-1-carboxylate (624c).



624b 624c

[00816] A mixture of **624b** (20 mg, 62.23 umol), 3-chloro-5-fluoro-pyridin-2-amine (18.24 mg, 124.47 umol) in ACN (2 ml) was added triethylsilane (53.55 mg, 460.53 umol, 73.56 uL) and TFA (53.93 mg, 472.97 umol, 35.02 ul) degassed and purged with N_2 for 3 times, and then the mixture was stirred at 70 °C for 4 h under N_2 atmosphere. After completion, the mixture was adjusted to pH=7 with saturated sodium bicarbonate solution water solution, extracted with ethyl acetate (20 ml*3). The combined organic layer was dried over Na_2SO_4, concentrated and purified by prep-TLC (PE/EA = 3:1) to afford the desired product **624c** (8 mg, 28.44% yield) as a white oil. m/z (ESI, +ve ion) = 452.1 $[M+H]^+$.

[00817] Step C: Methyl 2-(((2S,4S)-4-((2-(((3-chloro-5-fluoropyridin-2-yl)amino)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-

yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (624d).



[00818] To a solution of **624c** (60 mg, 132.77 umol) in TFA (0.2 ml) and DCM (0.6 ml) . The mixture was stirred at 25 °C for 1H . After completion, the mixture was adjusted to pH=7 with saturated sodium bicarbonate water solution, extracted with DCM (20 ml*3). The combined organic layer was dried over Na_2SO_4 and concentrated to afford the crude product (46 mg, 98.48% yield) as a yellow oil, which was used in the next step reaction without further purification. *m/z* (ESI, +ve ion) = 352.2 $[M+H]^+$.

[00819] A mixture of amine (170 mg, 483.22 umol) , methyl 2 -(chloromethyl) – 3 - [[(2S) – oxetan – 2 -yl] methyl] benzimidazole – 5 - carboxylate (185.15 mg, 628.19 umol), DIPEA (312.26 mg, 2.42 mmol, 420.84 ul) in DMF (2 ml) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 85 °C for 16 h under N_2 atmosphere. After completion, the reaction mixture was filtrated and concentrated in vacuo. The resulting residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=50/1 to 0/1) to afford the desired product **624d** (170 mg, 57.67% yield) as a yellow oil. m/z (ESI, +ve ion) = 610.3 $[M+H]^+$.

[00820] Step D: 2-(((2S,4S)-4-((2-(((3-Chloro-5-fluoropyridin-2-yl)amino)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid.



[00821] A mixture of **624d** (170 mg, 278.65 umol), $LiOH.H_2O$ (58.47 mg, 1.39 mmol) in THF (1 ml), MeOH (1 ml) and H_2O (1 ml) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 0-20 °C for 16 h under N_2 atmosphere. After completion, the reaction mixture was cooled to 0 °C, and pH was then adjusted to 5 by the addition of 1N HCl carefully. Aqueous layer was extracted with EtOAc (10 mL x 3). The combined organic layer was dried over Na_2SO_4, filtered, concentrated and purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150 * 40mm * 10um; mobile phase: [water (NH_4HCO_3) -ACN]; B%:

10%-45%,8min) to afford the desired product **624** (65.5 mg, 39.44% yield). ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 8.42 (d, 1H), 8.24 (s, 1H), 8.08 (d, 1H), 7.95 (d, 1H), 7.85 (d, 1H), 7.37 (dd, 1H), 6.55 (d, 1H), 6.17 (brt, 1H), 5.31 - 5.24 (m, 1H), 5.18 - 5.10 (m, 1H), 5.03 - 4.96 (m, 1H), 4.75 (brd, 2H), 4.69 - 4.53 (m, 3H), 4.34 - 4.27 (m, 1H), 3.69 (brd, 1H), 2.87 (brd, 1H), 2.72 (brdd, 2H), 2.49 - 2.30 (m, 3H), 2.15 (brd, 1H), 2.05 - 1.98 (m, 1H), 1.70 - 1.50 (m, 2H), 1.27 (brd, 3H); *m/z* (ESI, +ve ion) = 569.2$[M+H]^+$.

[00822] Example 625. 2-(((2S,4S)-4-((2-(((5-Cyano-3-fluoropyridin-2-yl)oxy)methyl)pyridin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (625).



625

[00823] Example **625** was prepared in a manner similar to **Example 606**. ^{1}H NMR (400 MHz, CD_3OD) δ = 8.35 (d, 1H), 8.32 (d, 1H), 8.15 (s, 1H), 7.97 (dd, 1H), 7.63 (d, 1H), 7.09 (d, 1H), 6.96 (dd, 1H), 5.54 (s, 2H), 5.33 - 5.24 (m, 1H), 4.97 (brd, 1H), 4.73 (brd, 1H), 4.64 - 4.56 (m, 4H), 4.32 (td, 1H), 3.65 (brd, 1H), 2.89 - 2.81 (m, 1H), 2.80 - 2.70 (m, 1H), 2.68 - 2.58 (m, 1H), 2.51 - 2.34 (m, 2H), 2.13 (brd, 1H), 2.09 - 2.01 (m, 1H), 1.69 - 1.50 (m, 2H), 1.25 (d, 3H); m/z (ESI, +ve ion) = 605.2 $[M+H]^+$.

[00824] Example 626. 2-(((2S,4S)-4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-((R)-2-(difluoromethoxy)propyl)-1H-benzo[d]imidazole-6-carboxylic acid.



626

[00825] Example **626** was prepared in a manner similar to **Example 606**. ^{1}H NMR (400 MHz, CD_3OD) δ = 8.38 (d, 1H), 8.26 (s, 2H), 8.05 (dd, 1H), 7.96 (d, 1H), 7.66 (d, 1H), 6.68 (d, 1H), 6.36 - 5.93 (m, 1H), 5.74 - 5.59 (m, 2H), 4.45 - 4.37 (m, 1H), 3.38 (d, 1H), 2.72 - 2.61 (m, 1H), 2.31 (brdd, 1H), 2.11 - 1.95 (m, 2H), 1.80 (brd, 1H), 1.56 - 1.37 (m, 5H), 1.31 (d, 3H); *m/z* (ESI, +ve ion) = 626.2.

[00826] Example 627. 2-(((2S,4S)-4-((2-(((3-Cyano-5-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-((R)-2-(difluoromethoxy)propyl)-1H-benzo[d]imidazole-6-carboxylic acid (627).



627

[00827] Example **627** was prepared in a manner similar to **Example 606**. ^{1}H NMR (400 MHz, DMSO-d6) δ = 8.54 (dd, 1H), 8.48 - 8.38 (m, 2H), 8.21 (s, 1H), 7.80 (d, 1H), 7.63 (d, 1H), 6.74 (d, 1H), 6.44 (t, 1H), 5.71 - 5.51 (m, 2H), 4.87 - 4.67 (m, 2H), 4.66 - 4.56 (m, 1H), 4.55 - 4.36 (m, 2H), 2.72 - 2.57 (m, 1H), 2.35 - 2.19 (m, 1H), 2.04 - 1.95 (m, 1H), 1.87 - 1.63 (m, 2H), 1.43 - 1.33 (m, 4H), 1.28 - 1.21 (m, 2H), 1.18 (d, 3H); *m/z* (ESI, +ve ion) = 626.1 $[M+H]^+$.

[00828] Example 628. (S)-2-((4-((2-(((3,5-difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (628).



628

[00829] Example **628** was was prepared in a manner similar to **Example 606**. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.30-8.39 (m, 1H), 7.83-7.96 (m, 1H), 7.65-7.71 (m, 1H), 7.57-7.65 (m, 1H), 6.46-6.54 (m, 1H), 5.43-5.56 (m, 2H), 5.08-5.18 (m, 1H), 4.89-4.98 (m, 1H), 4.52-4.71 (m, 3H), 4.27-4.38 (m, 1H), 3.84-4.02 (m, 2H), 2.59-2.80 (m, 3H), 2.26-2.44 (m, 4H), 2.00-2.13 (m, 3H), 1.92-1.96 (m, 1H), 1.74-1.89 (m, 4H), 1.65-1.70 (m, 1H), 1.62-1.64 (m, 1H), 1.17 (s, 2H); *m/z* (ESI, +ve ion) = 585.3 $[M+H]^+$.

[00830] Example 629. 2-(((2S,4S)-4-((2-(((3-cyano-5-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (629).



629

[00831] Example **629** was prepared in a manner similar to **Example 606**. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.31 (d, 1H), 8.06 (d, 1H), 7.97 (s, 1H), 7.63-7.69 (m, 2H), 6.46 (d, 1H), 5.48-5.57 (m, 2H), 5.14-5.21 (m, 1H), 4.82-4.93 (m, 2H), 4.44-4.58 (m, 3H), 4.22 (dt, 1H), 3.62 (d, 1H), 2.59-2.75 (m, 2H), 2.26-2.48 (m, 3H), 2.14-2.25 (m, 2H), 2.10 (brs, 1H), 1.94 (brd, 2H), 1.80 (brd, 2H), 1.34-1.54 (m, 3H), 1.04-1.26 (m, 4H); *m/z* (ESI, +ve ion) = 606.6 $[M+H]^+$.

[00832] Example 630. 2-(((2S,4S)-4-((2-(((3-Cyano-5-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (630)



630

[00833] Example **630** was prepared in a manner similar to **Example 606**. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.28 (d, 1H), 8.14 (s, 1H), 8.05 (d, 1H), 7.97 (dd, 1H), 7.73 (d, 1H), 7.61 (dd, 1H), 6.45 (d, 1H), 5.46-5.55 (m, 2H), 5.14-5.22 (m, 1H), 4.81-4.91 (m, 2H), 4.42-4.56 (m, 3H), 4.20 (dt, 1H), 3.54 (d, 1H), 2.58-2.73 (m, 2H), 2.25-2.44 (m, 2H), 2.06-2.22 (m, 2H), 1.84-2.00 (m, 2H), 1.70-1.83 (m, 3H), 1.34-1.52 (m, 4H), 1.07-1.22 (m, 4H); *m/z* (ESI, +ve ion) = 588.3 $[M+H]^+$.

[00834] Example 631. 2-(((2S,4S)-4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (631).



631

[00835] Example **631** was prepared in a manner similar to **Example 606**. ^{1}H NMR (400

MHz, $CDCl_3$) δ: 8.29 (d, 1H), 8.14 (s, 1H), 8.10 (d, 1H), 7.95 (dd, 1H), 7.71 (d, 1H), 7.52 (dd, 1H), 7.18 (s, 6H), 6.46 (d, 1H), 5.50-5.60 (m, 2H), 4.68-4.89 (m, 2H), 4.41 (d, 1H), 4.15-4.36 (m, 2H), 3.74-3.81 (m, 1H), 3.64-3.70 (m, 1H), 3.57 (d, 1H), 2.66-2.79 (m, 1H), 2.29-2.44 (m, 1H), 2.16 (brt, 1H), 1.87-2.01 (m, 3H), 1.70-1.85 (m, 4H), 1.36-1.62 (m, 6H), 1.04-1.29 (m, 5H); *m/z* (ESI, +ve ion) = 602.4 $[M+H]^+$.

[00836] Example 632. 2-(((2S,4S)-4-((2-(((3,5-Difluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-tetrahydrofuran-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (632).



632

[00837] Example **632** was prepared in a manner similar to **Example 606.** ^1H NMR (400 MHz, $CDCl_3$) δ: 8.30 (d, 1H), 8.15 (s, 1H), 7.95 (d, 1H), 7.70 (d, 1H), 7.66 (d, 1H), 6.44 (d, 1H), 5.48 (s, 2H), 4.81-4.90 (m, 1H), 4.74 (brdd, 1H), 4.18-4.43 (m, 3H), 3.78 (q, 1H), 3.63-3.70 (m, 1H), 3.56 (d, 1H), 2.61-2.79 (m, 1H), 2.26-2.45 (m, 1H), 2.07-2.23 (m, 2H), 1.74-2.02 (m, 6H), 1.72-1.73 (m, 1H), 1.33-1.58 (m, 4H), 1.14 (d, 4H); *m/z* (ESI, +ve ion) = 595.3 $[M+H]^+$.

[00838] Example 633. 2-(((2S,4S)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole (633).



633

[00839] Example **633** was prepared in a manner similar to **Example 599**. ^1H NMR (400 MHz, $CDCl_3$) δ: 8.32 (d, 1H), 7.64-7.71 (m, 1H), 7.30-7.36 (m, 1H), 7.15-7.21 (m, 2H), 6.75-6.90 (m, 2H), 6.61-6.68 (m, 1H), 6.47 (d, 1H), 5.11-5.16 (m, 2H), 4.91-4.99 (m, 1H), 4.87 (dd, 1H), 4.46-4.55 (m, 2H), 4.32 (dd, 1H), 4.17 (dt, 1H), 3.42 (d, 1H), 2.71 (dt, 1H), 2.52-2.64 (m, 1H), 2.28-2.40 (m, 2H), 2.06-2.17 (m, 1H), 1.90-1.99 (m, 2H), 1.82 (brd, 1H), 1.31-1.52 (m, 2H), 1.14 (d, 3H). m/z (ESI, +ve ion) = 536.0 $[M+H]^+$.

[00840] Example 634. (S)-2-((4-((2-(((5-Cyano-3-fluoropyridin-2-

yl)oxy)methyl)pyrimidin-4-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (634).



634

[00841] Example **634** was prepared in a manner similar to **Example 606**. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.39 (d, 1H), 8.18 (d, 1H), 7.94 (brs, 1H), 7.58-7.68 (m, 2H), 7.49-7.57 (m, 1H), 6.58 (d, 1H), 5.63 (s, 2H), 5.15 (brs, 1H), 4.98 (brs, 1H), 4.55-4.68 (m, 2H), 4.34 (brs, 1H), 3.95 (brs, 2H), 2.68-2.79 (m, 2H), 2.39 (brs, 3H), 2.27 (brs, 3H), 2.05 (brs, 1H), 1.85-1.92 (m, 2H), 1.67-1.72 (m, 1H), 1.37-1.37 (m, 1H), 1.35-1.52 (m, 1H), 1.26 (s, 2H), 0.80-0.94 (m, 1H), 0.04-0.13 (m, 1H). m/z (ESI, +ve ion) = 592.0 $[M+H]^+$.

[00842] Example 635. 2-(((2S,4S)-4-((2-(((5-Cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzo[d]imidazole-6-carboxylic acid (635).



635

[00843] Example **635** was prepared in a manner similar to **Example 606.** ^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.29 (d, 1H), 8.09 (d, 2H), 7.97 (brd, 1H), 7.70 (brd, 1H), 7.53 (dd, 1H), 6.46 (d, 1H), 5.55 (s, 2H), 4.78-4.93 (m, 2H), 4.33-4.49 (m, 2H), 3.80-4.01 (m, 2H), 3.53-3.68 (m, 2H), 3.42-3.52 (m, 1H), 2.65 (brd, 1H), 2.32 (brs, 1H), 2.03-2.16 (m, 1H), 1.87-2.00 (m, 1H), 1.78 (brd, 1H), 1.33-1.49 (m, 2H), 1.17 (brd, 3H). m/z (ESI, +ve ion) = 644.4 $[M+H]^+$.

[00844] Example 636. 2-(((2S,4S)-4-((2-(((5-cyano-3-fluoropyridin-2-yl)oxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-4-fluoro-1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzo[d]imidazole-6-carboxylic acid (636).



636

[00845] Example **636** was prepared in a manner similar to **Example 606.** ^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.29 (d, 1H), 8.05-8.11 (m, 1H), 7.86 (brs, 1H), 7.52-7.65 (m, 2H), 6.46 (d, 1H), 5.55 (s, 2H), 4.73-4.92 (m, 2H), 4.39 (brd, 2H), 3.79-3.98 (m, 2H), 3.65 (brdd, 2H), 3.49 (brd, 1H), 2.63 (brd, 1H), 2.33 (brs, 1H), 2.11 (brt, 1H), 1.88-2.01 (m, 1H), 1.70-1.85 (m, 1H), 1.31-1.47 (m, 2H), 1.16 (brd, 3H). m/z (ESI, +ve ion) = 662.3 $[M+H]^+$.

[00846] Example 637. 2-(2-(((2S,4S)-4-((2-((2,4-difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazol-6-yl)acetic acid (637).



637

[00847] Example **637** was prepared in a manner similar to **Example 599**. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.33 (d, 1H), 7.58-7.66 (m, 1H), 7.23-7.32 (m, 1H), 7.19 (s, 1H), 7.08-7.13 (m, 1H), 6.76-6.88 (m, 2H), 6.58-6.69 (m, 1H), 6.47 (d, 1H), 5.14 (s, 2H), 5.03-5.09 (m, 1H), 4.88-5.02 (m, 1H), 4.73-4.86 (m, 1H), 4.38-4.50 (m, 2H), 4.28 (brdd, 1H), 4.08-4.21 (m, 1H), 3.67 (s, 2H), 3.47 (brd, 1H), 2.68 (brd, 1H), 2.46-2.60 (m, 1H), 2.23-2.40 (m, 2H), 2.14 (brt, 1H), 1.88-2.02 (m, 1H), 1.80 (brd, 1H), 1.32-1.51 (m, 2H), 1.20-1.28 (m, 1H), 1.18 (brs, 1H), 1.12 (brd, 3H); m/z (ESI, +ve ion) = 594.3 $[M+H]^+$.

[00848] Example 638. 2-(((2S,4S)-4-((2-((2,4-Difluorophenoxy)methyl)pyrimidin-4-yl)oxy)-2-methylpiperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-N-(pyridin-3-yl)-1H-benzo[d]imidazole-6-carboxamide (638).



638



[00849] DIPEA (0.018 mL, 0.104 mmol) was added to a stirring solution of Compound **638a** (prepared as in **Example 599**) (20 mg, 0.035 mmol) in DMF (0.5 mL). After 5 minutes, HATU (16 mg, 0.069 mmol) was added, followed by the addition of pyridin-3-amine (3.6 mg, 0.038 mmol) in DMF (0.5 mL). The solution stirred o/n at rt. Pyridin-3-amine (7 mg, 0.076 mmol) was then added and the mixture stirred for another 4 h. The reaction was quenched with water, extracted with EtOAc (3 x 5 mL), dried with Na_2SO_4, filtered, and concentrated. Flash chromatographic purification (0-10% MeOH in DCM) afforded the desired product (7.9 mg, 35% yield). ^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.74 (d, 1H), 8.36-8.43 (m, 3H), 8.33 (brd, 1H), 8.13 (s, 1H), 7.77-7.82 (m, 1H), 7.74 (d, 1H), 7.29-7.38 (m, 1H), 6.84-7.01 (m, 2H), 6.69-6.77 (m, 1H), 6.56 (d, 1H), 5.22 (s, 2H), 5.00-5.09 (m, 1H), 4.94 (dd, 1H), 4.51-4.64 (m, 3H), 4.30 (dt, 1H), 3.59 (d, 1H), 2.64-2.83 (m, 2H), 2.38-2.50 (m, 2H), 2.20-2.33 (m, 1H), 2.04 (brd, 1H), 1.92 (brd, 1H), 1.58 (qd, 1H), 1.41-1.49 (m, 2H), 1.21 (d, 3H). *m/z* (ESI, +ve ion) = 656.4 $[M+H]^+$.

[00850] **Example 640 and 641. 2-(((1r,4S)-4-((2-((4-cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)cyclohexyl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (640) and 2-(((1s,4R)-4-((2-((4-cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)cyclohexyl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (641).**



[00851] **Step A: 4-((4-Chloropyrimidin-2-yl)methoxy)-3-fluorobenzonitrile (640b).**



[00852] A mixture of **640a** (1.0 g, 4.8 mmol, 1.0 eq), 3-fluoro-4-hydroxybenzonitrile (0.66 g, 4.8 mmol, 1.0 eq), K_2CO_3 (1.99 g, 14.4 mmol, 3.0 eq) in DMF (10 mL) was kept stirring at 20°C for 2H. The mixture was diluted with EA (20 mL), washed with H_2O (10 mL*2). The organic layer was dried over Na_2SO_4, filtrated and concentrated in vacuo. The residue was purified by SGC (UV254, EA/PE=1:10) to afford **640b** (1.1 g, 78% yield); *m/z* (ESI, +ve ion) = 264.0 $[M+H]^+$.

[00853] **Step B: Methyl 2-(4-((2-((4-cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)cyclohexyl)acetate (640c)**.



[00854] A mixture of **640b** (270 mg, 1.024 mmol, 1.0 eq), methyl 2-(4-hydroxycyclohexyl)acetate (264 mg,1.54 mmol, 1.1 eq) $Pd_2(dba)_3$ (94 mg, 0.10 mmol, 0.1 eq), BINAP (127 mg, 0.20 mmol, 0.2 eq), K_3PO_4 (652 mg, 3.07 mmol, 3.0 eq) in Tol (6 mL) was kept stirring at 100°C for 18h under N_2. The mixture was filtrated and concentrated in vacuo. The residue was purified by SGC (UV254, EA/PE=1:1) to afford **640c** (364 mg, 66%) as a yellow gum; *m/z* (ESI, +ve ion) = 400.1 $[M+H]^+$.

[00855] **Step C: Methyl (S)-4-(2-(4-((2-((4-cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)cyclohexyl)acetamido)-3-((oxetan-2-ylmethyl)amino)benzoate (640d)**.



[00856] A mixture of **640c** (280 mg, 0.701 mmol, 1.0 eq), LiOH (168 mg, 7.01 mmol, 10.0 eq) in a mix solution of THF/H_2O (2.5 mL/2.5 mL) was kept stirring at 30°C for 18h. The mixture was adjusted pH=6 with 6N HCl, extracted with EA (15 mL*2). The organic layer was dried over Na_2SO_4, filtrated and concentrated in vacuo to afford acid (202 mg, 60% yield). *m/z* (ESI, +ve ion) = 386.1 $[M+H]^+$.

[00857] A mixture of acid (202 mg, 0.847 mg, 1.0 eq), methyl 4-amino-3-{[(2S)-oxetan-2-ylmethyl]amino}benzoate (124 mg, 0.524 mmol, 1.0 eq), DIEA (203 mg, 1.572 mmol, 3.0 eq) in DCM (10 mL) was added T_3P (500 mg, 0.786 mmol, 1.5 eq, 50% in EA) at 0°C. The

mixture was kept stirring at 20°C for 1.5h. The mixture was concentrated and purified by Pre-TLC (UV254, EA/PE=2:1) to afford **640d** (162 mg, 46% yield) as a yellow oil; *m/z* (ESI, +ve ion) = 604.2.

[00858] Step D: Methyl (S)-2-((4-((2-((4-cyano-2-fluorophenoxy)methyl)pyrimidin-4-yl)oxy)cyclohexyl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (640e).



[00859] A mixture of **640d** (162 mg, 0.268 mmol, 1.0 eq) in HOAc (3 mL) was kept stirring at 100°C for 0.5h. The mixture was concentrated. The residue was purified by Pre-TLC (UV254, EA/PE=2:1) to afford less polar **640e** (51 mg) and more polar **640f** (28 mg). *m/z* (ESI, +ve ion) = 585.9. Both diasteromers **640e** and **640f** were separated by SFC chromatography.

[00860] Step E: 1-{[(2S)-Oxetan-2-yl]methyl}-2-{[(1r,4r)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)cyclohexyl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (640).



[00861] A mixture of **640e** (58 mg, 0.099 mmol, 1.0 eq) in THF/H_2O (1:1) (3.5 mL) was added LiOH (43 mg, 1.485 mmol, 15.0 eq). The mixture was kept stirring at 30°C for 32H. The mixture was adjusted pH=6 with 1N HCl. The mixture was extracted with EA (15 mL*2). The organic layer was concentrated and purified by reverse phase (UV214, CH_3CN/H_2O (0.5% NH_4OH) =29%) to afford **640** (19 mg,31.92%). ^1H NMR (400 MHz, CD_3OD) δ ppm 8.42 (d, 1H), 8.17 (s, 1H), 7.96 (d, 1H), 7.61 (t, 2H), 7.50 (d, 1H), 7.26 (t,

1H), 6.71 (d, 1H), 5.42 (s, 2H), 5.24 (d, 1H), 4.93 (s, 1H), 4.71 – 4.61 (m, 2H), 4.53 (d, 1H), 4.49 – 4.42 (m, 1H), 2.98 (d, 2H), 2.81 (s, 1H), 2.55 (d, 1H), 2.06 (s, 1H), 1.99 (d, 2H), 1.86 (d, 2H), 1.44 (t, 2H), 1.23 – 1.10 (m, 2H); *m/z* (ESI, +ve ion) = 571.9 $[M+H]^+$.

[00862] Step F: 1-{[(2S)-Oxetan-2-yl]methyl}-2-{[(1s,4s)-4-({2-[(4-cyano-2-fluorophenoxy)methyl]pyrimidin-4-yl}oxy)cyclohexyl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (641)



641

[00863] A mixture of **640f** (28 mg, 0.0478 mmol, 1.0 eq) in a mix solution of THF/H_2O (1:1) (3.5 mL) was added LiOH (17 mg, 0.717 mmol, 15.0 eq). The mixture was kept stirring at 30°C for 32h. The mixture was adjusted pH=6 with 1N HCl. The mixture was extracted with EA (15 mL*2). The organic layer was concentrated and purified by reverse phase (UV214, CH3CN/H_2O (0.5% NH_4OH)=27%) to afford **641** (6.2 mg, 21.55% yield). H NMR (400 MHz, CD_3OD) δ ppm 8.45 (d, 1H), 8.20 (s, 1H), 8.00 – 7.92 (m, 1H), 7.65 – 7.55 (m, 2H), 7.48 (d, 1H), 7.24 (t, 1H), 6.80 (d, 1H), 5.39 (s, 2H), 5.30 – 5.16 (m, 2H), 4.71 – 4.58 (m, 2H), 4.52 (dd, 1H), 4.42 (dt, 1H), 3.00 (dd, 2H), 2.86 – 2.74 (m, 1H), 2.58 – 2.45 (m, 1H), 2.18 (s, 1H), 1.96 (d, 2H), 1.59 (dt, 6H); *m/z* (ESI, +ve ion) = 571.9 $[M+H]^+$.

[00864] Biological Example 1

GLP-1R cAMP assay

[00865] cAMP accumulation was measured in Chinese hamster ovary (CHO) cells (10,000 cells/well) stably overexpressing the human GLP-1 receptor using the HitHunter cAMP Assay for Small Molecules Kit (Eurofins). Briefly, cells were grown in Ham's F12 Nutrient Mix with 10% FBS, and lifted with Cell Dissociation Buffer, Enzyme free, PBS based (ThermoFisher). Cells were pelleted, and resuspended in Hank's buffered saline solution with 10 mM HEPES, and 625 µM 3-isobutyl-1-methylxanthine. The anti-cAMP antibody reagent was then added to cells at a 1:2 ratio and 5 µL of mixture was seeded in 384-well small volume white assay plates, at 10,000 cells/well. Cells were then treated with 50 nL compound using an ECHO 550 acoustic dispenser (Labcyte) in a 20-point dose response format in triplicate for 30 min. Cells were then lysed, and detection reagents added according to the manufacturer's protocol. After overnight incubation, luminescence was

measured using a Perkin Elmer Envision plate reader. Dose response curves were analyzed using GraphPad Prism 9.0.

[00866] Results are reported in the Table below. In the Table, EC_{50} values are designated as follows:

A: 0 nM < EC_{50} < 0.1 nM;
B: 0.1 nM ≤ EC_{50} < 1.0 nM;
C: 1.0 nM ≤ EC_{50} < 10.0 nM;
D: 10.0 nM ≤ EC_{50} < 100 nM;
E: 100 nM ≤ EC_{50} < 500 nM; and
F: ≥ 500 nM

[00867] Molecular weights are calculated by standard techniques, and mass spectrometry results are reported according to the Examples above.

Table 3

Example Compound	EC_{50}	MW Calc.	$[M+H]^+$ Found
552	B	590.588	591.3
553	B	590.588	591.3
554	A	597.04	597.2
555	A	613.06	613.2
556	B	587.612	588.2
557	C	621.07	621.2
558	B	600.651	601.3
559	B	594.62	595.2
560	B	601.639	602.2
561	B	586.624	587.2
562	B	579.605	580.3
563	B	656.71	657.2
564	B	682.74	683.4
565	C	579.605	580.3
566	B	580.593	581.3
567	B	569.622	570.2
568	B	593.632	594.3
569	F	611.647	612.3
570	B	605.643	606.3
571	D	583.62	584.3
572	B	597.595	598.1

Example Compound	EC_{50}	MW Calc.	$[M+H]^+$ Found
573	A	604.615	605.2
574	C	587.612	588.2
575	B	593.632	594.2
576	A	597.595	598.3
577	B	609.631	610.3
578	B	600.651	601.2
579	B	600.651	601.3
580	C	573.585	574.2
581	A	597.595	598.2
582	B	597.595	598.3
583	B	629.613	630.3
584	B	593.632	594.2
585	B	593.632	594.1
586	C	600.651	601.1
587	A	600.651	601.1
588	A	635.592	636.5
589	B	593.631	594.2
590	B	577.632	578.2
591	B	617.601	618.2
592	A	617.601	618.2
594	C	649.619	650.2
595	B	653.032	654.3
596	A	642.612	643.3
597	A	615.035	615.3
598	B	649.619	650.2
599	B	640.596	641.2
600	B	607.659	608.3
601	A	642.612	643.3
602	B	635.041	635.2
603	A	597.044	597.2
604	B	587.612	588.3

Example Compound	EC_{50}	MW Calc.	$[M+H]^+$ Found
605	A	601.008	601.1
606	A	598.583	599.2
607	A	605.603	606.2
608	B	611.071	611.2
609	D	611.071	611.2
610	B	627.664	628.2
611	B	627.664	628.2
612	C	607.659	608.2
613	B	600.020	600.0
614	B	578.621	579.2
615	B	596.056	596.2
616	B	596.056	596.2
617	A	618.590	619.3
618	B	607.659	608.2
619	C	597.595	598.3
620	B	636.580	637.3
621	A	611.622	612.2
622	B	612.610	613.2
623	C	607.659	608.4
624	C	596.060	596.2
625	C	604.615	605.2
626	B	625.609	626.2
627	B	625.609	626.1
628	B	584.556	585.3
629	A	605.603	606.3
630	B	587.612	588.3
631	B	601.639	602.4
632	B	594.620	595.4
633	D	535.596	536.0
634	B	591.576	592.0
635	B	643.600	644.4

Example Compound	EC_{50}	MW Calc.	$[M+H]^+$ Found
636	B	661.590	662.3
637	C	593.632	594.3
638	D	655.707	656.4
639	D	565.622	566.4
640	A	571.609	571.9
641	E	571.609	571.9

[00868] In addition to potency, the compounds disclosed and claimed herein may have other beneficial and advantageous physiological properties that may enhance their utility as human or animal therapeutics. Those beneficial and advantageous properties may be determined using a variety of tests and assays known and available to the skilled person. For example, such tests and assays include but are not limited to the cAMP assay in serum; plasma protein binding-multiple species assays, ADME and Tox assays, including metabolic stability assays (LM stability assay for multiple species, Hepatocyte suspension stability assay for multiple species; Solubility assays-multiple pH or simulated fluid; Permeability assays-MDCK/Caco-2/Pampa; hERG Inhibition Assay-binding/patch-clamp; CYP Inhibition assays-Multiple isoforms; CYP induction assay; CYP TDI Assay; Liver transporter (substrate/inhibitor)-multiple species; Rat PK (IV/PO, cassette or discrete); Mouse PK (IV/PO, cassette or discrete) Dog PK (IV/PO, cassette or discrete); Cyno PK (IV/PO, cassette or discrete); huMouse Efficacy assays, Cyno Efficacy assays, Relay hepatocyte assays, Hepatocyte uptake assays (Drug Metab Dispos. 2007 Jun;35(6):859-65); 2D Co-culture Hepatocyte assay-multiple species (24thNorth American ISSX Meeting: Broadening Our Horizons September 13-17, 2021).

[00869] A number of vendors offer these assays as kits or services, including BioDuro-Sudia (9601 Jeronimo Road, Irvine, CA 92618), WuXi AppTec (288 Fute Zhong Road, Waigaoqiao FreeTrade Zone, Shanghai 200131, China), Eurofins Discovery X (42501 Albrae Street, Fremont, CA 94538, USA), Pharmaron (404 Wyman Street, Suite 405, Waltham, MA 02451), and Meadowhawk Biolabs (33 Locke Dr, Marlborough, MA, 01752).

Equivalents

[00870] The disclosure set forth above may encompass multiple distinct embodiments with independent utility. Although each of these embodiments has been disclosed, the specific

embodiments thereof as disclosed and illustrated herein are not to be considered in a limiting sense, because numerous variations are possible. The subject matter of the embodiments includes all novel and nonobvious combinations and subcombinations of the various elements, features, functions, and/or properties disclosed herein. The following claims particularly point out certain combinations and subcombinations regarded as novel and nonobvious. Alternative embodiments as in other combinations and subcombinations of features, functions, elements, and/or properties may be claimed in this application, in applications claiming priority from this application, or in related applications. Such claims, whether directed to a different embodiment or to the same embodiment, and whether broader, narrower, equal, or different in scope in comparison to the original claims, also are regarded as included within the subject matter of this disclosure.

[00871] One or more features from any embodiments described herein or in the figures may be combined with one or more features of any other embodiments described herein or in the figures without departing from the scope of this disclosure.

[00872] All publications, patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing disclosure has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this disclosure that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

CLAIMS

1. A compound according to Formula (**LVII**), (**LVIII**), (**LIX**), (**LX**), (**LXI**), or (**LXII**), or Compounds **552**, **553**, **558**, **561**, **562**, **572**, **573**, **576**, **578**, **581**, **640**, and **641**; or a pharmaceutically acceptable salt, or stereoisomer thereof:



(LVII);



(LVIII);



(LIX);



(LX);



(LXI); or



(LXII),

wherein:

when the compound is according to Formula (**LVII**), $\mathbf{B^4}$ is -CH-, -C($\mathbf{R^2}$)-, or -N-;

$\mathbf{D^1}$ is -CH-or -N-;

$\mathbf{D^2}$ is -CH-, -N-, -C(CH_3)-;

$\mathbf{D^4}$ is -CH- or -N-;

W is N, $\mathbf{CR^{14}}$, or C; when **W** is $\mathbf{CR^{14}}$, the adjacent dashed line indicates a single bond; when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=;

$\mathbf{L^1}$ is selected from the group consisting of -O-, $-CH_2-$, -NH-, -N(Me)-, -N(Et)-, $-OCH_2-$, -OC(H, Me)-, $-CH_2O-$, $-NHCH_2-$, $-CH_2NH-$, $-N(Me)CH_2-$, and $-SO_2NH-$;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, $-CH_2-$, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

$\mathbf{L^3}$ is $-CH_2-$, -C(O)-, or $-CH(CH_3)-$;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^3}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

$\mathbf{R^4}$ is selected from the group consisting of alkyl, substituted alkyl, unsubstituted arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl;

$\mathbf{R^5}$ is selected from the group consisting of -H, $-CH_2OH$, -COOH, $-CH_2COOH$, $-(CH_2)_2COOH$, $-COCF_3$, $-C(OH)CF_3$, -CONHCN, -CONHOH, CONHOMe, $-CONHSO_2N(Me)_2$, $-PO_3H_2$, -PO(Me)(OH), $-SO_3H$, $-SO_2NH_2$, $-SO_2NHMe$, $-B(OH)_2$, , , , , , tetrazolyl, and ;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

$\mathbf{R^{14}}$ is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4;

wherein when the compound is according to Formula (**LVIII**), $\mathbf{R^3}$ is independently selected from the group consisting of -CH_2CH_3, -CH_2F, -CH_2CN, and -CF_3; and all the other variables are as in Formula (**LVII**); wherein when $\mathbf{B^4}$ is -C- and $\mathbf{R^3}$ is -CH_2F, then the compound is not  ; wherein when $\mathbf{B^4}$ is -N- and $\mathbf{R^3}$ is -CH_2F, then the compound is not  ;

wherein when the compound is according to Formula (**LIX**), the variables are as in Formula (**LVII**);

wherein when the compound is according to Formula (**LX**), $\mathbf{R^4}$ is selected from the group consisting of: (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl,  , and  , wherein $\mathbf{R^7}$ is -CH_2F or -CHF_2; and all the other variables are as in Formula (**LVII**);

wherein when the compound is according to Formula (**LXI**), the other variables are as in Formula (**LVII**);

wherein when the compound is according to Formula (**LXII**),

either (a), (b), (c), (d), or (e)

(a) wherein when $\mathbf{D^1}$ is -N- and $\mathbf{D^2}$ and $\mathbf{D^4}$ are -CH-, then the compound is not

Compound No.	Structure
486	
512	 , and
513	

; and all the other variables are as in Formula (**LVII**);

or

(b) wherein $\mathbf{D^1}$ and $\mathbf{D^4}$ are -CH- and $\mathbf{D^2}$ is -N- and all the other variables are as in Formula (**LVII**);

or

(c) wherein $\mathbf{D^1}$ is -CH-, $\mathbf{D^4}$ is -CH- or -N-, and $\mathbf{D^2}$ is $-C(CH_3)$, and all the other variables are as in Formula (**LVII**);

or

(d) wherein $\mathbf{D^1}$, $\mathbf{D^2}$, and $\mathbf{D^4}$ are -CH- or -N-, wherein zero or one of $\mathbf{D^1}$, $\mathbf{D^2}$, and $\mathbf{D^4}$ is -N-and

$\mathbf{R^5}$ is selected from group consisting of: H, CH_2OH, $-CH_2COOH$, $-(CH_2)_2COOH$, 


, 
, and **R**^{13} is -CH_3 or -cyclopropyl; and all the other variables are as in Formula (**LVII**);

or

(e) **D**^{1}, **D**^{2}, and **D**^{4} are -CH- or -N-, wherein zero or one of **D**^{1}, **D**^{2}, and **D**^{4} is -N- and **L**^{3} is -$CH(CH_3)$-; and all the other variables are as in Formula (**LVII**);

or

Compound No.	Structure
552	
553	
558	
561	

Compound No.	Structure
562	
572	
573	
576	
578	

Compound No.	Structure
581	
640	 , and
641	

wherein when the compound is according to Formula **(LVII)**, **(LVIII)**, **(LIX)**, **(LX)**, or **(LXII)**, $\mathbf{L^1}$ is selected from the group consisting of -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H, Me)-, -CH_2O-, -OCH_2(cyclopropyl)-, -O-CH_2-CH_2-, -CH_2-O-CH_2-, -CH_2-O-C($(CH_3)_2$), -$NHCH_2$-, -CH_2NH-, -N(Me)CH_2-, and -SO_2NH-.

2. A compound according to Formula **LXIII** or a pharmaceutically acceptable salt, or stereoisomer thereof:



(LXIII) ,

wherein:

$\mathbf{D^1}$ is -CH-or -N-;

$\mathbf{D^2}$ is -CH-, -N-, -C(CH_3)-;

$\mathbf{D^4}$ is -CH- or -N-;

W is N, C$\mathbf{R^{14}}$, or C; when **W** is C$\mathbf{R^{14}}$, the adjacent dashed line indicates a single bond; when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=;

$\mathbf{L^1}$ is selected from the group consisting of -O-, -CH_2-, -NH-, -N(Me)-, -N(Et)-, -OCH_2-, -OC(H, Me)-, -CH_2O-, -$NHCH_2$-, -CH_2NH-, -N(Me)CH_2-, and -SO_2NH-;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, -CH_2-, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

$\mathbf{L^3}$ is -CH_2-, -C(O)-, or -$CH(CH_3)$-;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^3}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

$\mathbf{R^4}$ is selected from the group consisting of: : (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, , , , , , , , , , , , , , and ;

$\mathbf{R^5}$ is selected from the group consisting of -H, -CH_2OH, -COOH, -CH_2COOH, -$(CH_2)_2COOH$, -$COCF_3$, -C(OH)CF_3, -CONHCN, -CONHOH, CONHOMe, -$CONHSO_2N(Me)_2$, -PO_3H_2, -PO(Me)(OH), -SO_3H, -SO_2NH_2, -SO_2NHMe, -$B(OH)_2$, , , , , , tetrazolyl, and ;

$\mathbf{R^7}$ is $-CH_2F$ or $-CHF_2$;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

$\mathbf{R^{14}}$ is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

3. A compound according to Formula **LXIV** or a pharmaceutically acceptable salt, or stereoisomer thereof:



(**LXIV**),

wherein:

$\mathbf{D^1}$ is -CH-or -N-;

$\mathbf{D^2}$ is -CH-, -N-, $-C(CH_3)-$;

$\mathbf{D^4}$ is -CH- or -N-;

W is N, $\mathbf{CR^{14}}$, or C; when **W** is $\mathbf{CR^{14}}$, the adjacent dashed line indicates a single bond; when **W** is C, the adjacent dashed line indicates a double bond or $\mathbf{L^2}$ is -C(H)=;

$\mathbf{L^1}$ is selected from the group consisting of -O-, $-CH_2-$, -NH-, -N(Me)-, -N(Et)-, $-OCH_2-$, -OC(H, Me)-, $-CH_2O-$, $-NHCH_2-$, $-CH_2NH-$, $-N(Me)CH_2-$, and $-SO_2NH-$;

$\mathbf{L^2}$ is selected from the group consisting of a bond, -C(O)-, $-CH_2-$, -C(H)=, SO_2-, -O-, -NH-, -N(Me)-, and ;

$\mathbf{L^3}$ is $-CH_2-$, -C(O)-, or $-CH(CH_3)-$;

each $\mathbf{R^1}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^2}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

each $\mathbf{R^3}$ is independently selected from the group consisting of alkyl, substituted alkyl, halo, cyano, azido, alkoxy, haloalkoxy, and $\mathbf{R^{11}R^{12}}$NCO-;

$\mathbf{R^4}$ is alkyl, substituted alkyl, unsubstituted arylalkylene, substituted arylalkylene, heteroalkyl, substituted heteroalkyl, unsubstituted heteroarylalkylene, substituted heteroarylalkylene, unsubstituted heterocycloalkyl, or substituted heterocycloalkyl;

$\mathbf{R^5}$ is selected from the group consisting of H, CH_2OH, $-CH_2COOH$, $-(CH_2)_2COOH$, , , and ;

$\mathbf{R^7}$ is $-CH_2F$ or $-CHF_2$;

each $\mathbf{R^{11}}$ is hydrogen, or alkyl;

each $\mathbf{R^{12}}$ is hydrogen, or alkyl;

$\mathbf{R^{13}}$ is hydrogen, alkyl, or -cyclopropyl;

$\mathbf{R^{14}}$ is hydrogen or alkyl;

n is an integer from 0 to 4;

m is an integer from 0 to 3; and

o is an integer from 0 to 4.

4. The compound any one of the previous claims, wherein each $\mathbf{R^2}$ and $\mathbf{R^3}$ is H, or F.

5. The compound of any one of the previous claims, wherein **m** is 0, and **o** is 0.

6. The compound of any one of the previous claims, wherein **W** is N, or CH.

7. The compound of any one of the previous claims, wherein **W** is C.

8. The compound of any one of the previous claims, wherein **W** is CH.

9. The compound of any one of the previous claims, wherein **W** is N.

10 The compound of any one of the previous claims, wherein $\mathbf{D^4}$ is -CH-.

11. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is selected from the group consisting of azetidine-3-yl-methyl, (3*R*)-azetidine-3-yl-methyl, (3*S*)-azetidine-3-yl-methyl, (S)-buta-4-yl-1,3-diol, butan-1-yl-one, 1-(cyanomethyl)-cycloprop-1-yl-methyl, 3-(difluoromethyl)oxetan-3-yl-methyl, (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-

dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, (1-ethyl-1H-imidazol-5-yl)-methyl, 1-(fluoromethyl)-cycloprop-1-yl-methyl, 3-fluorooxetan-3-yl-methyl, 1-hydroxyl-cycloprop-1-yl-methyl, isoxazol-5-yl-methyl, (3R,4R)-4-methoxytetrahydrofuran-3-yl , (1-methyl-1H-imidazol-5-yl)-methyl, 1-methoxy-cycloprop-1yl-methyl, methoxyethan-2-yl, 1-(2-methoxyethyl)-cycloprop-1-yl-methyl, {[1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, {[(2R)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, {[(2S)-1-(1,2-oxazole-3-carbonyl)azetidin-2-yl]methyl}, oxetan-2-yl-methyl, (2*S*)-oxetan-2-yl-methyl, oxelan-3-yl-methyl, (3*R*)-oxelan-3-yl-methyl, 1,3-oxazol-2-yl-methyl, (*S*)-1,3-oxazol-2-yl-methyl, (*R*)-1,3-oxazol-2-yl-methyl, 2-oxabicyclo[2.1.1]hexa-1-yl-methyl, 1-cyclobutylmethyl, (R)-2-cyclopropoxypropyl, (S)-2-cyclopropoxypropyl, (2R)-2-(difluoromethoxy)propyl, (2S)-2-(difluoromethoxy)propyl, (2S)-oxolan-2-yl-methyl, (1-methoxycyclobutyl)methyl, (2R)-2-(2,2,2-trifluoroethoxy)propyl, (2S)-2-(2,2,2-trifluoroethoxy)propyl, and 2-(2,2,2-trifluoroethoxy)ethyl.

12. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is selected from the group consisting of (1-ethyl-1H-imidazol-5-yl)-methyl, oxetan-2-yl-methyl, (2*S*)-oxetan-2-yl-methyl, oxelan-3-yl-methyl, (3*R*)-oxelan-3-yl-methyl, and 1,3-oxazol-2-yl-methyl.

13. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is selected from the group consisting of (S)-buta-4-yl-1,3-diol, 3-(difluoromethyl)oxetan-3-yl-methyl, (1,1-dioxidothietan-2-yl)methyl, ((R)-1,1-dioxidothietan-2-yl)methyl, ((S)-1,1-dioxidothietan-2-yl)methyl, (1-ethyl-1H-imidazol-5-yl)-methyl, 3-fluorooxetan-3-yl-methyl, (3R,4R)-4-methoxytetrahydrofuran-3-yl, oxetan-2-yl-methyl, (2*S*)-oxetan-2-yl-methyl, 1,3-oxazol-2-yl-methyl, (*S*)-1,3-oxazol-2-yl-methyl, (*R*)-1,3-oxazol-2-yl-methyl, 2-oxabicyclo[2.1.1]hexa-1-yl-methyl, 1-cyclobutylmethyl, (R)-2-cyclopropoxypropyl, (S)-2-cyclopropoxypropyl, (2R)-2-(difluoromethoxy)propyl, (2S)-2-(difluoromethoxy)propyl, (2S)-oxolan-2-yl-methyl, (1-methoxycyclobutyl)methyl, (2R)-2-(2,2,2-trifluoroethoxy)propyl, (2S)-2-(2,2,2-trifluoroethoxy)propyl, and 2-(2,2,2-trifluoroethoxy)ethyl.

14. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (S)-buta-4-yl-1,3-diol.

15. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is 3-(difluoromethyl)oxetan-3-yl-methyl.

16. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (1-ethyl-1H-imidazol-5-yl)-methyl.

17. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is 3-fluorooxetan-3-yl-methyl.

18. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (3R,4R)-4-methoxytetrahydrofuran-3-yl.

19. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is oxetan-2-yl-methyl.

20. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (2*S*)-oxetan-2-yl-methyl.

21. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is 1,3-oxazol-2-yl-methyl.

22. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (*S*)-1,3-oxazol-2-yl-methyl.

23. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (*R*)-1,3-oxazol-2-yl-methyl.

24. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is 2-oxabicyclo[2.1.1]hexa-1-yl-methyl.

25. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is ((R)-1,1-dioxidothietan-2-yl)methyl.

26. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is ((S)-1,1-dioxidothietan-2-yl)methyl.

27. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is 1-cyclobutylmethyl.

28. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (R)-2-cyclopropoxypropyl.

29. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (S)-2-cyclopropoxypropyl.

30. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (2R)-2-(difluoromethoxy)propyl.

31. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (2S)-2-(difluoromethoxy)propyl.

32. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (2S)-oxolan-2-yl-methyl.

33. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (1-methoxycyclobutyl)methyl.

34. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (2R)-2-(2,2,2-trifluoroethoxy)propyl.

35. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is (2S)-2-(2,2,2-trifluoroethoxy)propyl.

36. The compound of any one of the previous claims, wherein $\mathbf{R^4}$ is 2-(2,2,2-trifluoroethoxy)ethyl.

37. The compound of any one of the previous claims, wherein $\mathbf{R^5}$ is -COOH.

38. The compound of any one of the previous claims, wherein $\mathbf{R^5}$ is .

39. The compound of any one of the previous claims, wherein $\mathbf{R^5}$ is , wherein $\mathbf{R^{13}}$ is -CH_3 or -cyclopropyl.

40. The compound of any one of the previous claims, wherein $\mathbf{R^5}$ is -CH_2COOH.

41. The compound of any one of the previous claims, wherein $\mathbf{R^5}$ is -$(CH_2)_2COOH$.

42. The compound of any one of the previous claims, wherein $\mathbf{R^5}$ is -H.

43. The compound of any one of the previous claims, wherein $\mathbf{R^5}$ is -CH_2OH.

44. The compound of any one of the previous claims, wherein $\mathbf{R^5}$ is .

45. The compound of any one of the previous claims 1-44, wherein $\mathbf{L^2}$ is -O-.

46. The compound of any one of the previous claims 1-45, wherein $\mathbf{L^3}$ is -CH_2-.

47. The compound of any one of the previous claims 1-45, wherein $\mathbf{L^3}$ is -$CH(CH_3)$-.

48. The compound of any one of claims 1-47, wherein $\mathbf{L^1}$ is -CH_2O-; and $\mathbf{L^2}$ is -O-.

49. The compound of any one of claims 1-47, wherein $\mathbf{L^1}$ is -OCH_2-; and $\mathbf{L^2}$ is -O-.

50. The compound of any one of claims 1-47, wherein $\mathbf{L^1}$ is -CH_2O-; and $\mathbf{L^3}$ is CH_2-.

51. The compound of any one of claims 1-47, wherein $\mathbf{L^1}$ is -CH_2O-; and $\mathbf{L^3}$ is -$CH(CH_3)$.

52. The compound of any one of claims 1-51, wherein $\mathbf{L^1}$ is -O-.

53. The compound of any one of claims 1-50, 51, 53, and 54, wherein $\mathbf{L^1}$ is -CH_2O-.

54. The compound of any one of claims 1-50 and 52, wherein $\mathbf{L^1}$ is $-OCH_2-$.

55. A compound selected from any of the compounds in Table 1 and Table 2, or a pharmaceutically acceptable salt or solvate thereof:

56. A pharmaceutical composition comprising the compound of any of the previous claims, or a pharmaceutically acceptable salt thereof, and one, or more pharmaceutically acceptable carriers, excipients, or diluents.

57. A method of treating a metabolic disease or disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-55, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition of claim 56.

58. The compound of any one of claims 1-55, or the pharmaceutical composition of claim 56 for use in therapy.

59. The compound of any of one claims 1-55, or the pharmaceutical composition of claim 56 for use in the treatment of a metabolic disease, or disorder.

60. Use of the compound of any one of claims 1-56, or the pharmaceutical composition of claim 56 in the manufacture of a medicament for the treatment of a metabolic disease, or disorder.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2023/071000

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D405/14 C07D401/14 C07D403/12 C07D471/04 A61P3/00
A61P3/10 A61K31/4184
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61P C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2020/103815 A1 (QILU REGOR THERAPEUTICS INC [CN]) 28 May 2020 (2020-05-28) abstract * compounds *; pages 62-64 examples 1-6 claims 1-40	1-54, 56-60
X Y	WO 2019/239371 A1 (PFIZER [US]) 19 December 2019 (2019-12-19) abstract examples 62-78 claims 1-20	1,2, 4-37,46, 50,53, 56-60 3,38-45, 47-49, 51,52, 54,55

-/--

[x] Further documents are listed in the continuation of Box C.
[x] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
25 October 2023	02/11/2023

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Dunet, Guillaume

1

Form PCT/ISA/210 (second sheet) (April 2005)

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2021/096284 A1 (ILDONG PHARMACEUTICAL CO LTD [KR]) 20 May 2021 (2021-05-20)	1,2, 4-37,46, 50,53, 56-60
Y	abstract page 72; compound 4 * compounds *; pages 72-82 claims 1-20	3,38-45, 47-49, 51,52, 54,55
X	WO 2022/042691 A1 (GASHERBRUM BIO INC [US]; MENG QINGHUA [CN]) 3 March 2022 (2022-03-03)	1,2, 4-37, 45-54, 56-60
Y	abstract * compounds *; pages 52-84 claims 1-256	3,38-44, 55
Y	WO 2021/160127 A1 (GASHERBRUM BIO INC [US]; MENG QINGHUA [CN]) 19 August 2021 (2021-08-19) abstract * compounds *; pages 38-73 claims 1-203	1-60
Y	WO 2022/109182 A1 (GILEAD SCIENCES INC [US]) 27 May 2022 (2022-05-27) abstract examples 1-32 claims 1-40	1-60
Y	WO 2022/078152 A1 (HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO LTD [CN]) 21 April 2022 (2022-04-21) abstract * compounds *; pages 17-27 claims 1-12	1-60
Y	WO 2021/197464 A1 (JIANGSU HENGRUI MEDICINE CO [CN] ET AL.) 7 October 2021 (2021-10-07) abstract * compounds *; pages 9-11 * compounds *; pages 12-14 claims 1-21	1-60

-/--

1

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2021/018023 A1 (THE TITAN LEADING MED TECH INC [CN]) 4 February 2021 (2021-02-04) abstract * compounds *; pages 10-13 claims 1-18	1-60
Y	WO 2022/078380 A1 (GASHERBRUM BIO INC [US]; MENG QINGHUA [CN]) 21 April 2022 (2022-04-21) abstract * compounds *; pages 78-108 claims 1-308	1-60
Y	WO 2022/078407 A1 (GASHERBRUM BIO INC [US]; MENG QINGHUA [CN]) 21 April 2022 (2022-04-21) abstract * compounds *; pages 81-281 claims 1-317	1-60
X,P A,P	WO 2022/165076 A1 (CARMOT THERAPEUTICS INC [US]) 4 August 2022 (2022-08-04) abstract * compounds *; pages 245-326 claims 1-56	1-39, 44-60 40-43
X,P A,P	WO 2022/235717 A1 (CARMOT THERAPEUTICS INC [US]; GARAI SUMANTA [US]) 10 November 2022 (2022-11-10) abstract * compounds *; pages 66-104 claims 1-38	1-39, 44-60 40-43

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2023/071000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2020103815 A1	28-05-2020	AU 2019382642 A1	10-06-2021
		BR 112021009877 A2	17-08-2021
		CA 3120499 A1	28-05-2020
		CL 2021001332 A1	05-11-2021
		CN 113227068 A	06-08-2021
		CO 2021008089 A2	09-09-2021
		CR 20210341 A	25-11-2021
		CU 20210042 A7	13-01-2022
		EA 202191432 A1	14-10-2021
		EP 3883928 A1	29-09-2021
		IL 283322 A	29-07-2021
		JP 2022508203 A	19-01-2022
		KR 20210106447 A	30-08-2021
		MA 54555 A	29-09-2021
		PE 20211871 A1	21-09-2021
		PH 12021551165 A1	25-10-2021
		SG 11202105241Y A	29-06-2021
		TW 202039458 A	01-11-2020
		US 2020283424 A1	10-09-2020
		US 2022024901 A1	27-01-2022
		WO 2020103815 A1	28-05-2020
WO 2019239371 A1	19-12-2019	AU 2019285570 A1	17-12-2020
		BR 112020024956 A2	09-03-2021
		CA 3103051 A1	19-12-2019
		CN 112566637 A	26-03-2021
		DK 3806855 T5	22-05-2023
		EP 3806855 A1	21-04-2021
		ES 2943510 T3	13-06-2023
		FI 3806855 T3	04-05-2023
		HU E061888 T2	28-08-2023
		IL 279224 A	31-01-2021
		JP 7053900 B2	12-04-2022
		JP 2021528394 A	21-10-2021
		KR 20210020095 A	23-02-2021
		PL 3806855 T3	24-07-2023
		PT 3806855 T	03-05-2023
		RU 2765721 C1	02-02-2022
		SG 11202011704X A	30-12-2020
		SI 3806855 T1	30-06-2023
		US 2021332034 A1	28-10-2021
		WO 2019239371 A1	19-12-2019
WO 2021096284 A1	20-05-2021	AU 2020384121 A1	23-06-2022
		BR 112022009287 A2	09-08-2022
		CA 3160518 A1	20-05-2021
		CL 2022001271 A1	03-02-2023
		CN 114728939 A	08-07-2022
		CN 114728940 A	08-07-2022
		CO 2022006183 A2	20-05-2022
		CU 20220028 A7	12-12-2022
		DO P2022000100 A	15-08-2022
		EP 4058445 A1	21-09-2022
		EP 4059929 A1	21-09-2022
		IL 292943 A	01-07-2022
		JP 2023502081 A	20-01-2023
		JP 2023502619 A	25-01-2023
		KR 20210059653 A	25-05-2021

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2023/071000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		KR 20210149005 A	08-12-2021
		KR 20220101092 A	19-07-2022
		PE 20221422 A1	20-09-2022
		TW 202313586 A	01-04-2023
		US 2023002348 A1	05-01-2023
		US 2023013143 A1	19-01-2023
		US 2023212140 A1	06-07-2023
		WO 2021096284 A1	20-05-2021
		WO 2021096304 A1	20-05-2021
WO 2022042691 A1	03-03-2022	CN 116406360 A	07-07-2023
		EP 4204415 A1	05-07-2023
		JP 2023538949 A	12-09-2023
		US 2023071840 A1	09-03-2023
		US 2023107793 A1	06-04-2023
		WO 2022042691 A1	03-03-2022
WO 2021160127 A1	19-08-2021	CN 115697999 A	03-02-2023
		EP 4103563 A1	21-12-2022
		JP 2023515404 A	13-04-2023
		US 2023165846 A1	01-06-2023
		WO 2021160127 A1	19-08-2021
WO 2022109182 A1	27-05-2022	EP 4247804 A1	27-09-2023
		TW 202237582 A	01-10-2022
		US 2022177449 A1	09-06-2022
		WO 2022109182 A1	27-05-2022
WO 2022078152 A1	21-04-2022	CN 116348464 A	27-06-2023
		EP 4227299 A1	16-08-2023
		WO 2022078152 A1	21-04-2022
WO 2021197464 A1	07-10-2021	CA 3172285 A1	07-10-2021
		CN 115244056 A	25-10-2022
		EP 4130003 A1	08-02-2023
		JP 2023520003 A	15-05-2023
		TW 202144340 A	01-12-2021
		US 2023126875 A1	27-04-2023
		WO 2021197464 A1	07-10-2021
WO 2021018023 A1	04-02-2021	NONE	
WO 2022078380 A1	21-04-2022	CN 116547278 A	04-08-2023
		EP 4229049 A1	23-08-2023
		WO 2022078380 A1	21-04-2022
WO 2022078407 A1	21-04-2022	CN 116547279 A	04-08-2023
		EP 4229050 A1	23-08-2023
		WO 2022078407 A1	21-04-2022
WO 2022165076 A1	04-08-2022	AU 2022212019 A1	03-08-2023
		CA 3209593 A1	04-08-2022
		IL 304521 A	01-09-2023
		US 2023089073 A1	23-03-2023
		WO 2022165076 A1	04-08-2022
WO 2022235717 A1	10-11-2022	US 2022396569 A1	15-12-2022
		WO 2022235717 A1	10-11-2022

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2023/071000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
----------			